{ "retrieved_on": "2026-10-31", "condition": "uterine-adenosarcoma", "author": "Grok", "window": { "from": "2026-10-24", "through": "2026-10-31", "inclusive": true }, "endpoints": [ "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi", "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi", "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi", "https://www.ebi.ac.uk/europepmc/webservices/rest/search", "https://clinicaltrials.gov/api/v2/studies", "https://api.crossref.org/works" ], "pubmed": [ { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "1", "retmax": "1", "retstart": "0", "idlist": [ "42951232" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND 2026/10/24:2026/10/31[Date - Publication]" } }, "topic": "all", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "2", "retmax": "2", "retstart": "0", "idlist": [ "42951389", "42951232" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND 2026/10/24:2026/10/31[Date - Entry]" } }, "topic": "all", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=uterine+adenosarcoma&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "uterine adenosarcoma", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "uterine adenosarcoma", "to": "\"adenosarcoma of the uterus\"[Supplementary Concept] OR \"adenosarcoma of the uterus\"[All Fields] OR \"uterine adenosarcoma\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma of the uterus\"[Supplementary Concept] OR \"adenosarcoma of the uterus\"[All Fields] OR \"uterine adenosarcoma\"[All Fields]) AND 2026/10/24:2026/10/31[Date - Publication]", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "uterine_all", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=uterine+adenosarcoma&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "uterine adenosarcoma", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "1", "retmax": "1", "retstart": "0", "idlist": [ "42951389" ], "translationset": [ { "from": "uterine adenosarcoma", "to": "\"adenosarcoma of the uterus\"[Supplementary Concept] OR \"adenosarcoma of the uterus\"[All Fields] OR \"uterine adenosarcoma\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma of the uterus\"[Supplementary Concept] OR \"adenosarcoma of the uterus\"[All Fields] OR \"uterine adenosarcoma\"[All Fields]) AND 2026/10/24:2026/10/31[Date - Entry]" } }, "topic": "uterine_all", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28pathology+OR+diagnosis+OR+polyp+OR+adenofibroma%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (pathology OR diagnosis OR polyp OR adenofibroma)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "1", "retmax": "1", "retstart": "0", "idlist": [ "42951232" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "pathology", "to": "\"pathology\"[MeSH Terms] OR \"pathology\"[All Fields] OR \"pathologies\"[All Fields] OR \"pathology\"[Subheading]" }, { "from": "diagnosis", "to": "\"diagnosable\"[All Fields] OR \"diagnosi\"[All Fields] OR \"diagnosis\"[MeSH Terms] OR \"diagnosis\"[All Fields] OR \"diagnose\"[All Fields] OR \"diagnosed\"[All Fields] OR \"diagnoses\"[All Fields] OR \"diagnosing\"[All Fields] OR \"diagnosis\"[Subheading]" }, { "from": "polyp", "to": "\"polyp's\"[All Fields] OR \"polypous\"[All Fields] OR \"polyps\"[MeSH Terms] OR \"polyps\"[All Fields] OR \"polyp\"[All Fields]" }, { "from": "adenofibroma", "to": "\"adenofibroma\"[MeSH Terms] OR \"adenofibroma\"[All Fields] OR \"adenofibromas\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"pathology\"[MeSH Terms] OR \"pathology\"[All Fields] OR \"pathologies\"[All Fields] OR \"pathology\"[MeSH Subheading] OR (\"diagnosable\"[All Fields] OR \"diagnosi\"[All Fields] OR \"diagnosis\"[MeSH Terms] OR \"diagnosis\"[All Fields] OR \"diagnose\"[All Fields] OR \"diagnosed\"[All Fields] OR \"diagnoses\"[All Fields] OR \"diagnosing\"[All Fields] OR \"diagnosis\"[MeSH Subheading]) OR (\"polyp s\"[All Fields] OR \"polypous\"[All Fields] OR \"polyps\"[MeSH Terms] OR \"polyps\"[All Fields] OR \"polyp\"[All Fields]) OR (\"adenofibroma\"[MeSH Terms] OR \"adenofibroma\"[All Fields] OR \"adenofibromas\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Publication]" } }, "topic": "pathology", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28pathology+OR+diagnosis+OR+polyp+OR+adenofibroma%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (pathology OR diagnosis OR polyp OR adenofibroma)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "2", "retmax": "2", "retstart": "0", "idlist": [ "42951389", "42951232" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "pathology", "to": "\"pathology\"[MeSH Terms] OR \"pathology\"[All Fields] OR \"pathologies\"[All Fields] OR \"pathology\"[Subheading]" }, { "from": "diagnosis", "to": "\"diagnosable\"[All Fields] OR \"diagnosi\"[All Fields] OR \"diagnosis\"[MeSH Terms] OR \"diagnosis\"[All Fields] OR \"diagnose\"[All Fields] OR \"diagnosed\"[All Fields] OR \"diagnoses\"[All Fields] OR \"diagnosing\"[All Fields] OR \"diagnosis\"[Subheading]" }, { "from": "polyp", "to": "\"polyp's\"[All Fields] OR \"polypous\"[All Fields] OR \"polyps\"[MeSH Terms] OR \"polyps\"[All Fields] OR \"polyp\"[All Fields]" }, { "from": "adenofibroma", "to": "\"adenofibroma\"[MeSH Terms] OR \"adenofibroma\"[All Fields] OR \"adenofibromas\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"pathology\"[MeSH Terms] OR \"pathology\"[All Fields] OR \"pathologies\"[All Fields] OR \"pathology\"[MeSH Subheading] OR (\"diagnosable\"[All Fields] OR \"diagnosi\"[All Fields] OR \"diagnosis\"[MeSH Terms] OR \"diagnosis\"[All Fields] OR \"diagnose\"[All Fields] OR \"diagnosed\"[All Fields] OR \"diagnoses\"[All Fields] OR \"diagnosing\"[All Fields] OR \"diagnosis\"[MeSH Subheading]) OR (\"polyp s\"[All Fields] OR \"polypous\"[All Fields] OR \"polyps\"[MeSH Terms] OR \"polyps\"[All Fields] OR \"polyp\"[All Fields]) OR (\"adenofibroma\"[MeSH Terms] OR \"adenofibroma\"[All Fields] OR \"adenofibromas\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Entry]" } }, "topic": "pathology", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28sarcomatous+overgrowth+OR+stage+OR+prognosis+OR+survival+OR+LVSI%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (sarcomatous overgrowth OR stage OR prognosis OR survival OR LVSI)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "1", "retmax": "1", "retstart": "0", "idlist": [ "42951232" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "overgrowth", "to": "\"overgrowth\"[All Fields] OR \"overgrowths\"[All Fields]" }, { "from": "stage", "to": "\"stage\"[All Fields] OR \"staged\"[All Fields] OR \"stages\"[All Fields] OR \"staging\"[All Fields] OR \"stagings\"[All Fields]" }, { "from": "prognosis", "to": "\"prognosis\"[MeSH Terms] OR \"prognosis\"[All Fields] OR \"prognoses\"[All Fields]" }, { "from": "survival", "to": "\"mortality\"[Subheading] OR \"mortality\"[All Fields] OR \"survival\"[All Fields] OR \"survival\"[MeSH Terms] OR \"survivability\"[All Fields] OR \"survivable\"[All Fields] OR \"survivals\"[All Fields] OR \"survive\"[All Fields] OR \"survived\"[All Fields] OR \"survives\"[All Fields] OR \"surviving\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND ((\"sarcomatous\"[All Fields] AND (\"overgrowth\"[All Fields] OR \"overgrowths\"[All Fields])) OR (\"stage\"[All Fields] OR \"staged\"[All Fields] OR \"stages\"[All Fields] OR \"staging\"[All Fields] OR \"stagings\"[All Fields]) OR (\"prognosis\"[MeSH Terms] OR \"prognosis\"[All Fields] OR \"prognoses\"[All Fields]) OR (\"mortality\"[MeSH Subheading] OR \"mortality\"[All Fields] OR \"survival\"[All Fields] OR \"survival\"[MeSH Terms] OR \"survivability\"[All Fields] OR \"survivable\"[All Fields] OR \"survivals\"[All Fields] OR \"survive\"[All Fields] OR \"survived\"[All Fields] OR \"survives\"[All Fields] OR \"surviving\"[All Fields]) OR \"LVSI\"[All Fields]) AND 2026/10/24:2026/10/31[Date - Publication]" } }, "topic": "overgrowth_prognosis", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28sarcomatous+overgrowth+OR+stage+OR+prognosis+OR+survival+OR+LVSI%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (sarcomatous overgrowth OR stage OR prognosis OR survival OR LVSI)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "2", "retmax": "2", "retstart": "0", "idlist": [ "42951389", "42951232" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "overgrowth", "to": "\"overgrowth\"[All Fields] OR \"overgrowths\"[All Fields]" }, { "from": "stage", "to": "\"stage\"[All Fields] OR \"staged\"[All Fields] OR \"stages\"[All Fields] OR \"staging\"[All Fields] OR \"stagings\"[All Fields]" }, { "from": "prognosis", "to": "\"prognosis\"[MeSH Terms] OR \"prognosis\"[All Fields] OR \"prognoses\"[All Fields]" }, { "from": "survival", "to": "\"mortality\"[Subheading] OR \"mortality\"[All Fields] OR \"survival\"[All Fields] OR \"survival\"[MeSH Terms] OR \"survivability\"[All Fields] OR \"survivable\"[All Fields] OR \"survivals\"[All Fields] OR \"survive\"[All Fields] OR \"survived\"[All Fields] OR \"survives\"[All Fields] OR \"surviving\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND ((\"sarcomatous\"[All Fields] AND (\"overgrowth\"[All Fields] OR \"overgrowths\"[All Fields])) OR (\"stage\"[All Fields] OR \"staged\"[All Fields] OR \"stages\"[All Fields] OR \"staging\"[All Fields] OR \"stagings\"[All Fields]) OR (\"prognosis\"[MeSH Terms] OR \"prognosis\"[All Fields] OR \"prognoses\"[All Fields]) OR (\"mortality\"[MeSH Subheading] OR \"mortality\"[All Fields] OR \"survival\"[All Fields] OR \"survival\"[MeSH Terms] OR \"survivability\"[All Fields] OR \"survivable\"[All Fields] OR \"survivals\"[All Fields] OR \"survive\"[All Fields] OR \"survived\"[All Fields] OR \"survives\"[All Fields] OR \"surviving\"[All Fields]) OR \"LVSI\"[All Fields]) AND 2026/10/24:2026/10/31[Date - Entry]" } }, "topic": "overgrowth_prognosis", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28molecular+OR+genomic+OR+MDM2+OR+CDK4+OR+DICER1+OR+BAP1+OR+TP53+OR+SMARCA4+OR+BRG1+OR+fusion%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (molecular OR genomic OR MDM2 OR CDK4 OR DICER1 OR BAP1 OR TP53 OR SMARCA4 OR BRG1 OR fusion)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "molecular", "to": "\"molecular\"[All Fields] OR \"moleculars\"[All Fields]" }, { "from": "genomic", "to": "\"genome\"[MeSH Terms] OR \"genome\"[All Fields] OR \"genomes\"[All Fields] OR \"genome's\"[All Fields] OR \"genomically\"[All Fields] OR \"genomics\"[MeSH Terms] OR \"genomics\"[All Fields] OR \"genomic\"[All Fields]" }, { "from": "DICER1", "to": "\"dicer1 protein, human\"[Supplementary Concept] OR \"dicer1 protein, human\"[All Fields] OR \"dicer1\"[All Fields]" }, { "from": "BAP1", "to": "\"bap1 protein, human\"[Supplementary Concept] OR \"bap1 protein, human\"[All Fields] OR \"bap1\"[All Fields]" }, { "from": "TP53", "to": "\"tp53 protein, human\"[Supplementary Concept] OR \"tp53 protein, human\"[All Fields] OR \"tp53\"[All Fields]" }, { "from": "SMARCA4", "to": "\"smarca4 protein, human\"[Supplementary Concept] OR \"smarca4 protein, human\"[All Fields] OR \"smarca4\"[All Fields]" }, { "from": "fusion", "to": "\"fusion\"[All Fields] OR \"fusions\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"molecular\"[All Fields] OR \"moleculars\"[All Fields] OR (\"genome\"[MeSH Terms] OR \"genome\"[All Fields] OR \"genomes\"[All Fields] OR \"genome s\"[All Fields] OR \"genomically\"[All Fields] OR \"genomics\"[MeSH Terms] OR \"genomics\"[All Fields] OR \"genomic\"[All Fields]) OR \"MDM2\"[All Fields] OR \"CDK4\"[All Fields] OR (\"dicer1 protein human\"[Supplementary Concept] OR \"dicer1 protein human\"[All Fields] OR \"dicer1\"[All Fields]) OR (\"bap1 protein human\"[Supplementary Concept] OR \"bap1 protein human\"[All Fields] OR \"bap1\"[All Fields]) OR (\"tp53 protein human\"[Supplementary Concept] OR \"tp53 protein human\"[All Fields] OR \"tp53\"[All Fields]) OR (\"smarca4 protein human\"[Supplementary Concept] OR \"smarca4 protein human\"[All Fields] OR \"smarca4\"[All Fields]) OR \"BRG1\"[All Fields] OR (\"fusion\"[All Fields] OR \"fusions\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Publication]", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "molecular", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28molecular+OR+genomic+OR+MDM2+OR+CDK4+OR+DICER1+OR+BAP1+OR+TP53+OR+SMARCA4+OR+BRG1+OR+fusion%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (molecular OR genomic OR MDM2 OR CDK4 OR DICER1 OR BAP1 OR TP53 OR SMARCA4 OR BRG1 OR fusion)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "molecular", "to": "\"molecular\"[All Fields] OR \"moleculars\"[All Fields]" }, { "from": "genomic", "to": "\"genome\"[MeSH Terms] OR \"genome\"[All Fields] OR \"genomes\"[All Fields] OR \"genome's\"[All Fields] OR \"genomically\"[All Fields] OR \"genomics\"[MeSH Terms] OR \"genomics\"[All Fields] OR \"genomic\"[All Fields]" }, { "from": "DICER1", "to": "\"dicer1 protein, human\"[Supplementary Concept] OR \"dicer1 protein, human\"[All Fields] OR \"dicer1\"[All Fields]" }, { "from": "BAP1", "to": "\"bap1 protein, human\"[Supplementary Concept] OR \"bap1 protein, human\"[All Fields] OR \"bap1\"[All Fields]" }, { "from": "TP53", "to": "\"tp53 protein, human\"[Supplementary Concept] OR \"tp53 protein, human\"[All Fields] OR \"tp53\"[All Fields]" }, { "from": "SMARCA4", "to": "\"smarca4 protein, human\"[Supplementary Concept] OR \"smarca4 protein, human\"[All Fields] OR \"smarca4\"[All Fields]" }, { "from": "fusion", "to": "\"fusion\"[All Fields] OR \"fusions\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"molecular\"[All Fields] OR \"moleculars\"[All Fields] OR (\"genome\"[MeSH Terms] OR \"genome\"[All Fields] OR \"genomes\"[All Fields] OR \"genome s\"[All Fields] OR \"genomically\"[All Fields] OR \"genomics\"[MeSH Terms] OR \"genomics\"[All Fields] OR \"genomic\"[All Fields]) OR \"MDM2\"[All Fields] OR \"CDK4\"[All Fields] OR (\"dicer1 protein human\"[Supplementary Concept] OR \"dicer1 protein human\"[All Fields] OR \"dicer1\"[All Fields]) OR (\"bap1 protein human\"[Supplementary Concept] OR \"bap1 protein human\"[All Fields] OR \"bap1\"[All Fields]) OR (\"tp53 protein human\"[Supplementary Concept] OR \"tp53 protein human\"[All Fields] OR \"tp53\"[All Fields]) OR (\"smarca4 protein human\"[Supplementary Concept] OR \"smarca4 protein human\"[All Fields] OR \"smarca4\"[All Fields]) OR \"BRG1\"[All Fields] OR (\"fusion\"[All Fields] OR \"fusions\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Entry]", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "molecular", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28epidemiology+OR+incidence+OR+registry+OR+SEER+OR+NCDB+OR+population+OR+burden%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (epidemiology OR incidence OR registry OR SEER OR NCDB OR population OR burden)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "1", "retmax": "1", "retstart": "0", "idlist": [ "42951232" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "epidemiology", "to": "\"epidemiologies\"[All Fields] OR \"epidemiology\"[Subheading] OR \"epidemiology\"[All Fields] OR \"epidemiology\"[MeSH Terms] OR \"epidemiology's\"[All Fields]" }, { "from": "incidence", "to": "\"epidemiology\"[Subheading] OR \"epidemiology\"[All Fields] OR \"incidence\"[All Fields] OR \"incidence\"[MeSH Terms] OR \"incidences\"[All Fields] OR \"incident\"[All Fields] OR \"incidents\"[All Fields]" }, { "from": "registry", "to": "\"registries\"[MeSH Terms] OR \"registries\"[All Fields] OR \"registry\"[All Fields] OR \"registry's\"[All Fields]" }, { "from": "population", "to": "\"populate\"[All Fields] OR \"populated\"[All Fields] OR \"populates\"[All Fields] OR \"populating\"[All Fields] OR \"population\"[MeSH Terms] OR \"population\"[All Fields] OR \"population groups\"[MeSH Terms] OR (\"population\"[All Fields] AND \"groups\"[All Fields]) OR \"population groups\"[All Fields] OR \"populations\"[All Fields] OR \"population's\"[All Fields] OR \"populational\"[All Fields] OR \"populations's\"[All Fields] OR \"populous\"[All Fields]" }, { "from": "burden", "to": "\"burden\"[All Fields] OR \"burdened\"[All Fields] OR \"burdening\"[All Fields] OR \"burdens\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"epidemiologies\"[All Fields] OR \"epidemiology\"[MeSH Subheading] OR \"epidemiology\"[All Fields] OR \"epidemiology\"[MeSH Terms] OR \"epidemiology s\"[All Fields] OR (\"epidemiology\"[MeSH Subheading] OR \"epidemiology\"[All Fields] OR \"incidence\"[All Fields] OR \"incidence\"[MeSH Terms] OR \"incidences\"[All Fields] OR \"incident\"[All Fields] OR \"incidents\"[All Fields]) OR (\"registries\"[MeSH Terms] OR \"registries\"[All Fields] OR \"registry\"[All Fields] OR \"registry s\"[All Fields]) OR \"SEER\"[All Fields] OR \"NCDB\"[All Fields] OR (\"populate\"[All Fields] OR \"populated\"[All Fields] OR \"populates\"[All Fields] OR \"populating\"[All Fields] OR \"population\"[MeSH Terms] OR \"population\"[All Fields] OR \"population groups\"[MeSH Terms] OR (\"population\"[All Fields] AND \"groups\"[All Fields]) OR \"population groups\"[All Fields] OR \"populations\"[All Fields] OR \"population s\"[All Fields] OR \"populational\"[All Fields] OR \"populous\"[All Fields]) OR (\"burden\"[All Fields] OR \"burdened\"[All Fields] OR \"burdening\"[All Fields] OR \"burdens\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Publication]" } }, "topic": "epidemiology", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28epidemiology+OR+incidence+OR+registry+OR+SEER+OR+NCDB+OR+population+OR+burden%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (epidemiology OR incidence OR registry OR SEER OR NCDB OR population OR burden)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "1", "retmax": "1", "retstart": "0", "idlist": [ "42951232" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "epidemiology", "to": "\"epidemiologies\"[All Fields] OR \"epidemiology\"[Subheading] OR \"epidemiology\"[All Fields] OR \"epidemiology\"[MeSH Terms] OR \"epidemiology's\"[All Fields]" }, { "from": "incidence", "to": "\"epidemiology\"[Subheading] OR \"epidemiology\"[All Fields] OR \"incidence\"[All Fields] OR \"incidence\"[MeSH Terms] OR \"incidences\"[All Fields] OR \"incident\"[All Fields] OR \"incidents\"[All Fields]" }, { "from": "registry", "to": "\"registries\"[MeSH Terms] OR \"registries\"[All Fields] OR \"registry\"[All Fields] OR \"registry's\"[All Fields]" }, { "from": "population", "to": "\"populate\"[All Fields] OR \"populated\"[All Fields] OR \"populates\"[All Fields] OR \"populating\"[All Fields] OR \"population\"[MeSH Terms] OR \"population\"[All Fields] OR \"population groups\"[MeSH Terms] OR (\"population\"[All Fields] AND \"groups\"[All Fields]) OR \"population groups\"[All Fields] OR \"populations\"[All Fields] OR \"population's\"[All Fields] OR \"populational\"[All Fields] OR \"populations's\"[All Fields] OR \"populous\"[All Fields]" }, { "from": "burden", "to": "\"burden\"[All Fields] OR \"burdened\"[All Fields] OR \"burdening\"[All Fields] OR \"burdens\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"epidemiologies\"[All Fields] OR \"epidemiology\"[MeSH Subheading] OR \"epidemiology\"[All Fields] OR \"epidemiology\"[MeSH Terms] OR \"epidemiology s\"[All Fields] OR (\"epidemiology\"[MeSH Subheading] OR \"epidemiology\"[All Fields] OR \"incidence\"[All Fields] OR \"incidence\"[MeSH Terms] OR \"incidences\"[All Fields] OR \"incident\"[All Fields] OR \"incidents\"[All Fields]) OR (\"registries\"[MeSH Terms] OR \"registries\"[All Fields] OR \"registry\"[All Fields] OR \"registry s\"[All Fields]) OR \"SEER\"[All Fields] OR \"NCDB\"[All Fields] OR (\"populate\"[All Fields] OR \"populated\"[All Fields] OR \"populates\"[All Fields] OR \"populating\"[All Fields] OR \"population\"[MeSH Terms] OR \"population\"[All Fields] OR \"population groups\"[MeSH Terms] OR (\"population\"[All Fields] AND \"groups\"[All Fields]) OR \"population groups\"[All Fields] OR \"populations\"[All Fields] OR \"population s\"[All Fields] OR \"populational\"[All Fields] OR \"populous\"[All Fields]) OR (\"burden\"[All Fields] OR \"burdened\"[All Fields] OR \"burdening\"[All Fields] OR \"burdens\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Entry]" } }, "topic": "epidemiology", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28imaging+OR+MRI+OR+ultrasound+OR+presentation%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (imaging OR MRI OR ultrasound OR presentation)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "imaging", "to": "\"image's\"[All Fields] OR \"imaged\"[All Fields] OR \"imager\"[All Fields] OR \"imager's\"[All Fields] OR \"imagers\"[All Fields] OR \"images\"[All Fields] OR \"imaging\"[All Fields] OR \"imaging's\"[All Fields] OR \"imagings\"[All Fields] OR \"intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies\"[Supplementary Concept] OR \"intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies\"[All Fields] OR \"image\"[All Fields]" }, { "from": "MRI", "to": "\"magnetic resonance imaging\"[MeSH Terms] OR (\"magnetic\"[All Fields] AND \"resonance\"[All Fields] AND \"imaging\"[All Fields]) OR \"magnetic resonance imaging\"[All Fields] OR \"mri\"[All Fields]" }, { "from": "ultrasound", "to": "\"diagnostic imaging\"[Subheading] OR (\"diagnostic\"[All Fields] AND \"imaging\"[All Fields]) OR \"diagnostic imaging\"[All Fields] OR \"ultrasound\"[All Fields] OR \"ultrasonography\"[MeSH Terms] OR \"ultrasonography\"[All Fields] OR \"ultrasonics\"[MeSH Terms] OR \"ultrasonics\"[All Fields] OR \"ultrasounds\"[All Fields] OR \"ultrasound's\"[All Fields]" }, { "from": "presentation", "to": "\"present\"[All Fields] OR \"presentation\"[All Fields] OR \"presentations\"[All Fields] OR \"presented\"[All Fields] OR \"presenter\"[All Fields] OR \"presenter's\"[All Fields] OR \"presenters\"[All Fields] OR \"presenting\"[All Fields] OR \"presents\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"image s\"[All Fields] OR \"imaged\"[All Fields] OR \"imager\"[All Fields] OR \"imager s\"[All Fields] OR \"imagers\"[All Fields] OR \"images\"[All Fields] OR \"imaging\"[All Fields] OR \"imaging s\"[All Fields] OR \"imagings\"[All Fields] OR \"intrauterine growth retardation metaphyseal dysplasia adrenal hypoplasia congenita and genital anomalies\"[Supplementary Concept] OR \"intrauterine growth retardation metaphyseal dysplasia adrenal hypoplasia congenita and genital anomalies\"[All Fields] OR \"image\"[All Fields] OR (\"magnetic resonance imaging\"[MeSH Terms] OR (\"magnetic\"[All Fields] AND \"resonance\"[All Fields] AND \"imaging\"[All Fields]) OR \"magnetic resonance imaging\"[All Fields] OR \"mri\"[All Fields]) OR (\"diagnostic imaging\"[MeSH Subheading] OR (\"diagnostic\"[All Fields] AND \"imaging\"[All Fields]) OR \"diagnostic imaging\"[All Fields] OR \"ultrasound\"[All Fields] OR \"ultrasonography\"[MeSH Terms] OR \"ultrasonography\"[All Fields] OR \"ultrasonics\"[MeSH Terms] OR \"ultrasonics\"[All Fields] OR \"ultrasounds\"[All Fields] OR \"ultrasound s\"[All Fields]) OR (\"present\"[All Fields] OR \"presentation\"[All Fields] OR \"presentations\"[All Fields] OR \"presented\"[All Fields] OR \"presenter\"[All Fields] OR \"presenter s\"[All Fields] OR \"presenters\"[All Fields] OR \"presenting\"[All Fields] OR \"presents\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Publication]", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "imaging", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28imaging+OR+MRI+OR+ultrasound+OR+presentation%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (imaging OR MRI OR ultrasound OR presentation)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "1", "retmax": "1", "retstart": "0", "idlist": [ "42951389" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "imaging", "to": "\"image's\"[All Fields] OR \"imaged\"[All Fields] OR \"imager\"[All Fields] OR \"imager's\"[All Fields] OR \"imagers\"[All Fields] OR \"images\"[All Fields] OR \"imaging\"[All Fields] OR \"imaging's\"[All Fields] OR \"imagings\"[All Fields] OR \"intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies\"[Supplementary Concept] OR \"intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies\"[All Fields] OR \"image\"[All Fields]" }, { "from": "MRI", "to": "\"magnetic resonance imaging\"[MeSH Terms] OR (\"magnetic\"[All Fields] AND \"resonance\"[All Fields] AND \"imaging\"[All Fields]) OR \"magnetic resonance imaging\"[All Fields] OR \"mri\"[All Fields]" }, { "from": "ultrasound", "to": "\"diagnostic imaging\"[Subheading] OR (\"diagnostic\"[All Fields] AND \"imaging\"[All Fields]) OR \"diagnostic imaging\"[All Fields] OR \"ultrasound\"[All Fields] OR \"ultrasonography\"[MeSH Terms] OR \"ultrasonography\"[All Fields] OR \"ultrasonics\"[MeSH Terms] OR \"ultrasonics\"[All Fields] OR \"ultrasounds\"[All Fields] OR \"ultrasound's\"[All Fields]" }, { "from": "presentation", "to": "\"present\"[All Fields] OR \"presentation\"[All Fields] OR \"presentations\"[All Fields] OR \"presented\"[All Fields] OR \"presenter\"[All Fields] OR \"presenter's\"[All Fields] OR \"presenters\"[All Fields] OR \"presenting\"[All Fields] OR \"presents\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"image s\"[All Fields] OR \"imaged\"[All Fields] OR \"imager\"[All Fields] OR \"imager s\"[All Fields] OR \"imagers\"[All Fields] OR \"images\"[All Fields] OR \"imaging\"[All Fields] OR \"imaging s\"[All Fields] OR \"imagings\"[All Fields] OR \"intrauterine growth retardation metaphyseal dysplasia adrenal hypoplasia congenita and genital anomalies\"[Supplementary Concept] OR \"intrauterine growth retardation metaphyseal dysplasia adrenal hypoplasia congenita and genital anomalies\"[All Fields] OR \"image\"[All Fields] OR (\"magnetic resonance imaging\"[MeSH Terms] OR (\"magnetic\"[All Fields] AND \"resonance\"[All Fields] AND \"imaging\"[All Fields]) OR \"magnetic resonance imaging\"[All Fields] OR \"mri\"[All Fields]) OR (\"diagnostic imaging\"[MeSH Subheading] OR (\"diagnostic\"[All Fields] AND \"imaging\"[All Fields]) OR \"diagnostic imaging\"[All Fields] OR \"ultrasound\"[All Fields] OR \"ultrasonography\"[MeSH Terms] OR \"ultrasonography\"[All Fields] OR \"ultrasonics\"[MeSH Terms] OR \"ultrasonics\"[All Fields] OR \"ultrasounds\"[All Fields] OR \"ultrasound s\"[All Fields]) OR (\"present\"[All Fields] OR \"presentation\"[All Fields] OR \"presentations\"[All Fields] OR \"presented\"[All Fields] OR \"presenter\"[All Fields] OR \"presenter s\"[All Fields] OR \"presenters\"[All Fields] OR \"presenting\"[All Fields] OR \"presents\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Entry]" } }, "topic": "imaging", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28surgery+OR+hysterectomy+OR+lymphadenectomy+OR+oophorectomy+OR+fertility+OR+morcellation%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (surgery OR hysterectomy OR lymphadenectomy OR oophorectomy OR fertility OR morcellation)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "1", "retmax": "1", "retstart": "0", "idlist": [ "42951232" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "surgery", "to": "\"surgery\"[Subheading] OR \"surgery\"[All Fields] OR \"surgical procedures, operative\"[MeSH Terms] OR (\"surgical\"[All Fields] AND \"procedures\"[All Fields] AND \"operative\"[All Fields]) OR \"operative surgical procedures\"[All Fields] OR \"general surgery\"[MeSH Terms] OR (\"general\"[All Fields] AND \"surgery\"[All Fields]) OR \"general surgery\"[All Fields] OR \"surgery's\"[All Fields] OR \"surgerys\"[All Fields] OR \"surgeries\"[All Fields]" }, { "from": "hysterectomy", "to": "\"hysterectomy\"[MeSH Terms] OR \"hysterectomy\"[All Fields] OR \"hysterectomies\"[All Fields]" }, { "from": "lymphadenectomy", "to": "\"lymph node excision\"[MeSH Terms] OR (\"lymph\"[All Fields] AND \"node\"[All Fields] AND \"excision\"[All Fields]) OR \"lymph node excision\"[All Fields] OR \"lymphadenectomies\"[All Fields] OR \"lymphadenectomy\"[All Fields]" }, { "from": "oophorectomy", "to": "\"ovariectomy\"[MeSH Terms] OR \"ovariectomy\"[All Fields] OR \"oophorectomies\"[All Fields] OR \"oophorectomy\"[All Fields]" }, { "from": "fertility", "to": "\"fertiles\"[All Fields] OR \"fertility\"[MeSH Terms] OR \"fertility\"[All Fields] OR \"fertile\"[All Fields] OR \"fertilities\"[All Fields]" }, { "from": "morcellation", "to": "\"morcellate\"[All Fields] OR \"morcellated\"[All Fields] OR \"morcellating\"[All Fields] OR \"morcellation\"[MeSH Terms] OR \"morcellation\"[All Fields] OR \"morcellator\"[All Fields] OR \"morcellators\"[All Fields] OR \"morcellement\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"surgery\"[MeSH Subheading] OR \"surgery\"[All Fields] OR \"surgical procedures, operative\"[MeSH Terms] OR (\"surgical\"[All Fields] AND \"procedures\"[All Fields] AND \"operative\"[All Fields]) OR \"operative surgical procedures\"[All Fields] OR \"general surgery\"[MeSH Terms] OR (\"general\"[All Fields] AND \"surgery\"[All Fields]) OR \"general surgery\"[All Fields] OR \"surgery s\"[All Fields] OR \"surgerys\"[All Fields] OR \"surgeries\"[All Fields] OR (\"hysterectomy\"[MeSH Terms] OR \"hysterectomy\"[All Fields] OR \"hysterectomies\"[All Fields]) OR (\"lymph node excision\"[MeSH Terms] OR (\"lymph\"[All Fields] AND \"node\"[All Fields] AND \"excision\"[All Fields]) OR \"lymph node excision\"[All Fields] OR \"lymphadenectomies\"[All Fields] OR \"lymphadenectomy\"[All Fields]) OR (\"ovariectomy\"[MeSH Terms] OR \"ovariectomy\"[All Fields] OR \"oophorectomies\"[All Fields] OR \"oophorectomy\"[All Fields]) OR (\"fertiles\"[All Fields] OR \"fertility\"[MeSH Terms] OR \"fertility\"[All Fields] OR \"fertile\"[All Fields] OR \"fertilities\"[All Fields]) OR (\"morcellate\"[All Fields] OR \"morcellated\"[All Fields] OR \"morcellating\"[All Fields] OR \"morcellation\"[MeSH Terms] OR \"morcellation\"[All Fields] OR \"morcellator\"[All Fields] OR \"morcellators\"[All Fields] OR \"morcellement\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Publication]" } }, "topic": "surgery_safety", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28surgery+OR+hysterectomy+OR+lymphadenectomy+OR+oophorectomy+OR+fertility+OR+morcellation%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (surgery OR hysterectomy OR lymphadenectomy OR oophorectomy OR fertility OR morcellation)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "1", "retmax": "1", "retstart": "0", "idlist": [ "42951232" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "surgery", "to": "\"surgery\"[Subheading] OR \"surgery\"[All Fields] OR \"surgical procedures, operative\"[MeSH Terms] OR (\"surgical\"[All Fields] AND \"procedures\"[All Fields] AND \"operative\"[All Fields]) OR \"operative surgical procedures\"[All Fields] OR \"general surgery\"[MeSH Terms] OR (\"general\"[All Fields] AND \"surgery\"[All Fields]) OR \"general surgery\"[All Fields] OR \"surgery's\"[All Fields] OR \"surgerys\"[All Fields] OR \"surgeries\"[All Fields]" }, { "from": "hysterectomy", "to": "\"hysterectomy\"[MeSH Terms] OR \"hysterectomy\"[All Fields] OR \"hysterectomies\"[All Fields]" }, { "from": "lymphadenectomy", "to": "\"lymph node excision\"[MeSH Terms] OR (\"lymph\"[All Fields] AND \"node\"[All Fields] AND \"excision\"[All Fields]) OR \"lymph node excision\"[All Fields] OR \"lymphadenectomies\"[All Fields] OR \"lymphadenectomy\"[All Fields]" }, { "from": "oophorectomy", "to": "\"ovariectomy\"[MeSH Terms] OR \"ovariectomy\"[All Fields] OR \"oophorectomies\"[All Fields] OR \"oophorectomy\"[All Fields]" }, { "from": "fertility", "to": "\"fertiles\"[All Fields] OR \"fertility\"[MeSH Terms] OR \"fertility\"[All Fields] OR \"fertile\"[All Fields] OR \"fertilities\"[All Fields]" }, { "from": "morcellation", "to": "\"morcellate\"[All Fields] OR \"morcellated\"[All Fields] OR \"morcellating\"[All Fields] OR \"morcellation\"[MeSH Terms] OR \"morcellation\"[All Fields] OR \"morcellator\"[All Fields] OR \"morcellators\"[All Fields] OR \"morcellement\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"surgery\"[MeSH Subheading] OR \"surgery\"[All Fields] OR \"surgical procedures, operative\"[MeSH Terms] OR (\"surgical\"[All Fields] AND \"procedures\"[All Fields] AND \"operative\"[All Fields]) OR \"operative surgical procedures\"[All Fields] OR \"general surgery\"[MeSH Terms] OR (\"general\"[All Fields] AND \"surgery\"[All Fields]) OR \"general surgery\"[All Fields] OR \"surgery s\"[All Fields] OR \"surgerys\"[All Fields] OR \"surgeries\"[All Fields] OR (\"hysterectomy\"[MeSH Terms] OR \"hysterectomy\"[All Fields] OR \"hysterectomies\"[All Fields]) OR (\"lymph node excision\"[MeSH Terms] OR (\"lymph\"[All Fields] AND \"node\"[All Fields] AND \"excision\"[All Fields]) OR \"lymph node excision\"[All Fields] OR \"lymphadenectomies\"[All Fields] OR \"lymphadenectomy\"[All Fields]) OR (\"ovariectomy\"[MeSH Terms] OR \"ovariectomy\"[All Fields] OR \"oophorectomies\"[All Fields] OR \"oophorectomy\"[All Fields]) OR (\"fertiles\"[All Fields] OR \"fertility\"[MeSH Terms] OR \"fertility\"[All Fields] OR \"fertile\"[All Fields] OR \"fertilities\"[All Fields]) OR (\"morcellate\"[All Fields] OR \"morcellated\"[All Fields] OR \"morcellating\"[All Fields] OR \"morcellation\"[MeSH Terms] OR \"morcellation\"[All Fields] OR \"morcellator\"[All Fields] OR \"morcellators\"[All Fields] OR \"morcellement\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Entry]" } }, "topic": "surgery_safety", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28chemotherapy+OR+radiotherapy+OR+hormonal+OR+adjuvant+OR+elacestrant+OR+fulvestrant+OR+trial%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (chemotherapy OR radiotherapy OR hormonal OR adjuvant OR elacestrant OR fulvestrant OR trial)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "chemotherapy", "to": "\"chemotherapy's\"[All Fields] OR \"drug therapy\"[MeSH Terms] OR (\"drug\"[All Fields] AND \"therapy\"[All Fields]) OR \"drug therapy\"[All Fields] OR \"chemotherapies\"[All Fields] OR \"drug therapy\"[Subheading] OR \"chemotherapy\"[All Fields]" }, { "from": "radiotherapy", "to": "\"radiotherapy\"[MeSH Terms] OR \"radiotherapy\"[All Fields] OR \"radiotherapies\"[All Fields] OR \"radiotherapy\"[Subheading] OR \"radiotherapy's\"[All Fields]" }, { "from": "hormonal", "to": "\"hormon\"[All Fields] OR \"hormonal\"[All Fields] OR \"hormonally\"[All Fields] OR \"hormonals\"[All Fields] OR \"hormone's\"[All Fields] OR \"hormones\"[Pharmacological Action] OR \"hormones\"[Supplementary Concept] OR \"hormones\"[All Fields] OR \"hormone\"[All Fields] OR \"hormones\"[MeSH Terms] OR \"hormons\"[All Fields]" }, { "from": "adjuvant", "to": "\"adjuvancy\"[All Fields] OR \"adjuvanted\"[All Fields] OR \"adjuvanting\"[All Fields] OR \"adjuvants\"[All Fields] OR \"adjuvants, pharmaceutic\"[Pharmacological Action] OR \"adjuvants, immunologic\"[Pharmacological Action] OR \"adjuvants, pharmaceutic\"[Supplementary Concept] OR \"adjuvants, pharmaceutic\"[All Fields] OR \"adjuvant\"[All Fields] OR \"adjuvants, immunologic\"[Supplementary Concept] OR \"adjuvants, immunologic\"[All Fields] OR \"adjuvants, pharmaceutic\"[MeSH Terms] OR (\"adjuvants\"[All Fields] AND \"pharmaceutic\"[All Fields]) OR \"pharmaceutic adjuvants\"[All Fields] OR \"adjuvants, immunologic\"[MeSH Terms] OR (\"adjuvants\"[All Fields] AND \"immunologic\"[All Fields]) OR \"immunologic adjuvants\"[All Fields] OR \"adjuvated\"[All Fields] OR \"adjuvation\"[All Fields] OR \"adjuvent\"[All Fields]" }, { "from": "elacestrant", "to": "\"elacestrant\"[Supplementary Concept] OR \"elacestrant\"[All Fields]" }, { "from": "fulvestrant", "to": "\"fulvestrant\"[Supplementary Concept] OR \"fulvestrant\"[All Fields] OR \"fulvestrant\"[MeSH Terms] OR \"fulvestrant's\"[All Fields]" }, { "from": "trial", "to": "\"clinical trials as topic\"[MeSH Terms] OR (\"clinical\"[All Fields] AND \"trials\"[All Fields] AND \"topic\"[All Fields]) OR \"clinical trials as topic\"[All Fields] OR \"trial\"[All Fields] OR \"trial's\"[All Fields] OR \"trialed\"[All Fields] OR \"trialing\"[All Fields] OR \"trials\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"chemotherapy s\"[All Fields] OR \"drug therapy\"[MeSH Terms] OR (\"drug\"[All Fields] AND \"therapy\"[All Fields]) OR \"drug therapy\"[All Fields] OR \"chemotherapies\"[All Fields] OR \"drug therapy\"[MeSH Subheading] OR \"chemotherapy\"[All Fields] OR (\"radiotherapy\"[MeSH Terms] OR \"radiotherapy\"[All Fields] OR \"radiotherapies\"[All Fields] OR \"radiotherapy\"[MeSH Subheading] OR \"radiotherapy s\"[All Fields]) OR (\"hormon\"[All Fields] OR \"hormonal\"[All Fields] OR \"hormonally\"[All Fields] OR \"hormonals\"[All Fields] OR \"hormone s\"[All Fields] OR \"hormones\"[Pharmacological Action] OR \"hormones\"[Supplementary Concept] OR \"hormones\"[All Fields] OR \"hormone\"[All Fields] OR \"hormones\"[MeSH Terms] OR \"hormons\"[All Fields]) OR (\"adjuvancy\"[All Fields] OR \"adjuvanted\"[All Fields] OR \"adjuvanting\"[All Fields] OR \"adjuvants\"[All Fields] OR \"adjuvants pharmaceutic\"[Pharmacological Action] OR \"adjuvants immunologic\"[Pharmacological Action] OR \"adjuvants pharmaceutic\"[Supplementary Concept] OR \"adjuvants pharmaceutic\"[All Fields] OR \"adjuvant\"[All Fields] OR \"adjuvants immunologic\"[Supplementary Concept] OR \"adjuvants immunologic\"[All Fields] OR \"adjuvants, pharmaceutic\"[MeSH Terms] OR (\"adjuvants\"[All Fields] AND \"pharmaceutic\"[All Fields]) OR \"pharmaceutic adjuvants\"[All Fields] OR \"adjuvants, immunologic\"[MeSH Terms] OR (\"adjuvants\"[All Fields] AND \"immunologic\"[All Fields]) OR \"immunologic adjuvants\"[All Fields] OR \"adjuvated\"[All Fields] OR \"adjuvation\"[All Fields] OR \"adjuvent\"[All Fields]) OR (\"elacestrant\"[Supplementary Concept] OR \"elacestrant\"[All Fields]) OR (\"fulvestrant\"[Supplementary Concept] OR \"fulvestrant\"[All Fields] OR \"fulvestrant\"[MeSH Terms]) OR (\"clinical trials as topic\"[MeSH Terms] OR (\"clinical\"[All Fields] AND \"trials\"[All Fields] AND \"topic\"[All Fields]) OR \"clinical trials as topic\"[All Fields] OR \"trial\"[All Fields] OR \"trial s\"[All Fields] OR \"trialed\"[All Fields] OR \"trialing\"[All Fields] OR \"trials\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Publication]", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "systemic_adjuvant", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28chemotherapy+OR+radiotherapy+OR+hormonal+OR+adjuvant+OR+elacestrant+OR+fulvestrant+OR+trial%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (chemotherapy OR radiotherapy OR hormonal OR adjuvant OR elacestrant OR fulvestrant OR trial)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "chemotherapy", "to": "\"chemotherapy's\"[All Fields] OR \"drug therapy\"[MeSH Terms] OR (\"drug\"[All Fields] AND \"therapy\"[All Fields]) OR \"drug therapy\"[All Fields] OR \"chemotherapies\"[All Fields] OR \"drug therapy\"[Subheading] OR \"chemotherapy\"[All Fields]" }, { "from": "radiotherapy", "to": "\"radiotherapy\"[MeSH Terms] OR \"radiotherapy\"[All Fields] OR \"radiotherapies\"[All Fields] OR \"radiotherapy\"[Subheading] OR \"radiotherapy's\"[All Fields]" }, { "from": "hormonal", "to": "\"hormon\"[All Fields] OR \"hormonal\"[All Fields] OR \"hormonally\"[All Fields] OR \"hormonals\"[All Fields] OR \"hormone's\"[All Fields] OR \"hormones\"[Pharmacological Action] OR \"hormones\"[Supplementary Concept] OR \"hormones\"[All Fields] OR \"hormone\"[All Fields] OR \"hormones\"[MeSH Terms] OR \"hormons\"[All Fields]" }, { "from": "adjuvant", "to": "\"adjuvancy\"[All Fields] OR \"adjuvanted\"[All Fields] OR \"adjuvanting\"[All Fields] OR \"adjuvants\"[All Fields] OR \"adjuvants, pharmaceutic\"[Pharmacological Action] OR \"adjuvants, immunologic\"[Pharmacological Action] OR \"adjuvants, pharmaceutic\"[Supplementary Concept] OR \"adjuvants, pharmaceutic\"[All Fields] OR \"adjuvant\"[All Fields] OR \"adjuvants, immunologic\"[Supplementary Concept] OR \"adjuvants, immunologic\"[All Fields] OR \"adjuvants, pharmaceutic\"[MeSH Terms] OR (\"adjuvants\"[All Fields] AND \"pharmaceutic\"[All Fields]) OR \"pharmaceutic adjuvants\"[All Fields] OR \"adjuvants, immunologic\"[MeSH Terms] OR (\"adjuvants\"[All Fields] AND \"immunologic\"[All Fields]) OR \"immunologic adjuvants\"[All Fields] OR \"adjuvated\"[All Fields] OR \"adjuvation\"[All Fields] OR \"adjuvent\"[All Fields]" }, { "from": "elacestrant", "to": "\"elacestrant\"[Supplementary Concept] OR \"elacestrant\"[All Fields]" }, { "from": "fulvestrant", "to": "\"fulvestrant\"[Supplementary Concept] OR \"fulvestrant\"[All Fields] OR \"fulvestrant\"[MeSH Terms] OR \"fulvestrant's\"[All Fields]" }, { "from": "trial", "to": "\"clinical trials as topic\"[MeSH Terms] OR (\"clinical\"[All Fields] AND \"trials\"[All Fields] AND \"topic\"[All Fields]) OR \"clinical trials as topic\"[All Fields] OR \"trial\"[All Fields] OR \"trial's\"[All Fields] OR \"trialed\"[All Fields] OR \"trialing\"[All Fields] OR \"trials\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"chemotherapy s\"[All Fields] OR \"drug therapy\"[MeSH Terms] OR (\"drug\"[All Fields] AND \"therapy\"[All Fields]) OR \"drug therapy\"[All Fields] OR \"chemotherapies\"[All Fields] OR \"drug therapy\"[MeSH Subheading] OR \"chemotherapy\"[All Fields] OR (\"radiotherapy\"[MeSH Terms] OR \"radiotherapy\"[All Fields] OR \"radiotherapies\"[All Fields] OR \"radiotherapy\"[MeSH Subheading] OR \"radiotherapy s\"[All Fields]) OR (\"hormon\"[All Fields] OR \"hormonal\"[All Fields] OR \"hormonally\"[All Fields] OR \"hormonals\"[All Fields] OR \"hormone s\"[All Fields] OR \"hormones\"[Pharmacological Action] OR \"hormones\"[Supplementary Concept] OR \"hormones\"[All Fields] OR \"hormone\"[All Fields] OR \"hormones\"[MeSH Terms] OR \"hormons\"[All Fields]) OR (\"adjuvancy\"[All Fields] OR \"adjuvanted\"[All Fields] OR \"adjuvanting\"[All Fields] OR \"adjuvants\"[All Fields] OR \"adjuvants pharmaceutic\"[Pharmacological Action] OR \"adjuvants immunologic\"[Pharmacological Action] OR \"adjuvants pharmaceutic\"[Supplementary Concept] OR \"adjuvants pharmaceutic\"[All Fields] OR \"adjuvant\"[All Fields] OR \"adjuvants immunologic\"[Supplementary Concept] OR \"adjuvants immunologic\"[All Fields] OR \"adjuvants, pharmaceutic\"[MeSH Terms] OR (\"adjuvants\"[All Fields] AND \"pharmaceutic\"[All Fields]) OR \"pharmaceutic adjuvants\"[All Fields] OR \"adjuvants, immunologic\"[MeSH Terms] OR (\"adjuvants\"[All Fields] AND \"immunologic\"[All Fields]) OR \"immunologic adjuvants\"[All Fields] OR \"adjuvated\"[All Fields] OR \"adjuvation\"[All Fields] OR \"adjuvent\"[All Fields]) OR (\"elacestrant\"[Supplementary Concept] OR \"elacestrant\"[All Fields]) OR (\"fulvestrant\"[Supplementary Concept] OR \"fulvestrant\"[All Fields] OR \"fulvestrant\"[MeSH Terms]) OR (\"clinical trials as topic\"[MeSH Terms] OR (\"clinical\"[All Fields] AND \"trials\"[All Fields] AND \"topic\"[All Fields]) OR \"clinical trials as topic\"[All Fields] OR \"trial\"[All Fields] OR \"trial s\"[All Fields] OR \"trialed\"[All Fields] OR \"trialing\"[All Fields] OR \"trials\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Entry]", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "systemic_adjuvant", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28recurrence+OR+surveillance+OR+follow-up%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (recurrence OR surveillance OR follow-up)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "1", "retmax": "1", "retstart": "0", "idlist": [ "42951232" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "recurrence", "to": "\"recurrance\"[All Fields] OR \"recurrence\"[MeSH Terms] OR \"recurrence\"[All Fields] OR \"recurrences\"[All Fields] OR \"recurrencies\"[All Fields] OR \"recurrency\"[All Fields] OR \"recurrent\"[All Fields] OR \"recurrently\"[All Fields] OR \"recurrents\"[All Fields]" }, { "from": "surveillance", "to": "\"epidemiology\"[Subheading] OR \"epidemiology\"[All Fields] OR \"surveillance\"[All Fields] OR \"epidemiology\"[MeSH Terms] OR \"surveilance\"[All Fields] OR \"surveillances\"[All Fields] OR \"surveilled\"[All Fields] OR \"surveillence\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"recurrance\"[All Fields] OR \"recurrence\"[MeSH Terms] OR \"recurrence\"[All Fields] OR \"recurrences\"[All Fields] OR \"recurrencies\"[All Fields] OR \"recurrency\"[All Fields] OR \"recurrent\"[All Fields] OR \"recurrently\"[All Fields] OR \"recurrents\"[All Fields] OR (\"epidemiology\"[MeSH Subheading] OR \"epidemiology\"[All Fields] OR \"surveillance\"[All Fields] OR \"epidemiology\"[MeSH Terms] OR \"surveilance\"[All Fields] OR \"surveillances\"[All Fields] OR \"surveilled\"[All Fields] OR \"surveillence\"[All Fields]) OR \"follow-up\"[All Fields]) AND 2026/10/24:2026/10/31[Date - Publication]" } }, "topic": "recurrence_surveillance", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=adenosarcoma+AND+%28recurrence+OR+surveillance+OR+follow-up%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "adenosarcoma AND (recurrence OR surveillance OR follow-up)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "1", "retmax": "1", "retstart": "0", "idlist": [ "42951232" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "recurrence", "to": "\"recurrance\"[All Fields] OR \"recurrence\"[MeSH Terms] OR \"recurrence\"[All Fields] OR \"recurrences\"[All Fields] OR \"recurrencies\"[All Fields] OR \"recurrency\"[All Fields] OR \"recurrent\"[All Fields] OR \"recurrently\"[All Fields] OR \"recurrents\"[All Fields]" }, { "from": "surveillance", "to": "\"epidemiology\"[Subheading] OR \"epidemiology\"[All Fields] OR \"surveillance\"[All Fields] OR \"epidemiology\"[MeSH Terms] OR \"surveilance\"[All Fields] OR \"surveillances\"[All Fields] OR \"surveilled\"[All Fields] OR \"surveillence\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"recurrance\"[All Fields] OR \"recurrence\"[MeSH Terms] OR \"recurrence\"[All Fields] OR \"recurrences\"[All Fields] OR \"recurrencies\"[All Fields] OR \"recurrency\"[All Fields] OR \"recurrent\"[All Fields] OR \"recurrently\"[All Fields] OR \"recurrents\"[All Fields] OR (\"epidemiology\"[MeSH Subheading] OR \"epidemiology\"[All Fields] OR \"surveillance\"[All Fields] OR \"epidemiology\"[MeSH Terms] OR \"surveilance\"[All Fields] OR \"surveillances\"[All Fields] OR \"surveilled\"[All Fields] OR \"surveillence\"[All Fields]) OR \"follow-up\"[All Fields]) AND 2026/10/24:2026/10/31[Date - Entry]" } }, "topic": "recurrence_surveillance", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%28adenosarcoma+OR+uterine+sarcoma%29+AND+%28guideline+OR+consensus+OR+ESGO+OR+GCIG+OR+NCCN+OR+ESMO+OR+FIGO%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "(adenosarcoma OR uterine sarcoma) AND (guideline OR consensus OR ESGO OR GCIG OR NCCN OR ESMO OR FIGO)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "uterine", "to": "\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]" }, { "from": "sarcoma", "to": "\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma's\"[All Fields]" }, { "from": "guideline", "to": "\"guideline\"[Publication Type] OR \"guidelines as topic\"[MeSH Terms] OR \"guideline\"[All Fields]" }, { "from": "consensus", "to": "\"consensual\"[All Fields] OR \"consensually\"[All Fields] OR \"consensus\"[MeSH Terms] OR \"consensus\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields] OR ((\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]) AND (\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma s\"[All Fields]))) AND (\"guideline\"[Publication Type] OR \"guidelines as topic\"[MeSH Terms] OR \"guideline\"[All Fields] OR (\"consensual\"[All Fields] OR \"consensually\"[All Fields] OR \"consensus\"[MeSH Terms] OR \"consensus\"[All Fields]) OR \"ESGO\"[All Fields] OR \"GCIG\"[All Fields] OR \"NCCN\"[All Fields] OR \"ESMO\"[All Fields] OR \"FIGO\"[All Fields]) AND 2026/10/24:2026/10/31[Date - Publication]", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "guidelines", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%28adenosarcoma+OR+uterine+sarcoma%29+AND+%28guideline+OR+consensus+OR+ESGO+OR+GCIG+OR+NCCN+OR+ESMO+OR+FIGO%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "(adenosarcoma OR uterine sarcoma) AND (guideline OR consensus OR ESGO OR GCIG OR NCCN OR ESMO OR FIGO)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "uterine", "to": "\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]" }, { "from": "sarcoma", "to": "\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma's\"[All Fields]" }, { "from": "guideline", "to": "\"guideline\"[Publication Type] OR \"guidelines as topic\"[MeSH Terms] OR \"guideline\"[All Fields]" }, { "from": "consensus", "to": "\"consensual\"[All Fields] OR \"consensually\"[All Fields] OR \"consensus\"[MeSH Terms] OR \"consensus\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields] OR ((\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]) AND (\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma s\"[All Fields]))) AND (\"guideline\"[Publication Type] OR \"guidelines as topic\"[MeSH Terms] OR \"guideline\"[All Fields] OR (\"consensual\"[All Fields] OR \"consensually\"[All Fields] OR \"consensus\"[MeSH Terms] OR \"consensus\"[All Fields]) OR \"ESGO\"[All Fields] OR \"GCIG\"[All Fields] OR \"NCCN\"[All Fields] OR \"ESMO\"[All Fields] OR \"FIGO\"[All Fields]) AND 2026/10/24:2026/10/31[Date - Entry]", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "guidelines", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%28adenosarcoma+OR+uterine+sarcoma%29+AND+%28quality+of+life+OR+patient+reported+OR+qualitative+OR+experience+OR+advocacy%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "(adenosarcoma OR uterine sarcoma) AND (quality of life OR patient reported OR qualitative OR experience OR advocacy)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "uterine", "to": "\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]" }, { "from": "sarcoma", "to": "\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma's\"[All Fields]" }, { "from": "quality of life", "to": "\"quality of life\"[MeSH Terms] OR (\"quality\"[All Fields] AND \"life\"[All Fields]) OR \"quality of life\"[All Fields]" }, { "from": "patient", "to": "\"patient's\"[All Fields] OR \"patients\"[MeSH Terms] OR \"patients\"[All Fields] OR \"patient\"[All Fields] OR \"patients's\"[All Fields]" }, { "from": "reported", "to": "\"reportable\"[All Fields] OR \"reporting\"[All Fields] OR \"reportings\"[All Fields] OR \"research report\"[MeSH Terms] OR (\"research\"[All Fields] AND \"report\"[All Fields]) OR \"research report\"[All Fields] OR \"report\"[All Fields] OR \"reported\"[All Fields] OR \"reports\"[All Fields]" }, { "from": "qualitative", "to": "\"qualitative\"[All Fields] OR \"qualitatively\"[All Fields] OR \"qualitatives\"[All Fields]" }, { "from": "experience", "to": "\"experience\"[All Fields] OR \"experience's\"[All Fields] OR \"experiences\"[All Fields]" }, { "from": "advocacy", "to": "\"advocacies\"[All Fields] OR \"advocacy\"[All Fields] OR \"advocacy's\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields] OR ((\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]) AND (\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma s\"[All Fields]))) AND (\"quality of life\"[MeSH Terms] OR (\"quality\"[All Fields] AND \"life\"[All Fields]) OR \"quality of life\"[All Fields] OR ((\"patient s\"[All Fields] OR \"patients\"[MeSH Terms] OR \"patients\"[All Fields] OR \"patient\"[All Fields] OR \"patients s\"[All Fields]) AND (\"reportable\"[All Fields] OR \"reporting\"[All Fields] OR \"reportings\"[All Fields] OR \"research report\"[MeSH Terms] OR (\"research\"[All Fields] AND \"report\"[All Fields]) OR \"research report\"[All Fields] OR \"report\"[All Fields] OR \"reported\"[All Fields] OR \"reports\"[All Fields])) OR (\"qualitative\"[All Fields] OR \"qualitatively\"[All Fields] OR \"qualitatives\"[All Fields]) OR (\"experience\"[All Fields] OR \"experience s\"[All Fields] OR \"experiences\"[All Fields]) OR (\"advocacies\"[All Fields] OR \"advocacy\"[All Fields] OR \"advocacy s\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Publication]", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "patient_experience", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%28adenosarcoma+OR+uterine+sarcoma%29+AND+%28quality+of+life+OR+patient+reported+OR+qualitative+OR+experience+OR+advocacy%29&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "(adenosarcoma OR uterine sarcoma) AND (quality of life OR patient reported OR qualitative OR experience OR advocacy)", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "1", "retmax": "1", "retstart": "0", "idlist": [ "42957266" ], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "uterine", "to": "\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]" }, { "from": "sarcoma", "to": "\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma's\"[All Fields]" }, { "from": "quality of life", "to": "\"quality of life\"[MeSH Terms] OR (\"quality\"[All Fields] AND \"life\"[All Fields]) OR \"quality of life\"[All Fields]" }, { "from": "patient", "to": "\"patient's\"[All Fields] OR \"patients\"[MeSH Terms] OR \"patients\"[All Fields] OR \"patient\"[All Fields] OR \"patients's\"[All Fields]" }, { "from": "reported", "to": "\"reportable\"[All Fields] OR \"reporting\"[All Fields] OR \"reportings\"[All Fields] OR \"research report\"[MeSH Terms] OR (\"research\"[All Fields] AND \"report\"[All Fields]) OR \"research report\"[All Fields] OR \"report\"[All Fields] OR \"reported\"[All Fields] OR \"reports\"[All Fields]" }, { "from": "qualitative", "to": "\"qualitative\"[All Fields] OR \"qualitatively\"[All Fields] OR \"qualitatives\"[All Fields]" }, { "from": "experience", "to": "\"experience\"[All Fields] OR \"experience's\"[All Fields] OR \"experiences\"[All Fields]" }, { "from": "advocacy", "to": "\"advocacies\"[All Fields] OR \"advocacy\"[All Fields] OR \"advocacy's\"[All Fields]" } ], "querytranslation": "(\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields] OR ((\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]) AND (\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma s\"[All Fields]))) AND (\"quality of life\"[MeSH Terms] OR (\"quality\"[All Fields] AND \"life\"[All Fields]) OR \"quality of life\"[All Fields] OR ((\"patient s\"[All Fields] OR \"patients\"[MeSH Terms] OR \"patients\"[All Fields] OR \"patient\"[All Fields] OR \"patients s\"[All Fields]) AND (\"reportable\"[All Fields] OR \"reporting\"[All Fields] OR \"reportings\"[All Fields] OR \"research report\"[MeSH Terms] OR (\"research\"[All Fields] AND \"report\"[All Fields]) OR \"research report\"[All Fields] OR \"report\"[All Fields] OR \"reported\"[All Fields] OR \"reports\"[All Fields])) OR (\"qualitative\"[All Fields] OR \"qualitatively\"[All Fields] OR \"qualitatives\"[All Fields]) OR (\"experience\"[All Fields] OR \"experience s\"[All Fields] OR \"experiences\"[All Fields]) OR (\"advocacies\"[All Fields] OR \"advocacy\"[All Fields] OR \"advocacy s\"[All Fields])) AND 2026/10/24:2026/10/31[Date - Entry]" } }, "topic": "patient_experience", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=uterine+sarcoma+OR+uterine+sarcomas&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=pdat", "http_status": 200, "params": { "db": "pubmed", "term": "uterine sarcoma OR uterine sarcomas", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "pdat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "2", "retmax": "2", "retstart": "0", "idlist": [ "42952303", "42951232" ], "translationset": [ { "from": "uterine", "to": "\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]" }, { "from": "sarcoma", "to": "\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma's\"[All Fields]" }, { "from": "sarcomas", "to": "\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma's\"[All Fields]" } ], "querytranslation": "(((\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]) AND (\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma s\"[All Fields])) OR ((\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]) AND (\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma s\"[All Fields]))) AND 2026/10/24:2026/10/31[Date - Publication]" } }, "topic": "uterine_sarcoma_broad", "datetype": "pdat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=uterine+sarcoma+OR+uterine+sarcomas&retmode=json&retmax=500&mindate=2026%2F10%2F24&maxdate=2026%2F10%2F31&datetype=edat", "http_status": 200, "params": { "db": "pubmed", "term": "uterine sarcoma OR uterine sarcomas", "retmode": "json", "retmax": "500", "mindate": "2026/10/24", "maxdate": "2026/10/31", "datetype": "edat" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "11", "retmax": "11", "retstart": "0", "idlist": [ "42957266", "42955969", "42952303", "42951390", "42951389", "42951388", "42951232", "42949538", "42948072", "42942324", "42939826" ], "translationset": [ { "from": "uterine", "to": "\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]" }, { "from": "sarcoma", "to": "\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma's\"[All Fields]" }, { "from": "sarcomas", "to": "\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma's\"[All Fields]" } ], "querytranslation": "(((\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]) AND (\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma s\"[All Fields])) OR ((\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]) AND (\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma s\"[All Fields]))) AND 2026/10/24:2026/10/31[Date - Entry]" } }, "topic": "uterine_sarcoma_broad", "datetype": "edat" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=uterine+adenosarcoma&retmode=json&retmax=20", "http_status": 200, "params": { "db": "pubmed", "term": "uterine adenosarcoma", "retmode": "json", "retmax": "20" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "263", "retmax": "20", "retstart": "0", "idlist": [ "42951389", "42862247", "42794871", "42746333", "42706489", "42564070", "42555852", "42495161", "42352405", "42334466", "42223588", "41932512", "41624694", "41555057", "41474243", "41161694", "40985083", "40941652", "40921671", "40906397" ], "translationset": [ { "from": "uterine adenosarcoma", "to": "\"adenosarcoma of the uterus\"[Supplementary Concept] OR \"adenosarcoma of the uterus\"[All Fields] OR \"uterine adenosarcoma\"[All Fields]" } ], "querytranslation": "\"adenosarcoma of the uterus\"[Supplementary Concept] OR \"adenosarcoma of the uterus\"[All Fields] OR \"uterine adenosarcoma\"[All Fields]" } }, "topic": "all_time_count" } ], "cochrane_pubmed": [ { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+%28adenosarcoma%29+AND+%282026%2F10%2F24%3A2026%2F10%2F31%5Bdp%5D+OR+2026%2F10%2F24%3A2026%2F10%2F31%5Bedat%5D%29&retmode=json&retmax=50", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND (adenosarcoma) AND (2026/10/24:2026/10/31[dp] OR 2026/10/24:2026/10/31[edat])", "retmode": "json", "retmax": "50" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND (\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (2026/10/24:2026/10/31[Date - Publication] OR 2026/10/24:2026/10/31[Date - Entry])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_all" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+%28adenosarcoma+AND+%28pathology+OR+diagnosis+OR+polyp+OR+adenofibroma%29%29+AND+%282026%2F10%2F24%3A2026%2F10%2F31%5Bdp%5D+OR+2026%2F10%2F24%3A2026%2F10%2F31%5Bedat%5D%29&retmode=json&retmax=50", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND (adenosarcoma AND (pathology OR diagnosis OR polyp OR adenofibroma)) AND (2026/10/24:2026/10/31[dp] OR 2026/10/24:2026/10/31[edat])", "retmode": "json", "retmax": "50" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "pathology", "to": "\"pathology\"[MeSH Terms] OR \"pathology\"[All Fields] OR \"pathologies\"[All Fields] OR \"pathology\"[Subheading]" }, { "from": "diagnosis", "to": "\"diagnosable\"[All Fields] OR \"diagnosi\"[All Fields] OR \"diagnosis\"[MeSH Terms] OR \"diagnosis\"[All Fields] OR \"diagnose\"[All Fields] OR \"diagnosed\"[All Fields] OR \"diagnoses\"[All Fields] OR \"diagnosing\"[All Fields] OR \"diagnosis\"[Subheading]" }, { "from": "polyp", "to": "\"polyp's\"[All Fields] OR \"polypous\"[All Fields] OR \"polyps\"[MeSH Terms] OR \"polyps\"[All Fields] OR \"polyp\"[All Fields]" }, { "from": "adenofibroma", "to": "\"adenofibroma\"[MeSH Terms] OR \"adenofibroma\"[All Fields] OR \"adenofibromas\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND ((\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"pathology\"[MeSH Terms] OR \"pathology\"[All Fields] OR \"pathologies\"[All Fields] OR \"pathology\"[MeSH Subheading] OR (\"diagnosable\"[All Fields] OR \"diagnosi\"[All Fields] OR \"diagnosis\"[MeSH Terms] OR \"diagnosis\"[All Fields] OR \"diagnose\"[All Fields] OR \"diagnosed\"[All Fields] OR \"diagnoses\"[All Fields] OR \"diagnosing\"[All Fields] OR \"diagnosis\"[MeSH Subheading]) OR (\"polyp s\"[All Fields] OR \"polypous\"[All Fields] OR \"polyps\"[MeSH Terms] OR \"polyps\"[All Fields] OR \"polyp\"[All Fields]) OR (\"adenofibroma\"[MeSH Terms] OR \"adenofibroma\"[All Fields] OR \"adenofibromas\"[All Fields]))) AND (2026/10/24:2026/10/31[Date - Publication] OR 2026/10/24:2026/10/31[Date - Entry])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_pathology" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+%28adenosarcoma+AND+%28sarcomatous+overgrowth+OR+stage+OR+prognosis+OR+survival+OR+LVSI%29%29+AND+%282026%2F10%2F24%3A2026%2F10%2F31%5Bdp%5D+OR+2026%2F10%2F24%3A2026%2F10%2F31%5Bedat%5D%29&retmode=json&retmax=50", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND (adenosarcoma AND (sarcomatous overgrowth OR stage OR prognosis OR survival OR LVSI)) AND (2026/10/24:2026/10/31[dp] OR 2026/10/24:2026/10/31[edat])", "retmode": "json", "retmax": "50" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "overgrowth", "to": "\"overgrowth\"[All Fields] OR \"overgrowths\"[All Fields]" }, { "from": "stage", "to": "\"stage\"[All Fields] OR \"staged\"[All Fields] OR \"stages\"[All Fields] OR \"staging\"[All Fields] OR \"stagings\"[All Fields]" }, { "from": "prognosis", "to": "\"prognosis\"[MeSH Terms] OR \"prognosis\"[All Fields] OR \"prognoses\"[All Fields]" }, { "from": "survival", "to": "\"mortality\"[Subheading] OR \"mortality\"[All Fields] OR \"survival\"[All Fields] OR \"survival\"[MeSH Terms] OR \"survivability\"[All Fields] OR \"survivable\"[All Fields] OR \"survivals\"[All Fields] OR \"survive\"[All Fields] OR \"survived\"[All Fields] OR \"survives\"[All Fields] OR \"surviving\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND ((\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND ((\"sarcomatous\"[All Fields] AND (\"overgrowth\"[All Fields] OR \"overgrowths\"[All Fields])) OR (\"stage\"[All Fields] OR \"staged\"[All Fields] OR \"stages\"[All Fields] OR \"staging\"[All Fields] OR \"stagings\"[All Fields]) OR (\"prognosis\"[MeSH Terms] OR \"prognosis\"[All Fields] OR \"prognoses\"[All Fields]) OR (\"mortality\"[MeSH Subheading] OR \"mortality\"[All Fields] OR \"survival\"[All Fields] OR \"survival\"[MeSH Terms] OR \"survivability\"[All Fields] OR \"survivable\"[All Fields] OR \"survivals\"[All Fields] OR \"survive\"[All Fields] OR \"survived\"[All Fields] OR \"survives\"[All Fields] OR \"surviving\"[All Fields]) OR \"LVSI\"[All Fields])) AND (2026/10/24:2026/10/31[Date - Publication] OR 2026/10/24:2026/10/31[Date - Entry])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_overgrowth_prognosis" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+%28adenosarcoma+AND+%28molecular+OR+genomic+OR+MDM2+OR+CDK4+OR+DICER1+OR+BAP1+OR+TP53+OR+SMARCA4+OR+BRG1+OR+fusion%29%29+AND+%282026%2F10%2F24%3A2026%2F10%2F31%5Bdp%5D+OR+2026%2F10%2F24%3A2026%2F10%2F31%5Bedat%5D%29&retmode=json&retmax=50", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND (adenosarcoma AND (molecular OR genomic OR MDM2 OR CDK4 OR DICER1 OR BAP1 OR TP53 OR SMARCA4 OR BRG1 OR fusion)) AND (2026/10/24:2026/10/31[dp] OR 2026/10/24:2026/10/31[edat])", "retmode": "json", "retmax": "50" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "molecular", "to": "\"molecular\"[All Fields] OR \"moleculars\"[All Fields]" }, { "from": "genomic", "to": "\"genome\"[MeSH Terms] OR \"genome\"[All Fields] OR \"genomes\"[All Fields] OR \"genome's\"[All Fields] OR \"genomically\"[All Fields] OR \"genomics\"[MeSH Terms] OR \"genomics\"[All Fields] OR \"genomic\"[All Fields]" }, { "from": "DICER1", "to": "\"dicer1 protein, human\"[Supplementary Concept] OR \"dicer1 protein, human\"[All Fields] OR \"dicer1\"[All Fields]" }, { "from": "BAP1", "to": "\"bap1 protein, human\"[Supplementary Concept] OR \"bap1 protein, human\"[All Fields] OR \"bap1\"[All Fields]" }, { "from": "TP53", "to": "\"tp53 protein, human\"[Supplementary Concept] OR \"tp53 protein, human\"[All Fields] OR \"tp53\"[All Fields]" }, { "from": "SMARCA4", "to": "\"smarca4 protein, human\"[Supplementary Concept] OR \"smarca4 protein, human\"[All Fields] OR \"smarca4\"[All Fields]" }, { "from": "fusion", "to": "\"fusion\"[All Fields] OR \"fusions\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND ((\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"molecular\"[All Fields] OR \"moleculars\"[All Fields] OR (\"genome\"[MeSH Terms] OR \"genome\"[All Fields] OR \"genomes\"[All Fields] OR \"genome s\"[All Fields] OR \"genomically\"[All Fields] OR \"genomics\"[MeSH Terms] OR \"genomics\"[All Fields] OR \"genomic\"[All Fields]) OR \"MDM2\"[All Fields] OR \"CDK4\"[All Fields] OR (\"dicer1 protein human\"[Supplementary Concept] OR \"dicer1 protein human\"[All Fields] OR \"dicer1\"[All Fields]) OR (\"bap1 protein human\"[Supplementary Concept] OR \"bap1 protein human\"[All Fields] OR \"bap1\"[All Fields]) OR (\"tp53 protein human\"[Supplementary Concept] OR \"tp53 protein human\"[All Fields] OR \"tp53\"[All Fields]) OR (\"smarca4 protein human\"[Supplementary Concept] OR \"smarca4 protein human\"[All Fields] OR \"smarca4\"[All Fields]) OR \"BRG1\"[All Fields] OR (\"fusion\"[All Fields] OR \"fusions\"[All Fields]))) AND (2026/10/24:2026/10/31[Date - Publication] OR 2026/10/24:2026/10/31[Date - Entry])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_molecular" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+%28adenosarcoma+AND+%28epidemiology+OR+incidence+OR+registry+OR+SEER+OR+NCDB+OR+population+OR+burden%29%29+AND+%282026%2F10%2F24%3A2026%2F10%2F31%5Bdp%5D+OR+2026%2F10%2F24%3A2026%2F10%2F31%5Bedat%5D%29&retmode=json&retmax=50", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND (adenosarcoma AND (epidemiology OR incidence OR registry OR SEER OR NCDB OR population OR burden)) AND (2026/10/24:2026/10/31[dp] OR 2026/10/24:2026/10/31[edat])", "retmode": "json", "retmax": "50" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "epidemiology", "to": "\"epidemiologies\"[All Fields] OR \"epidemiology\"[Subheading] OR \"epidemiology\"[All Fields] OR \"epidemiology\"[MeSH Terms] OR \"epidemiology's\"[All Fields]" }, { "from": "incidence", "to": "\"epidemiology\"[Subheading] OR \"epidemiology\"[All Fields] OR \"incidence\"[All Fields] OR \"incidence\"[MeSH Terms] OR \"incidences\"[All Fields] OR \"incident\"[All Fields] OR \"incidents\"[All Fields]" }, { "from": "registry", "to": "\"registries\"[MeSH Terms] OR \"registries\"[All Fields] OR \"registry\"[All Fields] OR \"registry's\"[All Fields]" }, { "from": "population", "to": "\"populate\"[All Fields] OR \"populated\"[All Fields] OR \"populates\"[All Fields] OR \"populating\"[All Fields] OR \"population\"[MeSH Terms] OR \"population\"[All Fields] OR \"population groups\"[MeSH Terms] OR (\"population\"[All Fields] AND \"groups\"[All Fields]) OR \"population groups\"[All Fields] OR \"populations\"[All Fields] OR \"population's\"[All Fields] OR \"populational\"[All Fields] OR \"populations's\"[All Fields] OR \"populous\"[All Fields]" }, { "from": "burden", "to": "\"burden\"[All Fields] OR \"burdened\"[All Fields] OR \"burdening\"[All Fields] OR \"burdens\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND ((\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"epidemiologies\"[All Fields] OR \"epidemiology\"[MeSH Subheading] OR \"epidemiology\"[All Fields] OR \"epidemiology\"[MeSH Terms] OR \"epidemiology s\"[All Fields] OR (\"epidemiology\"[MeSH Subheading] OR \"epidemiology\"[All Fields] OR \"incidence\"[All Fields] OR \"incidence\"[MeSH Terms] OR \"incidences\"[All Fields] OR \"incident\"[All Fields] OR \"incidents\"[All Fields]) OR (\"registries\"[MeSH Terms] OR \"registries\"[All Fields] OR \"registry\"[All Fields] OR \"registry s\"[All Fields]) OR \"SEER\"[All Fields] OR \"NCDB\"[All Fields] OR (\"populate\"[All Fields] OR \"populated\"[All Fields] OR \"populates\"[All Fields] OR \"populating\"[All Fields] OR \"population\"[MeSH Terms] OR \"population\"[All Fields] OR \"population groups\"[MeSH Terms] OR (\"population\"[All Fields] AND \"groups\"[All Fields]) OR \"population groups\"[All Fields] OR \"populations\"[All Fields] OR \"population s\"[All Fields] OR \"populational\"[All Fields] OR \"populous\"[All Fields]) OR (\"burden\"[All Fields] OR \"burdened\"[All Fields] OR \"burdening\"[All Fields] OR \"burdens\"[All Fields]))) AND (2026/10/24:2026/10/31[Date - Publication] OR 2026/10/24:2026/10/31[Date - Entry])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_epidemiology" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+%28adenosarcoma+AND+%28imaging+OR+MRI+OR+ultrasound+OR+presentation%29%29+AND+%282026%2F10%2F24%3A2026%2F10%2F31%5Bdp%5D+OR+2026%2F10%2F24%3A2026%2F10%2F31%5Bedat%5D%29&retmode=json&retmax=50", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND (adenosarcoma AND (imaging OR MRI OR ultrasound OR presentation)) AND (2026/10/24:2026/10/31[dp] OR 2026/10/24:2026/10/31[edat])", "retmode": "json", "retmax": "50" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "imaging", "to": "\"image's\"[All Fields] OR \"imaged\"[All Fields] OR \"imager\"[All Fields] OR \"imager's\"[All Fields] OR \"imagers\"[All Fields] OR \"images\"[All Fields] OR \"imaging\"[All Fields] OR \"imaging's\"[All Fields] OR \"imagings\"[All Fields] OR \"intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies\"[Supplementary Concept] OR \"intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies\"[All Fields] OR \"image\"[All Fields]" }, { "from": "MRI", "to": "\"magnetic resonance imaging\"[MeSH Terms] OR (\"magnetic\"[All Fields] AND \"resonance\"[All Fields] AND \"imaging\"[All Fields]) OR \"magnetic resonance imaging\"[All Fields] OR \"mri\"[All Fields]" }, { "from": "ultrasound", "to": "\"diagnostic imaging\"[Subheading] OR (\"diagnostic\"[All Fields] AND \"imaging\"[All Fields]) OR \"diagnostic imaging\"[All Fields] OR \"ultrasound\"[All Fields] OR \"ultrasonography\"[MeSH Terms] OR \"ultrasonography\"[All Fields] OR \"ultrasonics\"[MeSH Terms] OR \"ultrasonics\"[All Fields] OR \"ultrasounds\"[All Fields] OR \"ultrasound's\"[All Fields]" }, { "from": "presentation", "to": "\"present\"[All Fields] OR \"presentation\"[All Fields] OR \"presentations\"[All Fields] OR \"presented\"[All Fields] OR \"presenter\"[All Fields] OR \"presenter's\"[All Fields] OR \"presenters\"[All Fields] OR \"presenting\"[All Fields] OR \"presents\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND ((\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"image s\"[All Fields] OR \"imaged\"[All Fields] OR \"imager\"[All Fields] OR \"imager s\"[All Fields] OR \"imagers\"[All Fields] OR \"images\"[All Fields] OR \"imaging\"[All Fields] OR \"imaging s\"[All Fields] OR \"imagings\"[All Fields] OR \"intrauterine growth retardation metaphyseal dysplasia adrenal hypoplasia congenita and genital anomalies\"[Supplementary Concept] OR \"intrauterine growth retardation metaphyseal dysplasia adrenal hypoplasia congenita and genital anomalies\"[All Fields] OR \"image\"[All Fields] OR (\"magnetic resonance imaging\"[MeSH Terms] OR (\"magnetic\"[All Fields] AND \"resonance\"[All Fields] AND \"imaging\"[All Fields]) OR \"magnetic resonance imaging\"[All Fields] OR \"mri\"[All Fields]) OR (\"diagnostic imaging\"[MeSH Subheading] OR (\"diagnostic\"[All Fields] AND \"imaging\"[All Fields]) OR \"diagnostic imaging\"[All Fields] OR \"ultrasound\"[All Fields] OR \"ultrasonography\"[MeSH Terms] OR \"ultrasonography\"[All Fields] OR \"ultrasonics\"[MeSH Terms] OR \"ultrasonics\"[All Fields] OR \"ultrasounds\"[All Fields] OR \"ultrasound s\"[All Fields]) OR (\"present\"[All Fields] OR \"presentation\"[All Fields] OR \"presentations\"[All Fields] OR \"presented\"[All Fields] OR \"presenter\"[All Fields] OR \"presenter s\"[All Fields] OR \"presenters\"[All Fields] OR \"presenting\"[All Fields] OR \"presents\"[All Fields]))) AND (2026/10/24:2026/10/31[Date - Publication] OR 2026/10/24:2026/10/31[Date - Entry])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_imaging" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+%28adenosarcoma+AND+%28surgery+OR+hysterectomy+OR+lymphadenectomy+OR+oophorectomy+OR+fertility+OR+morcellation%29%29+AND+%282026%2F10%2F24%3A2026%2F10%2F31%5Bdp%5D+OR+2026%2F10%2F24%3A2026%2F10%2F31%5Bedat%5D%29&retmode=json&retmax=50", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND (adenosarcoma AND (surgery OR hysterectomy OR lymphadenectomy OR oophorectomy OR fertility OR morcellation)) AND (2026/10/24:2026/10/31[dp] OR 2026/10/24:2026/10/31[edat])", "retmode": "json", "retmax": "50" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "surgery", "to": "\"surgery\"[Subheading] OR \"surgery\"[All Fields] OR \"surgical procedures, operative\"[MeSH Terms] OR (\"surgical\"[All Fields] AND \"procedures\"[All Fields] AND \"operative\"[All Fields]) OR \"operative surgical procedures\"[All Fields] OR \"general surgery\"[MeSH Terms] OR (\"general\"[All Fields] AND \"surgery\"[All Fields]) OR \"general surgery\"[All Fields] OR \"surgery's\"[All Fields] OR \"surgerys\"[All Fields] OR \"surgeries\"[All Fields]" }, { "from": "hysterectomy", "to": "\"hysterectomy\"[MeSH Terms] OR \"hysterectomy\"[All Fields] OR \"hysterectomies\"[All Fields]" }, { "from": "lymphadenectomy", "to": "\"lymph node excision\"[MeSH Terms] OR (\"lymph\"[All Fields] AND \"node\"[All Fields] AND \"excision\"[All Fields]) OR \"lymph node excision\"[All Fields] OR \"lymphadenectomies\"[All Fields] OR \"lymphadenectomy\"[All Fields]" }, { "from": "oophorectomy", "to": "\"ovariectomy\"[MeSH Terms] OR \"ovariectomy\"[All Fields] OR \"oophorectomies\"[All Fields] OR \"oophorectomy\"[All Fields]" }, { "from": "fertility", "to": "\"fertiles\"[All Fields] OR \"fertility\"[MeSH Terms] OR \"fertility\"[All Fields] OR \"fertile\"[All Fields] OR \"fertilities\"[All Fields]" }, { "from": "morcellation", "to": "\"morcellate\"[All Fields] OR \"morcellated\"[All Fields] OR \"morcellating\"[All Fields] OR \"morcellation\"[MeSH Terms] OR \"morcellation\"[All Fields] OR \"morcellator\"[All Fields] OR \"morcellators\"[All Fields] OR \"morcellement\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND ((\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"surgery\"[MeSH Subheading] OR \"surgery\"[All Fields] OR \"surgical procedures, operative\"[MeSH Terms] OR (\"surgical\"[All Fields] AND \"procedures\"[All Fields] AND \"operative\"[All Fields]) OR \"operative surgical procedures\"[All Fields] OR \"general surgery\"[MeSH Terms] OR (\"general\"[All Fields] AND \"surgery\"[All Fields]) OR \"general surgery\"[All Fields] OR \"surgery s\"[All Fields] OR \"surgerys\"[All Fields] OR \"surgeries\"[All Fields] OR (\"hysterectomy\"[MeSH Terms] OR \"hysterectomy\"[All Fields] OR \"hysterectomies\"[All Fields]) OR (\"lymph node excision\"[MeSH Terms] OR (\"lymph\"[All Fields] AND \"node\"[All Fields] AND \"excision\"[All Fields]) OR \"lymph node excision\"[All Fields] OR \"lymphadenectomies\"[All Fields] OR \"lymphadenectomy\"[All Fields]) OR (\"ovariectomy\"[MeSH Terms] OR \"ovariectomy\"[All Fields] OR \"oophorectomies\"[All Fields] OR \"oophorectomy\"[All Fields]) OR (\"fertiles\"[All Fields] OR \"fertility\"[MeSH Terms] OR \"fertility\"[All Fields] OR \"fertile\"[All Fields] OR \"fertilities\"[All Fields]) OR (\"morcellate\"[All Fields] OR \"morcellated\"[All Fields] OR \"morcellating\"[All Fields] OR \"morcellation\"[MeSH Terms] OR \"morcellation\"[All Fields] OR \"morcellator\"[All Fields] OR \"morcellators\"[All Fields] OR \"morcellement\"[All Fields]))) AND (2026/10/24:2026/10/31[Date - Publication] OR 2026/10/24:2026/10/31[Date - Entry])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_surgery_safety" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+%28adenosarcoma+AND+%28chemotherapy+OR+radiotherapy+OR+hormonal+OR+adjuvant+OR+elacestrant+OR+fulvestrant+OR+trial%29%29+AND+%282026%2F10%2F24%3A2026%2F10%2F31%5Bdp%5D+OR+2026%2F10%2F24%3A2026%2F10%2F31%5Bedat%5D%29&retmode=json&retmax=50", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND (adenosarcoma AND (chemotherapy OR radiotherapy OR hormonal OR adjuvant OR elacestrant OR fulvestrant OR trial)) AND (2026/10/24:2026/10/31[dp] OR 2026/10/24:2026/10/31[edat])", "retmode": "json", "retmax": "50" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "chemotherapy", "to": "\"chemotherapy's\"[All Fields] OR \"drug therapy\"[MeSH Terms] OR (\"drug\"[All Fields] AND \"therapy\"[All Fields]) OR \"drug therapy\"[All Fields] OR \"chemotherapies\"[All Fields] OR \"drug therapy\"[Subheading] OR \"chemotherapy\"[All Fields]" }, { "from": "radiotherapy", "to": "\"radiotherapy\"[MeSH Terms] OR \"radiotherapy\"[All Fields] OR \"radiotherapies\"[All Fields] OR \"radiotherapy\"[Subheading] OR \"radiotherapy's\"[All Fields]" }, { "from": "hormonal", "to": "\"hormon\"[All Fields] OR \"hormonal\"[All Fields] OR \"hormonally\"[All Fields] OR \"hormonals\"[All Fields] OR \"hormone's\"[All Fields] OR \"hormones\"[Pharmacological Action] OR \"hormones\"[Supplementary Concept] OR \"hormones\"[All Fields] OR \"hormone\"[All Fields] OR \"hormones\"[MeSH Terms] OR \"hormons\"[All Fields]" }, { "from": "adjuvant", "to": "\"adjuvancy\"[All Fields] OR \"adjuvanted\"[All Fields] OR \"adjuvanting\"[All Fields] OR \"adjuvants\"[All Fields] OR \"adjuvants, pharmaceutic\"[Pharmacological Action] OR \"adjuvants, immunologic\"[Pharmacological Action] OR \"adjuvants, pharmaceutic\"[Supplementary Concept] OR \"adjuvants, pharmaceutic\"[All Fields] OR \"adjuvant\"[All Fields] OR \"adjuvants, immunologic\"[Supplementary Concept] OR \"adjuvants, immunologic\"[All Fields] OR \"adjuvants, pharmaceutic\"[MeSH Terms] OR (\"adjuvants\"[All Fields] AND \"pharmaceutic\"[All Fields]) OR \"pharmaceutic adjuvants\"[All Fields] OR \"adjuvants, immunologic\"[MeSH Terms] OR (\"adjuvants\"[All Fields] AND \"immunologic\"[All Fields]) OR \"immunologic adjuvants\"[All Fields] OR \"adjuvated\"[All Fields] OR \"adjuvation\"[All Fields] OR \"adjuvent\"[All Fields]" }, { "from": "elacestrant", "to": "\"elacestrant\"[Supplementary Concept] OR \"elacestrant\"[All Fields]" }, { "from": "fulvestrant", "to": "\"fulvestrant\"[Supplementary Concept] OR \"fulvestrant\"[All Fields] OR \"fulvestrant\"[MeSH Terms] OR \"fulvestrant's\"[All Fields]" }, { "from": "trial", "to": "\"clinical trials as topic\"[MeSH Terms] OR (\"clinical\"[All Fields] AND \"trials\"[All Fields] AND \"topic\"[All Fields]) OR \"clinical trials as topic\"[All Fields] OR \"trial\"[All Fields] OR \"trial's\"[All Fields] OR \"trialed\"[All Fields] OR \"trialing\"[All Fields] OR \"trials\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND ((\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"chemotherapy s\"[All Fields] OR \"drug therapy\"[MeSH Terms] OR (\"drug\"[All Fields] AND \"therapy\"[All Fields]) OR \"drug therapy\"[All Fields] OR \"chemotherapies\"[All Fields] OR \"drug therapy\"[MeSH Subheading] OR \"chemotherapy\"[All Fields] OR (\"radiotherapy\"[MeSH Terms] OR \"radiotherapy\"[All Fields] OR \"radiotherapies\"[All Fields] OR \"radiotherapy\"[MeSH Subheading] OR \"radiotherapy s\"[All Fields]) OR (\"hormon\"[All Fields] OR \"hormonal\"[All Fields] OR \"hormonally\"[All Fields] OR \"hormonals\"[All Fields] OR \"hormone s\"[All Fields] OR \"hormones\"[Pharmacological Action] OR \"hormones\"[Supplementary Concept] OR \"hormones\"[All Fields] OR \"hormone\"[All Fields] OR \"hormones\"[MeSH Terms] OR \"hormons\"[All Fields]) OR (\"adjuvancy\"[All Fields] OR \"adjuvanted\"[All Fields] OR \"adjuvanting\"[All Fields] OR \"adjuvants\"[All Fields] OR \"adjuvants pharmaceutic\"[Pharmacological Action] OR \"adjuvants immunologic\"[Pharmacological Action] OR \"adjuvants pharmaceutic\"[Supplementary Concept] OR \"adjuvants pharmaceutic\"[All Fields] OR \"adjuvant\"[All Fields] OR \"adjuvants immunologic\"[Supplementary Concept] OR \"adjuvants immunologic\"[All Fields] OR \"adjuvants, pharmaceutic\"[MeSH Terms] OR (\"adjuvants\"[All Fields] AND \"pharmaceutic\"[All Fields]) OR \"pharmaceutic adjuvants\"[All Fields] OR \"adjuvants, immunologic\"[MeSH Terms] OR (\"adjuvants\"[All Fields] AND \"immunologic\"[All Fields]) OR \"immunologic adjuvants\"[All Fields] OR \"adjuvated\"[All Fields] OR \"adjuvation\"[All Fields] OR \"adjuvent\"[All Fields]) OR (\"elacestrant\"[Supplementary Concept] OR \"elacestrant\"[All Fields]) OR (\"fulvestrant\"[Supplementary Concept] OR \"fulvestrant\"[All Fields] OR \"fulvestrant\"[MeSH Terms]) OR (\"clinical trials as topic\"[MeSH Terms] OR (\"clinical\"[All Fields] AND \"trials\"[All Fields] AND \"topic\"[All Fields]) OR \"clinical trials as topic\"[All Fields] OR \"trial\"[All Fields] OR \"trial s\"[All Fields] OR \"trialed\"[All Fields] OR \"trialing\"[All Fields] OR \"trials\"[All Fields]))) AND (2026/10/24:2026/10/31[Date - Publication] OR 2026/10/24:2026/10/31[Date - Entry])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_systemic_adjuvant" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+%28adenosarcoma+AND+%28recurrence+OR+surveillance+OR+follow-up%29%29+AND+%282026%2F10%2F24%3A2026%2F10%2F31%5Bdp%5D+OR+2026%2F10%2F24%3A2026%2F10%2F31%5Bedat%5D%29&retmode=json&retmax=50", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND (adenosarcoma AND (recurrence OR surveillance OR follow-up)) AND (2026/10/24:2026/10/31[dp] OR 2026/10/24:2026/10/31[edat])", "retmode": "json", "retmax": "50" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "recurrence", "to": "\"recurrance\"[All Fields] OR \"recurrence\"[MeSH Terms] OR \"recurrence\"[All Fields] OR \"recurrences\"[All Fields] OR \"recurrencies\"[All Fields] OR \"recurrency\"[All Fields] OR \"recurrent\"[All Fields] OR \"recurrently\"[All Fields] OR \"recurrents\"[All Fields]" }, { "from": "surveillance", "to": "\"epidemiology\"[Subheading] OR \"epidemiology\"[All Fields] OR \"surveillance\"[All Fields] OR \"epidemiology\"[MeSH Terms] OR \"surveilance\"[All Fields] OR \"surveillances\"[All Fields] OR \"surveilled\"[All Fields] OR \"surveillence\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND ((\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]) AND (\"recurrance\"[All Fields] OR \"recurrence\"[MeSH Terms] OR \"recurrence\"[All Fields] OR \"recurrences\"[All Fields] OR \"recurrencies\"[All Fields] OR \"recurrency\"[All Fields] OR \"recurrent\"[All Fields] OR \"recurrently\"[All Fields] OR \"recurrents\"[All Fields] OR (\"epidemiology\"[MeSH Subheading] OR \"epidemiology\"[All Fields] OR \"surveillance\"[All Fields] OR \"epidemiology\"[MeSH Terms] OR \"surveilance\"[All Fields] OR \"surveillances\"[All Fields] OR \"surveilled\"[All Fields] OR \"surveillence\"[All Fields]) OR \"follow-up\"[All Fields])) AND (2026/10/24:2026/10/31[Date - Publication] OR 2026/10/24:2026/10/31[Date - Entry])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_recurrence_surveillance" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+%28%28adenosarcoma+OR+uterine+sarcoma%29+AND+%28guideline+OR+consensus+OR+ESGO+OR+GCIG+OR+NCCN+OR+ESMO+OR+FIGO%29%29+AND+%282026%2F10%2F24%3A2026%2F10%2F31%5Bdp%5D+OR+2026%2F10%2F24%3A2026%2F10%2F31%5Bedat%5D%29&retmode=json&retmax=50", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND ((adenosarcoma OR uterine sarcoma) AND (guideline OR consensus OR ESGO OR GCIG OR NCCN OR ESMO OR FIGO)) AND (2026/10/24:2026/10/31[dp] OR 2026/10/24:2026/10/31[edat])", "retmode": "json", "retmax": "50" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "uterine", "to": "\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]" }, { "from": "sarcoma", "to": "\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma's\"[All Fields]" }, { "from": "guideline", "to": "\"guideline\"[Publication Type] OR \"guidelines as topic\"[MeSH Terms] OR \"guideline\"[All Fields]" }, { "from": "consensus", "to": "\"consensual\"[All Fields] OR \"consensually\"[All Fields] OR \"consensus\"[MeSH Terms] OR \"consensus\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND ((\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields] OR ((\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]) AND (\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma s\"[All Fields]))) AND (\"guideline\"[Publication Type] OR \"guidelines as topic\"[MeSH Terms] OR \"guideline\"[All Fields] OR (\"consensual\"[All Fields] OR \"consensually\"[All Fields] OR \"consensus\"[MeSH Terms] OR \"consensus\"[All Fields]) OR \"ESGO\"[All Fields] OR \"GCIG\"[All Fields] OR \"NCCN\"[All Fields] OR \"ESMO\"[All Fields] OR \"FIGO\"[All Fields])) AND (2026/10/24:2026/10/31[Date - Publication] OR 2026/10/24:2026/10/31[Date - Entry])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_guidelines" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+%28%28adenosarcoma+OR+uterine+sarcoma%29+AND+%28quality+of+life+OR+patient+reported+OR+qualitative+OR+experience+OR+advocacy%29%29+AND+%282026%2F10%2F24%3A2026%2F10%2F31%5Bdp%5D+OR+2026%2F10%2F24%3A2026%2F10%2F31%5Bedat%5D%29&retmode=json&retmax=50", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND ((adenosarcoma OR uterine sarcoma) AND (quality of life OR patient reported OR qualitative OR experience OR advocacy)) AND (2026/10/24:2026/10/31[dp] OR 2026/10/24:2026/10/31[edat])", "retmode": "json", "retmax": "50" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" }, { "from": "uterine", "to": "\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]" }, { "from": "sarcoma", "to": "\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma's\"[All Fields]" }, { "from": "quality of life", "to": "\"quality of life\"[MeSH Terms] OR (\"quality\"[All Fields] AND \"life\"[All Fields]) OR \"quality of life\"[All Fields]" }, { "from": "patient", "to": "\"patient's\"[All Fields] OR \"patients\"[MeSH Terms] OR \"patients\"[All Fields] OR \"patient\"[All Fields] OR \"patients's\"[All Fields]" }, { "from": "reported", "to": "\"reportable\"[All Fields] OR \"reporting\"[All Fields] OR \"reportings\"[All Fields] OR \"research report\"[MeSH Terms] OR (\"research\"[All Fields] AND \"report\"[All Fields]) OR \"research report\"[All Fields] OR \"report\"[All Fields] OR \"reported\"[All Fields] OR \"reports\"[All Fields]" }, { "from": "qualitative", "to": "\"qualitative\"[All Fields] OR \"qualitatively\"[All Fields] OR \"qualitatives\"[All Fields]" }, { "from": "experience", "to": "\"experience\"[All Fields] OR \"experience's\"[All Fields] OR \"experiences\"[All Fields]" }, { "from": "advocacy", "to": "\"advocacies\"[All Fields] OR \"advocacy\"[All Fields] OR \"advocacy's\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND ((\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields] OR ((\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]) AND (\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma s\"[All Fields]))) AND (\"quality of life\"[MeSH Terms] OR (\"quality\"[All Fields] AND \"life\"[All Fields]) OR \"quality of life\"[All Fields] OR ((\"patient s\"[All Fields] OR \"patients\"[MeSH Terms] OR \"patients\"[All Fields] OR \"patient\"[All Fields] OR \"patients s\"[All Fields]) AND (\"reportable\"[All Fields] OR \"reporting\"[All Fields] OR \"reportings\"[All Fields] OR \"research report\"[MeSH Terms] OR (\"research\"[All Fields] AND \"report\"[All Fields]) OR \"research report\"[All Fields] OR \"report\"[All Fields] OR \"reported\"[All Fields] OR \"reports\"[All Fields])) OR (\"qualitative\"[All Fields] OR \"qualitatively\"[All Fields] OR \"qualitatives\"[All Fields]) OR (\"experience\"[All Fields] OR \"experience s\"[All Fields] OR \"experiences\"[All Fields]) OR (\"advocacies\"[All Fields] OR \"advocacy\"[All Fields] OR \"advocacy s\"[All Fields]))) AND (2026/10/24:2026/10/31[Date - Publication] OR 2026/10/24:2026/10/31[Date - Entry])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_patient_experience" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+%28uterine+sarcoma+OR+uterine+sarcomas%29+AND+%282026%2F10%2F24%3A2026%2F10%2F31%5Bdp%5D+OR+2026%2F10%2F24%3A2026%2F10%2F31%5Bedat%5D%29&retmode=json&retmax=50", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND (uterine sarcoma OR uterine sarcomas) AND (2026/10/24:2026/10/31[dp] OR 2026/10/24:2026/10/31[edat])", "retmode": "json", "retmax": "50" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "uterine", "to": "\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]" }, { "from": "sarcoma", "to": "\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma's\"[All Fields]" }, { "from": "sarcomas", "to": "\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma's\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND (((\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]) AND (\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma s\"[All Fields])) OR ((\"uterin\"[All Fields] OR \"uterines\"[All Fields] OR \"uterus\"[MeSH Terms] OR \"uterus\"[All Fields] OR \"uterine\"[All Fields]) AND (\"sarcoma\"[MeSH Terms] OR \"sarcoma\"[All Fields] OR \"sarcomas\"[All Fields] OR \"sarcoma s\"[All Fields]))) AND (2026/10/24:2026/10/31[Date - Publication] OR 2026/10/24:2026/10/31[Date - Entry])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_uterine_sarcoma_broad" }, { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&term=%22Cochrane+Database+Syst+Rev%22%5Bjour%5D+AND+adenosarcoma&retmode=json&retmax=20", "http_status": 200, "params": { "db": "pubmed", "term": "\"Cochrane Database Syst Rev\"[jour] AND adenosarcoma", "retmode": "json", "retmax": "20" }, "response": { "header": { "type": "esearch", "version": "0.3" }, "esearchresult": { "count": "0", "retmax": "0", "retstart": "0", "idlist": [], "translationset": [ { "from": "adenosarcoma", "to": "\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields]" } ], "querytranslation": "\"Cochrane Database Syst Rev\"[Journal] AND (\"adenosarcoma\"[MeSH Terms] OR \"adenosarcoma\"[All Fields] OR \"adenosarcomas\"[All Fields])", "warninglist": { "phrasesignored": [], "quotedphrasesnotfound": [], "outputmessages": [ "No items found." ] } } }, "topic": "cochrane_adenosarcoma_all_time" } ], "europepmc": [ { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=adenosarcoma+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "adenosarcoma AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 1, "results": [ { "id": "42951232", "source": "MED", "pmid": "42951232", "doi": "10.1016/j.ajog.2026.10.034", "title": "Hysterectomy-corrected, age-specific incidence and survival of uterine sarcomas by histotype, race and ethnicity in the United States, 2000-2019.", "authorString": "Dave D, Arend RC, Leath CA, Toboni MD, Wentzensen N, K\u00f6bel M, Erickson BK, Wijayabahu AT, Clarke MA.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-28", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null } ], "raw_hitCount": 1, "topic": "all_first_pdate" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=adenosarcoma+AND+CREATION_DATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "adenosarcoma AND CREATION_DATE:[2026-10-24 TO 2026-10-31]", "hitCount": 6, "results": [ { "id": "42951232", "source": "MED", "pmid": "42951232", "doi": "10.1016/j.ajog.2026.10.034", "title": "Hysterectomy-corrected, age-specific incidence and survival of uterine sarcomas by histotype, race and ethnicity in the United States, 2000-2019.", "authorString": "Dave D, Arend RC, Leath CA, Toboni MD, Wentzensen N, K\u00f6bel M, Erickson BK, Wijayabahu AT, Clarke MA.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-28", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "42951389", "source": "MED", "pmid": "42951389", "doi": "10.1016/j.path.2026.06.009", "title": "Uterine Adenosarcoma: Unusual Presentations and Mimics.", "authorString": "Dinh TA, Chapel DB.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-08-05", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "42914689", "source": "MED", "pmid": "42914689", "doi": "10.1097/pgp.0000000000001222", "title": "Bizarre But Benign: A Case Report of an EHHADH::RAD51B Rearranged Endometrial Polyp With Bizarre Stromal Cells.", "authorString": "Cardenas JC, Felicelli C.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-22", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "42942324", "source": "MED", "pmid": "42942324", "doi": "10.3390/life16101738", "title": "Pretreatment Assessment of Occult Uterine Sarcoma Risk Before Uterus-Preserving Treatment of Presumed Fibroids: A Narrative Review.", "authorString": "Solomon Condriuc IP, Mogos RA, Popovici R, Matasariu DR, Cosovanu EO, Buzduga CM, Scripcariu IS, Socolov D, Carauleanu A.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-16", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "42923274", "source": "MED", "pmid": "42923274", "doi": "10.7759/cureus.116700", "title": "When Mammary-Like Anogenital Glands Go Rogue: Vulvar Phyllodes Tumor With Incorporated Hidradenoma Papilliferum.", "authorString": "Albrahim MN, Arora R, Samudrala R.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-09-22", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "42953178", "source": "MED", "pmid": "42953178", "doi": "10.3389/fimmu.2026.1873651", "title": "Human platelet lysate enables robust expansion of tumor infiltrating lymphocytes from endometrial cancer. ", "authorString": "Iwema W, van Rooij N, Rockstein L, Plat A, Yigit R, Bart J, Gareb B, Nijman HW, Bremer E, de Bruyn M.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-14", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null } ], "raw_hitCount": 6, "topic": "all_creation" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%22uterine+adenosarcoma%22+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "\"uterine adenosarcoma\" AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 0, "results": [], "raw_hitCount": 0, "topic": "uterine_first_pdate" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%22uterine+adenosarcoma%22+AND+CREATION_DATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "\"uterine adenosarcoma\" AND CREATION_DATE:[2026-10-24 TO 2026-10-31]", "hitCount": 1, "results": [ { "id": "42951389", "source": "MED", "pmid": "42951389", "doi": "10.1016/j.path.2026.06.009", "title": "Uterine Adenosarcoma: Unusual Presentations and Mimics.", "authorString": "Dinh TA, Chapel DB.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-08-05", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null } ], "raw_hitCount": 1, "topic": "uterine_creation" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=adenosarcoma+AND+%28pathology+OR+diagnosis+OR+polyp+OR+adenofibroma%29+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "adenosarcoma AND (pathology OR diagnosis OR polyp OR adenofibroma) AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 1, "results": [ { "id": "42951232", "source": "MED", "pmid": "42951232", "doi": "10.1016/j.ajog.2026.10.034", "title": "Hysterectomy-corrected, age-specific incidence and survival of uterine sarcomas by histotype, race and ethnicity in the United States, 2000-2019.", "authorString": "Dave D, Arend RC, Leath CA, Toboni MD, Wentzensen N, K\u00f6bel M, Erickson BK, Wijayabahu AT, Clarke MA.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-28", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null } ], "raw_hitCount": 1, "topic": "pathology" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=adenosarcoma+AND+%28sarcomatous+overgrowth+OR+prognosis+OR+LVSI%29+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "adenosarcoma AND (sarcomatous overgrowth OR prognosis OR LVSI) AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 0, "results": [], "raw_hitCount": 0, "topic": "overgrowth" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=adenosarcoma+AND+%28SMARCA4+OR+BRG1+OR+MDM2+OR+CDK4+OR+DICER1+OR+BAP1+OR+TP53+OR+fusion%29+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "adenosarcoma AND (SMARCA4 OR BRG1 OR MDM2 OR CDK4 OR DICER1 OR BAP1 OR TP53 OR fusion) AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 0, "results": [], "raw_hitCount": 0, "topic": "molecular" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=adenosarcoma+AND+%28epidemiology+OR+incidence+OR+registry+OR+SEER+OR+NCDB%29+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "adenosarcoma AND (epidemiology OR incidence OR registry OR SEER OR NCDB) AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 1, "results": [ { "id": "42951232", "source": "MED", "pmid": "42951232", "doi": "10.1016/j.ajog.2026.10.034", "title": "Hysterectomy-corrected, age-specific incidence and survival of uterine sarcomas by histotype, race and ethnicity in the United States, 2000-2019.", "authorString": "Dave D, Arend RC, Leath CA, Toboni MD, Wentzensen N, K\u00f6bel M, Erickson BK, Wijayabahu AT, Clarke MA.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-28", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null } ], "raw_hitCount": 1, "topic": "epidemiology" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=adenosarcoma+AND+%28MRI+OR+imaging+OR+ultrasound%29+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "adenosarcoma AND (MRI OR imaging OR ultrasound) AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 0, "results": [], "raw_hitCount": 0, "topic": "imaging" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=adenosarcoma+AND+%28hysterectomy+OR+lymphadenectomy+OR+fertility+OR+morcellation%29+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "adenosarcoma AND (hysterectomy OR lymphadenectomy OR fertility OR morcellation) AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 1, "results": [ { "id": "42951232", "source": "MED", "pmid": "42951232", "doi": "10.1016/j.ajog.2026.10.034", "title": "Hysterectomy-corrected, age-specific incidence and survival of uterine sarcomas by histotype, race and ethnicity in the United States, 2000-2019.", "authorString": "Dave D, Arend RC, Leath CA, Toboni MD, Wentzensen N, K\u00f6bel M, Erickson BK, Wijayabahu AT, Clarke MA.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-28", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null } ], "raw_hitCount": 1, "topic": "surgery" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=adenosarcoma+AND+%28chemotherapy+OR+adjuvant+OR+fulvestrant+OR+elacestrant%29+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "adenosarcoma AND (chemotherapy OR adjuvant OR fulvestrant OR elacestrant) AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 0, "results": [], "raw_hitCount": 0, "topic": "systemic" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=adenosarcoma+AND+%28recurrence+OR+surveillance%29+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "adenosarcoma AND (recurrence OR surveillance) AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 0, "results": [], "raw_hitCount": 0, "topic": "recurrence" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28adenosarcoma+OR+%22uterine+sarcoma%22%29+AND+%28guideline+OR+ESGO+OR+NCCN+OR+FIGO%29+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "(adenosarcoma OR \"uterine sarcoma\") AND (guideline OR ESGO OR NCCN OR FIGO) AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 1, "results": [ { "id": "PMC13691476", "source": "PMC", "pmid": null, "doi": null, "title": "From image biomarkers to treatment decisions: multimodal AI and clinical translation in gynecologic oncology", "authorString": "Bakir M, Al Masri M, Mushtaha Y, Shaikh N, Raddaoui M, Mohammad K.", "journalTitle": null, "pubYear": null, "firstPublicationDate": "2026-10-24", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null } ], "raw_hitCount": 1, "topic": "guidelines" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28adenosarcoma+OR+%22uterine+sarcoma%22%29+AND+%28%22quality+of+life%22+OR+qualitative+OR+%22patient+reported%22%29+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "(adenosarcoma OR \"uterine sarcoma\") AND (\"quality of life\" OR qualitative OR \"patient reported\") AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 2, "results": [ { "id": "42948235", "source": "MED", "pmid": "42948235", "doi": "10.2490/prm.20260059", "title": "Randomized, Controlled, Crossover Trial Comparing Immediate Effects of Components of Complex Decongestive Therapy in Lower-limb Lymphedema Patients.", "authorString": "Oka A, Tsuji T, Abe K, Nakamura T, Kawakami M, Muraoka K, Hohri H, Sano Y, Shoji J, Kamisako M, Liu M.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-28", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "PMC13691476", "source": "PMC", "pmid": null, "doi": null, "title": "From image biomarkers to treatment decisions: multimodal AI and clinical translation in gynecologic oncology", "authorString": "Bakir M, Al Masri M, Mushtaha Y, Shaikh N, Raddaoui M, Mohammad K.", "journalTitle": null, "pubYear": null, "firstPublicationDate": "2026-10-24", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null } ], "raw_hitCount": 2, "topic": "patient" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28%22uterine+sarcoma%22+OR+%22uterine+sarcomas%22%29+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "(\"uterine sarcoma\" OR \"uterine sarcomas\") AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 4, "results": [ { "id": "42951232", "source": "MED", "pmid": "42951232", "doi": "10.1016/j.ajog.2026.10.034", "title": "Hysterectomy-corrected, age-specific incidence and survival of uterine sarcomas by histotype, race and ethnicity in the United States, 2000-2019.", "authorString": "Dave D, Arend RC, Leath CA, Toboni MD, Wentzensen N, K\u00f6bel M, Erickson BK, Wijayabahu AT, Clarke MA.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-28", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "42952303", "source": "MED", "pmid": "42952303", "doi": "10.1158/1535-7163.mct-26-0434", "title": "ATR inhibitors and gemcitabine synergize to induce cell death in TP53-mutant, ATRX-wildtype uterine leiomyosarcoma.", "authorString": "Doherty ME, Malik M, Otsuka Y, Bateman NW, Risinger JI, Pyskir N, Conrads TP, Darcy KM, Maxwell GL, Ganakammal SR, Dalgard CL, Wilkerson MD, Sukumar G, LaMorte JP, Finniff BA, Kortum RL, Catherino WH.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-29", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PMC13691476", "source": "PMC", "pmid": null, "doi": null, "title": "From image biomarkers to treatment decisions: multimodal AI and clinical translation in gynecologic oncology", "authorString": "Bakir M, Al Masri M, Mushtaha Y, Shaikh N, Raddaoui M, Mohammad K.", "journalTitle": null, "pubYear": null, "firstPublicationDate": "2026-10-24", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "42948235", "source": "MED", "pmid": "42948235", "doi": "10.2490/prm.20260059", "title": "Randomized, Controlled, Crossover Trial Comparing Immediate Effects of Components of Complex Decongestive Therapy in Lower-limb Lymphedema Patients.", "authorString": "Oka A, Tsuji T, Abe K, Nakamura T, Kawakami M, Muraoka K, Hohri H, Sano Y, Shoji J, Kamisako M, Liu M.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-28", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null } ], "raw_hitCount": 4, "topic": "uterine_sarcoma_first" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%28%22uterine+sarcoma%22+OR+%22uterine+sarcomas%22%29+AND+CREATION_DATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "(\"uterine sarcoma\" OR \"uterine sarcomas\") AND CREATION_DATE:[2026-10-24 TO 2026-10-31]", "hitCount": 17, "results": [ { "id": "42951232", "source": "MED", "pmid": "42951232", "doi": "10.1016/j.ajog.2026.10.034", "title": "Hysterectomy-corrected, age-specific incidence and survival of uterine sarcomas by histotype, race and ethnicity in the United States, 2000-2019.", "authorString": "Dave D, Arend RC, Leath CA, Toboni MD, Wentzensen N, K\u00f6bel M, Erickson BK, Wijayabahu AT, Clarke MA.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-28", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "42942324", "source": "MED", "pmid": "42942324", "doi": "10.3390/life16101738", "title": "Pretreatment Assessment of Occult Uterine Sarcoma Risk Before Uterus-Preserving Treatment of Presumed Fibroids: A Narrative Review.", "authorString": "Solomon Condriuc IP, Mogos RA, Popovici R, Matasariu DR, Cosovanu EO, Buzduga CM, Scripcariu IS, Socolov D, Carauleanu A.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-16", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "42928860", "source": "MED", "pmid": "42928860", "doi": "10.7759/cureus.116888", "title": "Locally Advanced Primary Cervical Endometrial Stromal Sarcoma: A Case Report.", "authorString": "Bali A, Khater K, Jebrouni F, Chibani H, Al Jarroudi O, Brahmi SA, Afqir S.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-09-25", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "42939826", "source": "MED", "pmid": "42939826", "doi": "10.3390/antiox15101252", "title": "Oxidative Stress and Its Molecular Effectors in Uterine Smooth Muscle Tumors: Bridging Epigenetic Regulation and Glycoprotein Biomarkers.", "authorString": "Kourti A, Karioti P, Chouliara F, Georgiou E, Makedou K, Kalogiannidis I.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-09-30", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "42929828", "source": "MED", "pmid": "42929828", "doi": "10.3390/cells15201856", "title": "BCOR Biology in Development and Cancer.", "authorString": "Royston HN, Taddia A, Santori FR, Ivanova N, Funato K.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-13", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "42955969", "source": "MED", "pmid": "42955969", "doi": "10.4103/jcrt.jcrt_582_26", "title": "A retrospective analysis of BCOR-immunohistochemistry positive uterine sarcomas: Clinical features and survival. ", "authorString": "Sekar A, Rekhi B, Ghosh J, Menon S, Shetty O, Deodhar K, Rath S, Mittal N, Mehta A, Gulia S, Maheshwari A, Chopra S, Gupta S.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-07-01", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "42909529", "source": "MED", "pmid": "42909529", "doi": "10.1007/s40477-026-01245-6", "title": "Diagnostic overlap between necrotic leiomyoma, adenomyoma and uterine sarcoma: an ultrasound challenge.", "authorString": "Pellecchia G, Moro F, Campolo F, Finelli A, Ianieri MM.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-23", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "42951388", "source": "MED", "pmid": "42951388", "doi": "10.1016/j.path.2026.06.003", "title": "DNA Methylation Profiling: Current and Emerging Uses in Gynecologic Pathology.", "authorString": "Gu W, Howitt BE.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-08-05", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "42951389", "source": "MED", "pmid": "42951389", "doi": "10.1016/j.path.2026.06.009", "title": "Uterine Adenosarcoma: Unusual Presentations and Mimics.", "authorString": "Dinh TA, Chapel DB.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-08-05", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "42952303", "source": "MED", "pmid": "42952303", "doi": "10.1158/1535-7163.mct-26-0434", "title": "ATR inhibitors and gemcitabine synergize to induce cell death in TP53-mutant, ATRX-wildtype uterine leiomyosarcoma.", "authorString": "Doherty ME, Malik M, Otsuka Y, Bateman NW, Risinger JI, Pyskir N, Conrads TP, Darcy KM, Maxwell GL, Ganakammal SR, Dalgard CL, Wilkerson MD, Sukumar G, LaMorte JP, Finniff BA, Kortum RL, Catherino WH.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-29", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PMC13691476", "source": "PMC", "pmid": null, "doi": null, "title": "From image biomarkers to treatment decisions: multimodal AI and clinical translation in gynecologic oncology", "authorString": "Bakir M, Al Masri M, Mushtaha Y, Shaikh N, Raddaoui M, Mohammad K.", "journalTitle": null, "pubYear": null, "firstPublicationDate": "2026-10-24", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "42948072", "source": "MED", "pmid": "42948072", "doi": "10.3389/fmed.2026.1859849", "title": "KAT6B::KANSL1 fusion-positive uterine mesenchymal neoplasm with hybrid endometrial stromal and smooth muscle features: a case report.", "authorString": "Li Q, Wu M.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-13", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "PMC13718666", "source": "PMC", "pmid": null, "doi": null, "title": "Clear cell carcinoma of the uterine corpus arising in long-standing adenomyosis after menopause: a case report", "authorString": "To G, Shinto A, Fukuda A, Hashiguchi M, Kato S, Umezaki Y, Okugawa K.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-21", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "42948235", "source": "MED", "pmid": "42948235", "doi": "10.2490/prm.20260059", "title": "Randomized, Controlled, Crossover Trial Comparing Immediate Effects of Components of Complex Decongestive Therapy in Lower-limb Lymphedema Patients.", "authorString": "Oka A, Tsuji T, Abe K, Nakamura T, Kawakami M, Muraoka K, Hohri H, Sano Y, Shoji J, Kamisako M, Liu M.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-28", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "42930195", "source": "MED", "pmid": "42930195", "doi": "10.3390/curroncol33100628", "title": "Electroacupuncture Combined with Cognitive Behavioral Therapy for Insomnia Alleviates Insomnia-Anxiety Comorbidity in Gynecological Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial.", "authorString": "Xu T, Rao Y, Cao Q, Yue Y.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-19", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "42938198", "source": "MED", "pmid": "42938198", "doi": "10.3390/diagnostics16203358", "title": "Uterine Fibroids in Pregnancy: Maternal, Obstetric, and Neonatal Outcomes in a Retrospective Cohort Study.", "authorString": "Martire FG, d'Abate C, Costantini E, Gavanelli G, Ianes I, De Bonis M, Sorrenti G, Zupi E, Lazzeri L.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-15", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null }, { "id": "42953178", "source": "MED", "pmid": "42953178", "doi": "10.3389/fimmu.2026.1873651", "title": "Human platelet lysate enables robust expansion of tumor infiltrating lymphocytes from endometrial cancer. ", "authorString": "Iwema W, van Rooij N, Rockstein L, Plat A, Yigit R, Bart J, Gareb B, Nijman HW, Bremer E, de Bruyn M.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-14", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null } ], "raw_hitCount": 17, "topic": "uterine_sarcoma_creation" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=%22Cochrane+Database+Syst+Rev%22+AND+adenosarcoma+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "\"Cochrane Database Syst Rev\" AND adenosarcoma AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 0, "results": [], "raw_hitCount": 0, "topic": "cochrane" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=SRC%3APPR+AND+adenosarcoma+AND+FIRST_PDATE%3A%5B2026-10-24+TO+2026-10-31%5D&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "SRC:PPR AND adenosarcoma AND FIRST_PDATE:[2026-10-24 TO 2026-10-31]", "hitCount": 0, "results": [], "raw_hitCount": 0, "topic": "preprints" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=SRC%3APPR+AND+adenosarcoma&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "SRC:PPR AND adenosarcoma", "hitCount": 15, "results": [ { "id": "PPR1083105", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-7455828/v1", "title": "Cervical Dumbbell Meningioma Exhibiting Distinct Histopathological Subtypes in Intradural and Extradural Components: A Case Report", "authorString": "Chen C, Liao W, Jan C.", "journalTitle": null, "pubYear": "2025", "firstPublicationDate": "2025-09-11", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR795094", "source": "PPR", "pmid": null, "doi": "10.22541/au.170665847.71918421/v1", "title": "High-grade Ovarian Adenosarcoma with Heterologous elements Arising from Recurrence of Benign Mucinous Cystadenoma: a rare child case and brief review of the literatures", "authorString": "Li J, du r, Zhang L, Jiang H, chen s, Shu H.", "journalTitle": null, "pubYear": "2024", "firstPublicationDate": "2024-01-30", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR893906", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-4740736/v1", "title": "\u03b2-catenin is a potential prognostic biomarker in uterine sarcoma", "authorString": "Cai Y, Wang Y, Yang L, Huang Y, Chen M, Zhang C, Jin S, Frey B, Gaipl US, Ma H, Zhou J.", "journalTitle": null, "pubYear": "2024", "firstPublicationDate": "2024-08-11", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR744465", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-3431536/v1", "title": "Clinicopathological analysis of mullerian adenosarcoma of 22 cases and the sequencing of DICER1 mutation", "authorString": "Yao X, He Y, Wang W.", "journalTitle": null, "pubYear": "2023", "firstPublicationDate": "2023-10-18", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR537440", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-1995945/v1", "title": "Differential diagnosis of uterine adenosarcoma: identification of JAZF1-BCORL1 rearrangement by comprehensive cancer genome profiling", "authorString": "Hasegawa C, Washimi K, Hiroshima Y, Kasajima R, Kikuchi K, Notomi T, Kato H, Hiruma T, Sato S, Okubo Y, Yoshioka E, Ono K, Miyagi Y, Yokose T.", "journalTitle": null, "pubYear": "2022", "firstPublicationDate": "2022-08-29", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR550640", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-1983452/v2", "title": "Comorbidities in patients with uterine adenosarcoma. A single-center case series of 12 patients", "authorString": "Du H, Jiang J, Wang Z, Peng H.", "journalTitle": null, "pubYear": "2022", "firstPublicationDate": "2022-09-26", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR645043", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-2800882/v1", "title": "Embryonal rhabdomyosarcoma of the female gynecologic tract: a retrospective clinical study of 14 cases", "authorString": "Shi S, Wu L, Li T, Zhang H, Sun H.", "journalTitle": null, "pubYear": "2023", "firstPublicationDate": "2023-04-13", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR630414", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-2630102/v1", "title": "Role of lymph node involvement and lymphadenectomy in patients with different subtypes of uterine sarcoma: a systematic review and meta-analysis", "authorString": "Fan Y, Zhang Y, Song T, Mu Y, Ruan J, Li J.", "journalTitle": null, "pubYear": "2023", "firstPublicationDate": "2023-03-14", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR631548", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-2556598/v1", "title": "Clinicopathological characteristics and prognosis of uterine sarcoma: A retrospective 10-year single-center study in China\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0", "authorString": "Wang J, Li C, Yang Z, Yang J, Wang Y, Ji J.", "journalTitle": null, "pubYear": "2023", "firstPublicationDate": "2023-03-16", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR502371", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-1702918/v1", "title": "Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors", "authorString": "Boroujeni AM, Kertowidjojo E, Wu X, Soslow R, Chiang S, Silva Ed, Weigelt B, Chui MH.", "journalTitle": null, "pubYear": "2022", "firstPublicationDate": "2022-06-03", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR541611", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-2012621/v1", "title": "Primary sarcoma of the uterine cervix: Experience of a single center", "authorString": "Yuan H, Li N.", "journalTitle": null, "pubYear": "2022", "firstPublicationDate": "2022-09-08", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR534572", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-1885973/v1", "title": "Clinical characteristics and prognosis analysis of uterine sarcoma: a single- institution retrospective study", "authorString": "Wang F, Dai X, Hu X, Chen H, Wang Y.", "journalTitle": null, "pubYear": "2022", "firstPublicationDate": "2022-08-22", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR520426", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-1850991/v1", "title": "Uterine sarcomas resembling dermatofibrosarcoma protuberans showing COL1A1-PDGFB fusion: a case report and review of the literature\u00a0", "authorString": "Wang Z, Zhou J, Liu S, Ding Y.", "journalTitle": null, "pubYear": "2022", "firstPublicationDate": "2022-07-19", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR190990", "source": "PPR", "pmid": null, "doi": "10.21203/rs.3.rs-46820/v1", "title": "Immunohistochemical Markers and the Clinical Course of Adenosarcoma: a Series of Seven Cases", "authorString": "Omi M, Tonooka A, Chiba T, Nomura H, Kanao H, Takazawa Y.", "journalTitle": null, "pubYear": "2020", "firstPublicationDate": "2020-07-23", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null }, { "id": "PPR413523", "source": "PPR", "pmid": null, "doi": "10.1101/2021.10.28.21265587", "title": "Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets", "authorString": "Nacev BA, Sanchez-Vega F, Smith SA, Antonescu CR, Rosenbaum E, Shi H, Tang C, Socci ND, Rana S, Gularte-M\u00e9rida R, Zehir A, Gounder MM, Bowler TG, Luthra A, Jadeja B, Okada A, Strong JA, Stoller J, Chan JE, Chi P, D\u2019Angelo SP, Dickson MA, Kelly CM, Keohan ML, Movva S, Thornton K, Meyers PA, Wexler LH, Slotkin EK, Glade Bender JL, Shukla NN, Hensley ML, Healey JH, La Quaglia MP, Alektiar KM, Crago AM, Yoon SS, Untch BR, Chiang S, Agaram NP, Hameed MR, Berger MF, Solit DB, Schultz N, Ladanyi M, Singer S, Tap WD.", "journalTitle": null, "pubYear": "2021", "firstPublicationDate": "2021-10-30", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null } ], "raw_hitCount": 15, "topic": "preprints_all_time" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID%3A42862247&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "EXT_ID:42862247", "hitCount": 1, "results": [ { "id": "42862247", "source": "MED", "pmid": "42862247", "doi": "10.1177/10668969261483647", "title": "A SMARCA4-Deficient Uterine Sarcoma Arising in a Uterine Adenosarcoma: Expanding the Spectrum of SMARCA4-Deficient Uterine Neoplasms With Hybrid Morphologic Features.", "authorString": "Rosas-Chavez F, Baltodano B, Fan F, Chang S, S\u00e1nchez-S\u00e1nchez AA, Arias-Stella JA.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-10-12", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null } ], "raw_hitCount": 1, "topic": "pmid_42862247" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID%3A38724237&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "EXT_ID:38724237", "hitCount": 1, "results": [ { "id": "38724237", "source": "MED", "pmid": "38724237", "doi": "10.1136/ijgc-2023-005229", "title": "An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study).", "authorString": "Trozzi R, Tuyaerts S, Annibali D, Herreros Pomares A, Boog L, Van Dam P, Leunen K, Deroose C, Trum H, Amant F.", "journalTitle": null, "pubYear": "2024", "firstPublicationDate": "2024-08-05", "isOpenAccess": "N", "inPMC": "N", "inEPMC": "N", "hasFullText": true, "pubType": null } ], "raw_hitCount": 1, "topic": "pmid_38724237" }, { "url": "https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID%3A42794871&format=json&pageSize=50&resultType=core", "http_status": 200, "query": "EXT_ID:42794871", "hitCount": 1, "results": [ { "id": "42794871", "source": "MED", "pmid": "42794871", "doi": "10.3390/cancers18182903", "title": "Clinical Outcomes and Prognostic Factors in Uterine Adenosarcoma: A Multicenter Retrospective Cohort Study.", "authorString": "Aytekin AM, Ozcivit Erkan IB, Okumus S, Saglik B, Yavuz A, Akgor U, Zaim OC, Urfalioglu M, Aslantas BB, Sozen H, Khatib G, Yuksel IT, Talmac MA, Acikgoz AS, Bese T, Kuru O.", "journalTitle": null, "pubYear": "2026", "firstPublicationDate": "2026-09-08", "isOpenAccess": "Y", "inPMC": "Y", "inEPMC": "Y", "hasFullText": true, "pubType": null } ], "raw_hitCount": 1, "topic": "pmid_42794871" } ], "clinicaltrials": { "tracked": [ { "nct": "NCT03926936", "url": "https://clinicaltrials.gov/api/v2/studies/NCT03926936?format=json", "http_status": 200, "briefTitle": "FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study", "officialTitle": "An Open-label, Single Arm, Prospective, Multi-center, Tandem Two Stage Designed, Phase II Study to Evaluate the Efficacy of Fulvestrant in Women With Recurrent/Metastatic Estrogen Receptor Positive Gynecological Malignancies", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-05-28", "startDate": "2019-03-13", "completionDate": "2022-12-27", "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 17, "enrollmentType": "ACTUAL", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "conditions": [ "Endometrial Stromal Sarcoma", "Adenosarcoma of Uterus", "Leiomyosarcoma Uterus", "Endometrial Cancer", "Sex Cord Stromal Tumor", "Serous Ovarian Tumor" ], "eligibilityText": "Inclusion Criteria:\n\n* Written informed consent prior admission to the study\n* Age \u2265 18 years at the moment of signing the informed consent\n* Recurrent or metastatic low grade uterine sarcomas (low grade endometrial stromal sarcoma, low grade adenosarcoma without sarcomatous overgrowth and low grade leiomyosarcoma), low-grade endometrial carcinomas, sex cord stromal tumors (granulosa cell tumors...) and low grade serous ovarian cancer\n* Measurable disease, according to RECIST v1.1 criteria, assessed by CT scans\n* ER-positive tumors based on immunohistochemistry, assessed using the Allred scoring system (based on intensity and percentage of positive cells, see Appendix 4), and archival tissue available\n* At least and maximum of 1 prior line of hormonal therapy (tamoxifen, progestins and/or aromatase inhibitors). Response on 1st line hormonal therapy must have lasted for at least 3 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status: 0-2\n* Demonstrate adequate organ function: platelets \\> 100 x 10E9/L, serum total bilirubin \\< 1.5x Upper Limit of Normal (ULN) (patients with confirmed Gilbert's syndrome may be included in the study), alanine transaminase or aspartate transaminase \\< 2.5x ULN if no demonstrable liver metastases or \\< 5x ULN in presence of liver metastases\n* Post-menopausal status as defined by (i) age 60 or more, or (ii) age 45-59 and satisfying the following criteria: amenorrhea for at least 12 months and FSH in postmenopausal range, or (iii) \u2265 18 years of age and having had a bilateral oophorectomy\n* Be willing to receive 18F-FES PET scan. Exceptions will be made in case of (i) patients living far from one of the imaging centers and for whom travelling would be a too high burden for their physical conditions; (ii) patients who received tamoxifen within 8 weeks prior to study Day 1. These patients will be enrolled, but they will not receive a FES PET scan\n* Be willing to donate a core tumor biopsy if technically feasible\n\nExclusion Criteria:\n\n* Any other active malignancy or primary malignancy diagnosed within the previous 5 years, except for adequately treated squamous or basal cell carcinoma of the skin or in situ cervical carcinoma\n* Patients currently receiving (and unwilling to discontinue) any estrogen replacement therapy.\n* Patients participating in a study or having participated in a study of an investigational agent and received study therapy (or used an investigational device) within 4 weeks prior to study Day 1\n* Patients who received prior chemo- or targeted therapy within 4 weeks prior to study Day 1 or who has not recovered from adverse events (i.e., adverse event not resolved to \u2264 Grade 1 or baseline), due to a previously administered agent\n* Patients with no archival tissue available, except for patients from whom an additional fresh core biopsy can be obtained for ER assessment\n* Any other disease, metabolic dysfunction, physical examination or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interfere with obtaining informed consent.\n* Any condition not permitting compliance with the study protocol", "briefSummary": "This phase 2 clinical trial aims to evaluate the efficacy of Fulvestrant, an ER-antagonist, in women with estrogen receptor positive (ER+) low-grade gynecological cancers. The primary objective is to determine the response rate (RR) to Fulvestrant, defined by partial or complete response according to RECIST v1.1 criteria. Secondary objectives include assessing progression-free survival (PFS) over 3 years, clinical benefit (CB), duration of response, safety and tolerability, and quality of life (QoL) in each tumor type group. Exploratory objectives involve evaluating the feasibility of 18F-FES PET imaging for detecting ER expression, the predictive value of sequential 18F-FES PET scans for treatment response, and collecting tumor biopsies and cf-DNA for genetic analysis to identify adaptive response mechanisms to Fulvestrant.", "adenosarcoma_in_eligibility": true, "adenosarcoma_in_conditions": true, "adenosarcoma_anywhere": true }, { "nct": "NCT07467772", "url": "https://clinicaltrials.gov/api/v2/studies/NCT07467772?format=json", "http_status": 200, "briefTitle": "Ph 2 Elacestrant in ER Positive Uterine Sarcomas", "officialTitle": "A Phase 2 Study Evaluating the Efficacy of Elacestrant in Patients With Estrogen Receptor Positive Uterine Sarcomas", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-05-22", "startDate": "2026-03-25", "completionDate": "2028-04", "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 30, "enrollmentType": "ESTIMATED", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "conditions": [ "Uterine Sarcoma", "Uterine Leiomyosarcoma", "Endometrial Stromal Sarcoma", "ESS", "Perivascular Epithelioid Cell Tumors", "Uterine Adenosarcoma", "Uterine PEComa", "Estrogen Receptor Positive Tumor", "uLMS" ], "eligibilityText": "Inclusion Criteria:\n\nParticipant must have histologically confirmed uterine sarcoma of one of the following subtypes: uterine leiomyosarcoma (uLMS), endometrial stromal sarcoma (ESS), uterine adenosarcoma, or uterine PEComa.\n\nTumor must have moderate to strong immunohistochemical expression in \u226575% of tumor cells of estrogen receptor (ER) as assessed by institutional pathology review.\n\nParticipants must have locally advanced or metastatic disease that is not amenable to surgery.\n\nParticipants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as \u226520 mm (\u22652 cm) by chest x-ray or as \u226510 mm (\u22651 cm) with CT scan, MRI, or calipers by clinical exam. See Section 12 (Measurement of Effect) for the evaluation of measurable disease.\n\nAge \u226518 years at the time of consent\n\nECOG performance status \u22642 (Karnofsky \u226560%, see Appendix A).\n\nParticipants must have adequate organ and marrow function as defined below:\n\nHemoglobin \u2265 8.0 g/dL\n\nabsolute neutrophil count \u22651,000/mcL\n\nplatelets \u2265100,000/mcL\n\ntotal bilirubin \u22641.5 \u00d7 institutional upper limit of normal (ULN)\n\nAST(SGOT)/ALT(SGPT) \u22643.0 \u00d7 institutional ULN (unless liver metastases are present in which case it must be \u2264 5 \u00d7 ULN)\n\nglomerular filtration rate (GFR) \u226560 mL/min/1.73 m2\n\nHuman immunodeficiency virus (HIV)-infected participants on effective non-CYP3A4 interacting (see Section 3.2.3) anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n\nFor participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n\nParticipants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n\nParticipants with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.\n\nParticipants must be disease-free of prior invasive malignancies for \\> 5 years with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. NOTE: If there is a history of prior malignancy, participants must not be receiving other specific treatment for that cancer.\n\nParticipants should have completed prior treatment for their cancer: chemotherapy or radiotherapy must have been completed for greater than 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study.\n\nParticipants should have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia.\n\nParticipants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.\n\nParticipants must have a QTc interval length of below 450 msec. QTc will be calculated via the Fridericia's formula.\n\nParticipant must be willing to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n\nParticipant must be able to swallow and maintain pills.\n\nAbility to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) and/or family member available will also be eligible.\n\nWomen of childbearing age, women who are made postmenopausal through use of GNRH agonists must agree to use adequate contraception for the duration of protocol treatment and for at least 6 months af", "briefSummary": "This study is to evaluate the efficacy and safety of elacestrant, in participants with advanced estrogen receptor (ER)-positive uterine sarcomas. The name of the study drug involved in this research study is:\n\n-Elacestrant (a type of selective estrogen receptor degrader)", "adenosarcoma_in_eligibility": true, "adenosarcoma_in_conditions": true, "adenosarcoma_anywhere": true }, { "nct": "NCT02834013", "url": "https://clinicaltrials.gov/api/v2/studies/NCT02834013?format=json", "http_status": 200, "briefTitle": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "officialTitle": "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors", "overallStatus": "ACTIVE_NOT_RECRUITING", "lastUpdatePostDate": "2026-06-17", "startDate": "2017-01-30", "completionDate": "2027-06-01", "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 798, "enrollmentType": "ACTUAL", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "conditions": [ "Acinar Cell Carcinoma", "Adenoid Cystic Carcinoma", "Adrenal Cortical Carcinoma", "Adrenal Gland Pheochromocytoma", "Anal Canal Neuroendocrine Carcinoma", "Anal Canal Undifferentiated Carcinoma", "Angiosarcoma", "Apocrine Neoplasm", "Appendix Mucinous Adenocarcinoma", "Bartholin Gland Transitional Cell Carcinoma", "Basal Cell Carcinoma", "Bladder Adenocarcinoma", "Breast Metaplastic Carcinoma", "Cervical Adenocarcinoma", "Cholangiocarcinoma", "Chordoma", "Colorectal Squamous Cell Carcinoma", "Desmoid Fibromatosis", "Endometrial Transitional Cell Carcinoma", "Endometrioid Adenocarcinoma", "Esophageal Neuroendocrine Carcinoma", "Esophageal Undifferentiated Carcinoma", "Extrahepatic Bile Duct Carcinoma", "Extramammary Paget Disease", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fibromyxoid Tumor", "Gallbladder Carcinoma", "Gastric Neuroendocrine Carcinoma", "Gastric Squamous Cell Carcinoma", "Gastric Undifferentiated Carcinoma", "Gastrointestinal Stromal Tumor", "Gestational Trophoblastic Tumor", "Giant Cell Carcinoma", "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type", "Intestinal Neuroendocrine Carcinoma", "Intrahepatic Cholangiocarcinoma", "Lung Neuroendocrine Tumor", "Lung Sarcomatoid Carcinoma", "Major Salivary Gland Carcinoma", "Malignant Neoplasm of Unknown Primary", "Malignant Odontogenic Neoplasm", "Malignant Peripheral Nerve Sheath Tumor", "Malignant Solid Neoplasm", "Malignant Testicular Sex Cord-Stromal Tumor", "Metastatic Pituitary Neuroendocrine Tumor", "Minimally Invasive Lung Adenocarcinoma", "Mixed Mesodermal (Mullerian) Tumor", "Mucinous Adenocarcinoma", "Mucinous Cystadenocarcinoma", "Nasal Cavity Adenocarcinoma", "Nasal Cavity Carcinoma", "Nasopharyngeal Carcinoma", "Nasopharyngeal Low Grade Papillary Adenocarcinoma", "Nasopharyngeal Undifferentiated Carcinoma", "Oral Cavity Carcinoma", "Oropharyngeal Undifferentiated Carcinoma", "Ovarian Adenocarcinoma", "Ovarian Germ Cell Tumor", "Ovarian Mucinous Adenocarcinoma", "Ovarian Squamous Cell Carcinoma", "Ovarian Transitional Cell Carcinoma", "Pancreatic Acinar Cell Carcinoma", "Pancreatic Neuroendocrine Carcinoma", "Paraganglioma", "Paranasal Sinus Adenocarcinoma", "Paranasal Sinus Carcinoma", "Parathyroid Gland Carcinoma", "PEComa", "Penile Squamous Cell Carcinoma", "Peritoneal Mesothelial Neoplasm", "Placental Choriocarcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Pseudomyxoma Peritonei", "Rare Disorder", "Scrotal Squamous Cell Carcinoma", "Seminal Vesicle Adenocarcinoma", "Seminoma", "Serous Cystadenocarcinoma", "Small Intestinal Adenocarcinoma", "Small Intestinal Squamous Cell Carcinoma", "Spindle Cell Neoplasm", "Teratoma With Somatic-Type Malignancy", "Testicular Non-Seminomatous Germ Cell Tumor", "Thyroid Gland Carcinoma", "Tracheal Carcinoma", "Transitional Cell Carcinoma", "Ureter Adenocarcinoma", "Ureter Squamous Cell Carcinoma", "Urethral Adenocarcinoma", "Urethral Squamous Cell Carcinoma", "Vaginal Adenocarcinoma", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified", "Vulvar Carcinoma" ], "eligibilityText": "Inclusion Criteria:\n\n* Patients are eligible under ONE of the following criteria:\n\n * For all cohorts except the gestational trophoblastic disease (GTD) (Cohort #47), patients must have histologically and/or biochemically confirmed rare cancer and must be able to submit specimens; to be eligible for the GTD cohort: patients must have disease confirmed by quantitative serum beta-human chorionic gonadotropin (hCG) within 28 days prior to registration and must be able to submit blood specimens (tissue submission is not required for patients who will be registered to the GTD cohort \\[Cohort #47\\]); NOTE: Subsequent to site's Institutional Review Board (IRB) approval of revision 3, patients are NOT required to participate in EAY131 \"National Cancer Institute (NCI)-Molecular Analysis for Therapy Choice (MATCH)\" to register to S1609 OR\n * FOR PATIENTS WITH PD-L1 AMPLIFICATION (COHORT #50) ONLY: All solid tumors (excluding lymphoma) are allowed for the PD-L1 amplified cohort if they have PD-L1 amplification; patients may be considered for registration to the PD-L1 amplified cohort (Cohort #50) with the confirmation of at least one of the study chairs; PD-L1 amplification is defined as having deoxyribonucleic acid (DNA) copy number of equal to or greater than six by any of the following Clinical Laboratory Improvement Act (CLIA)-approved lab; (Immunohisochemistry \\[IHC\\] and fluorescence in situ hybridization \\[FISH\\] are not allowed); the assay must be done at or after the diagnosis of advanced disease, but PRIOR TO REGISTRATION; NOTE: patients with PD-L1 overexpression by IHC or PD-L1 amplification by FISH do not quality for this cohort; OR\n * FOR PATIENTS ENROLLED IN EAY131 \"NCI-MATCH\" PRIOR TO EAY131 ADDENDUM 10 ONLY: Patients must have histologically confirmed rare cancer that did not have a match to a molecularly-guided therapy on EAY131 \"NCI-MATCH\" protocol or who are off protocol treatment on EAY131, \"NCI-MATCH\" and have no further molecularly-matched treatment recommendations per EAY131, \"NCI-MATCH\" or who are otherwise unable to receive EAY131, \"NCI-MATCH\" therapy\n* Patients who do not qualify for one of the histologic cohorts and are not on the ineligible histology list may be considered for registration in the \"Not Otherwise Categorized\" Rare Tumors cohort with confirmation of at least one of the study chairs via email\n\n * NOTE: The \"Not Otherwise Categorized\" Rare Tumors cohort was permanently closed to accrual on 3/15/2019\n* Patients who are determined to have a rare cancer with unknown primary site are eligible under cohort #32 (tumor of unknown primary \\[cancer of unknown primary; CuP\\]), provided that there is histologic documentation of metastatic malignancy with no discernible primary site identified from histopathologic review, physical exam and associated cross-sectional imaging of the chest, abdomen, and pelvis\n\n * NOTE: The \"Tumor of unknown primary (Cancer of Unknown Primary; CuP\" cohort was permanently closed to accrual on 12/22/2017\n* Patients must also meet one of the following:\n\n * Patients must have progressed following at least one line of standard systemic therapy and there must not be other approved/standard therapy available that has been shown to prolong overall survival (i.e. in a randomized trial against another standard treatment or by comparison to historical controls); patients who cannot receive other standard therapy that has been shown to prolonged survival due to medical issues will be eligible, if other eligibility criteria are met; OR\n * Patients for whose disease no standard treatment exists that has been shown to prolong overall survival\n* For all cohorts except the GTD cohort (Cohort #47): Patients must have a diagnostic quality computed tomography (CT) scan or magnetic resonance imaging (MRI), performed within 28 days prior to registration, which demonstrates measurable disease, as defined in RECIST v. 1.1; scans must include imaging of the chest, abdomen and pelvis, with the exce", "briefSummary": "This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.\n\nThis trial enrolls participants for the following cohorts based on condition:\n\n1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer \\[NPC\\], and squamous cell carcinoma of the head and neck \\[SCCHN\\]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07/27/2018)\n2. Epithelial tumors of major salivary glands (closed to accrual 03/20/2018)\n3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual)\n4. Undifferentiated carcinoma of gastrointestinal (GI) tract\n5. Adenocarcinoma with variants of small intestine (closed to accrual 05/10/2018)\n6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10/17/2018)\n7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018)\n8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible (closed to accrual)\n9. Intrahepatic cholangiocarcinoma (closed to accrual 03/20/2018)\n10. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03/20/2018)\n11. Sarcomatoid carcinoma of lung\n12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma\n13. Non-epithelial tumors of the ovary: A) Germ cell t", "adenosarcoma_in_eligibility": false, "adenosarcoma_in_conditions": false, "adenosarcoma_anywhere": true }, { "nct": "NCT02020707", "url": "https://clinicaltrials.gov/api/v2/studies/NCT02020707?format=json", "http_status": 200, "briefTitle": "Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers", "officialTitle": "Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-07-26", "startDate": "2014-02-24", "completionDate": "2024-07-18", "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 43, "enrollmentType": "ACTUAL", "phases": [ "PHASE1" ], "studyType": "INTERVENTIONAL", "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosarcoma", "Cervical Adenosquamous Carcinoma", "Cervical Carcinosarcoma", "Cervical Squamous Cell Carcinoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Carcinosarcoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Squamous Cell Carcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Malignant Female Reproductive System Neoplasm", "Malignant Ovarian Clear Cell Tumor", "Malignant Ovarian Endometrioid Tumor", "Malignant Ovarian Epithelial Tumor", "Malignant Ovarian Mucinous Tumor", "Malignant Peritoneal Neoplasm", "Malignant Solid Neoplasm", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal Clear Cell Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Primary Peritoneal Transitional Cell Carcinoma", "Primary Peritoneal Undifferentiated Carcinoma", "Unresectable Melanoma", "Uterine Corpus Carcinosarcoma" ], "eligibilityText": "Inclusion Criteria:\n\n* Age \\>= 18 years\n* Melanoma cohort only: histologic proof of surgically unresectable stage IV malignant melanoma\n* Melanoma cohort only: measurable disease defined as at least one lesion whose longest diameter can be accurately measured as \\>= 2.0 cm with chest x-ray, or as \\>= 1.0 cm with computed tomography (CT) scan or magnetic resonance imaging (MRI) scan; or CT component of a positron emission tomography (PET)/CT; NOTE: disease that is measurable by physical examination only is not eligible\n* Gynecologic cancer cohorts only (dose escalation and dose expansion cohorts)\n\n * Dose escalation cohort only: Histologic proof of epithelial cervical, endometrial, ovarian, fallopian, or primary peritoneal cancers; allowable histologies for cervical cancer include squamous cell carcinoma, adenocarcinoma, and mixed/adenosquamous carcinoma; allowable histologies for endometrial cancer include endometrioid, serous, clear cell, mucinous, squamous, transitional cell, undifferentiated, mixed, and carcinosarcoma (this is considered a poorly differentiated epithelial tumor); allowable histologies for ovarian, fallopian, and peritoneal cancer include serous, clear cell, endometrioid, mucinous, transitional cell, undifferentiated, mixed, and carcinosarcoma\n* Endometrial cancer expansion cohort only:\n\n * Histologic proof of endometrial cancer including endometrioid, serous, clear cell, mucinous, undifferentiated, mixed, and carcinosarcoma histologies\n * 1-3 lines of cytotoxic or immune checkpoint inhibitor therapy (not including hormonal therapy or other regimens not containing cytotoxic agents or immune checkpoint inhibitors)\n\n * If one (1) prior line of therapy, must have contained a taxane, a platinum drug, and and immune checkpoint inhibitor\n * If 2-3 prior lines of therapy, at least one must have contained a taxane and a platinum drug, and at least one must have contained an immune checkpoint inhibitor\n* Ovarian cancer expansion cohort only:\n\n * Histologic proof of ovarian cancer including high grade serous, endometrioid, clear cell, mucinous, transitional cell, undifferentiated, mixed, and carcinosarcoma histologies\n * 1-4 lines of cytotoxic chemotherapy (not including hormonal therapy or other non-cytotoxic regimens)\n\n * At least one prior line of chemotherapy must have contained a taxane and a platinum agent\n * If 1 or 2 prior lines of chemotherapy, patient's disease must be platinum-resistant\n\n * NOTE: Platinum-resistance is defined as any of the following occurring \\< 183 days after the last dose of platinum-based chemotherapy:\n\n * Development of measurable disease (per Response Evaluation Criteria in Solid Tumors \\[RECIST\\] 1.1)\n * Progression of radiographic disease (per RECIST 1.1)\n * Increase in CA-125 level to \\>= 2 x upper limit of normal (ULN) (if within normal limits \\[WNL\\] at the completion of platinum-based chemotherapy)\n\n * If CA-125 is used to determine the date of progression then it must be confirmed by a second CA-125 value \\>= 7 days after the first level; the date of the first qualifying CA-125 is used to compute the platinum-free interval\n * Increase in CA-125 level to \\>= 2 x nadir (if nadir \\> ULN)\n\n * If CA-125 is used to determine the date of progression then it must be confirmed by a second CA-125 value \\>= 7 days after the first level; the date of the first qualifying CA-125 is used to compute the platinum-free interval\n * If 3-4 prior lines of chemotherapy, may be platinum-resistant or platinum-sensitive\n * At least one prior line of cytotoxic chemotherapy must also have contained bevacizumab\n* Dose escalation cohort: For ovarian, fallopian tube, and peritoneal cancers only: Must meet criteria for one option below:\n\n * Platinum-resistant, defined as =\\< 183 days from the date of the most recent dose of chemotherapy containing either carboplatin or cisplatin until the first evidence of cancer recurrence or progressi", "briefSummary": "This phase I trial studies the side effects and best dose of nab-paclitaxel and bevacizumab in treating patients with stage IV melanoma that cannot be removed by surgery (unresectable), cancer of the cervix, endometrium, ovary, fallopian tube or peritoneal cavity. Drugs used in chemotherapy, such as nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may stop or slow tumor growth by blocking the growth of new blood vessels necessary for tumor growth. Giving nab paclitaxel and bevacizumab may kill more tumor cells than nab-paclitaxel alone.", "adenosarcoma_in_eligibility": false, "adenosarcoma_in_conditions": true, "adenosarcoma_anywhere": true }, { "nct": "NCT07394413", "url": "https://clinicaltrials.gov/api/v2/studies/NCT07394413?format=json", "http_status": 200, "briefTitle": "Surgical Handling of Fertility-preserving Treatments for Cervical Adenocarcinomas", "officialTitle": "Surgical Handling of Fertility-preserving Treatments for Cervical Adenocarcinomas", "overallStatus": "NOT_YET_RECRUITING", "lastUpdatePostDate": "2026-02-06", "startDate": "2026-02-01", "completionDate": "2027-02-01", "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 100, "enrollmentType": "ESTIMATED", "phases": null, "studyType": "OBSERVATIONAL", "conditions": [ "Cervical Adenosarcoma" ], "eligibilityText": "Inclusion Criteria:\n\n* Adult women of reproductive age with a diagnosis of cervical adenocarcinoma\n* Undergoing fertility-sparing surgery\n* Minimum 12-month follow-up\n* Signed informed consent\n\nExclusion Criteria:\n\n* Histotypes other than cervical adenocarcinoma\n* Undergoing radical surgery\n* Follow-up less than 12 months", "briefSummary": "Despite a growing body of literature on the subject, there is still uncertainty regarding direct comparisons between different conservative surgical techniques for cervical adenocarcinomas. In particular, it remains unclear whether fertility-sparing surgery for cervical adenocarcinomas - characterized by skip lesions - can ensure optimal disease control while achieving adequate obstetric outcomes.\n\nFor this reason, a systematic review and meta-analysis of the literature, along with an analysis of our center's data, is warranted. This approach will allow a critical, comparative evaluation of the efficacy of the different techniques (conization, simple trachelectomy, and radical trachelectomy) and the identification of prognostic factors to guide therapeutic choice.", "adenosarcoma_in_eligibility": false, "adenosarcoma_in_conditions": true, "adenosarcoma_anywhere": true }, { "nct": "NCT00162721", "url": "https://clinicaltrials.gov/api/v2/studies/NCT00162721?format=json", "http_status": 200, "briefTitle": "The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas", "officialTitle": "Phase III Study About the Effects of the Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2007-08-10", "startDate": "2001-09", "completionDate": null, "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 270, "enrollmentType": "ESTIMATED", "phases": [ "PHASE3" ], "studyType": "INTERVENTIONAL", "conditions": [ "Uterine Sarcoma" ], "eligibilityText": "Inclusion Criteria:\n\n* Histologically confirmed uterine sarcoma (rereading in reference centers)\n* Leiomyosarcoma, adenosarcoma, carcinosarcoma and high grade endometrial stromal sarcoma\n* All stages \\<= stage III (FIGO modified for endometrial carcinoma)\n* Full surgical exeresis\n* Age \\>= 18 years and physiological age \\<= 65 years\n* Negative extension check-up (thoracic and abdomino-pelvic TDM)\n* Performance status (PS) \\<= 2 (ECOG)\n* Normal haematologic functions (absolute neutrophil count \\> 1,500/mm3, platelets \\> 100,000/mm3)\n* Serum creatinine \\< 1.25 x ULN\n* Good hepatic check-up (total serum bilirubin \\< 1.5 x ULN; AST or ALT \\< 2.5 x ULN)\n* Absence of neuropathy \\> grade 1\n* Left ventricular ejection fraction \\> 50% (by isotopic or ultrasound scan determination)\n* Written informed consent\n\nExclusion Criteria:\n\n* Low grade endometrial stromal sarcoma\n* Time since surgery \\> 8 weeks\n* Specific contraindications to the studied treatment (cardiac, kidney, or hepatic ones)\n* Antecedents or evolutive psychiatric disorder\n* Concurrent active infection or other serious uncontrolled systemic disease\n* Antecedents of cancer but a cutaneous basocellular one or an in situ epithelioma of the cervix", "briefSummary": "This is a Phase III study about the effects of the addition of polychemotherapy to adjuvant radiotherapy in the treatment of non-metastatic uterine sarcomas.", "adenosarcoma_in_eligibility": true, "adenosarcoma_in_conditions": false, "adenosarcoma_anywhere": true }, { "nct": "NCT01979393", "url": "https://clinicaltrials.gov/api/v2/studies/NCT01979393?format=json", "http_status": 200, "briefTitle": "IRCI Gynae Sarcomas, High Grade Uterine Sarcoma", "officialTitle": "A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Uterine Sarcoma (HGUtS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2025-08-01", "startDate": "2015-02-02", "completionDate": "2024-01-15", "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 58, "enrollmentType": "ACTUAL", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "conditions": [ "Uterine Sarcoma" ], "eligibilityText": "Inclusion Criteria:\n\n* Patients who are suitable for treatment with doxorubicin +/- ifosfamide and fall within one of the following patient populations:\n\n \u2022 HGUS, HGESS, HGLMS and HG adenosarcoma\n * FIGO stage II and stage III : if adjuvant chemotherapy is proposed\n * FIGO stage IV: if first line chemotherapy is proposed\n* Metastatic: diagnosed with disease relapse after local treatment for primary tumor\n* at least 18 years old\n* written informed consent\n* Central pathological confirmation: Histological evidence of HGUS, HGESS, HGLMS and HG adenosarcoma\n* Non-progressive patients (CR, PR, SD) at the end of the first line treatment (standard chemotherapy consisting of 4 to 6 cycles of anthracyclines alone or in combination with ifosfamide)\n* WHO/ECOG performance status 0-2\n* Adequate organ and bone marrow function within 3 days prior to the first dose of study treatment (Cabozantinib/placebo)\n* Clinically normal cardiac function\n* Women of child bearing potential must have a negative serum/urine pregnancy test within 3 days prior to the first dose of study treatment\n* Adequate birth control measures\n\nExclusion Criteria:\n\n* low-grade ESS, leiomyosarcoma (low or intermediate), carcinosarcoma, low-grade adenosarcoma, rhabdomyosarcoma (alveolar or embryonal) and soft tissue PNET of uterus/cervix.\n* contraindications to cabozantinib\n* not able to swallow and retain oral tablets\n* planned use of chemotherapy, radiation therapy, radionuclide treatment, small molecule tyrosine kinase inhibitor or hormonal therapy, and any other investigational agent (Cabozantinib/placebo) during the treatment period\n* concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment\n* patient with poorly controlled hypertension defined at baseline as blood pressure \\>150/90\n* patients who have suffered a cerebrovascular accident at any time in the past, patients who have suffered a transient ischemic attack in the past 6 months, patients who have suffered a deep venous thrombosis (DVT) or a pulmonary embolism in the past 6 months\n* Gastrointestinal disorders\n* patients with radiographic evidence of cavitating pulmonary lesion(s)\n* patients with tumor in contact with, invading or encasing any major blood vessels\n* patients evidence of tumor invading the GI tract\n* evidence of active bleeding or bleeding diathesis\n* hemoptysis \u2265 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose of study treatment\n* signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment\n* clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment\n* prior major surgery or trauma within 6 weeks prior to first dose of study drug and any wound, fracture, or ulcer should be completely healed\n* concurrent or planned treatment with strong inhibitors or inducers of cytochrome P450 3A4/5", "briefSummary": "This study aims to investigate a drug called Cabozantinib which belongs to a family of drugs that have effects on tumour growth, blood supply, invasion and spread.\n\nTherefore, we want to find out whether taking cabozantinib after treatment with surgery and chemotherapy is effective and safe for patients who responded or had stable disease after their chemotherapy.\n\nAll participants will receive 4-6 cycles of standard chemotherapy. Those with stabilization or response to the standard chemotherapy will be split into 2 groups (cabozantinib or placebo).", "adenosarcoma_in_eligibility": true, "adenosarcoma_in_conditions": false, "adenosarcoma_anywhere": true }, { "nct": "NCT03509207", "url": "https://clinicaltrials.gov/api/v2/studies/NCT03509207?format=json", "http_status": 200, "briefTitle": "Vorinostat (SAHA) in Uterine Sarcoma", "officialTitle": "A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2020-08-04", "startDate": "2017-12-14", "completionDate": "2019-02-04", "resultsFirstPostDate": "2020-07-27", "hasResults": true, "enrollmentCount": 3, "enrollmentType": "ACTUAL", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "conditions": [ "Leiomyosarcoma", "Endometrial Stromal Tumors", "Carcinosarcomas Uterine" ], "eligibilityText": "Inclusion Criteria:\n\n* Histologically confirmed metastatic uterine sarcoma (endometrial stromal sarcoma, undifferentiated uterine sarcoma, leiomyosarcoma, adenosarcoma and carcinosarcoma\n\n * High HDAC-positivity of the tumor determined by immunohistochemistry\n * Patients must have received prior systemic antineoplastic therapy\n * Patient is not amenable for curative therapy\n * Age \\>= 18 years\n * Estimated life expectancy \\> 3 months\n * Measurable disease on CT/MRI (at least one measurable lesion \\>1cm) or chest X-ray (at least one measurable lesion \\>2cm)\n * Karnofsky performance status of 60-100\n * Adequate hematologic, renal and hepatic function\n * Subject is able to swallow and retain oral medication and does not have uncontrolled emesis\n * No fertility preserved\n * Written informed consent\n\nExclusion Criteria:\n\n* Lack of or low expression of HDAC (see 4.1 \"Pre-Screening\")\n\n * Significant cardiac disease\n * Other invasive malignant tumor diagnosed within the last 5 years (e.g. metastases from breast cancer in the last 3 years)\n * Significant bowel obstruction\n * Severe uncontrolled infection\n * Known HIV-positivity\n * Symptomatic brain metastasis or leptomeningeal disease\n * Pre-existing significant liver disease, severe hepatic impairment (Bilirubin no greater than 1.5 times upper limit of normal (ULN) and/or aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) greater than 2.5 times ULN)\n * Known history of allergic reaction to vorinostat or similar medications\n * Systemic therapy or an investigational agent within 21 days prior to study inclusion\n * Uncontrolled hypertension (sustained systolic blood pressure \\> 150 mmHg or diastolic pressure \\> 100 mmHg despite optimal medical management)\n * Major surgery within 3 weeks of enrollment when diagnosed at an early stage\n * Symptomatic congestive heart failure\n * Unstable angina pectoris or cardiac arrhythmia\n * Myocardial infarction within last 6 months\n * Known active hepatitis B or hepatitis C\n * Psychiatric illness/social situations that would limit compliance with study requirements-\n * Prior history of thrombotic or thromboembolic events, unless adequately controlled by anticoagulant therapy", "briefSummary": "Uterine sarcomas are rare tumors with a poor prognosis.\n\nThe main purpose of this phase II proof-of-principle- pilot study is to test the efficacy of the hydroxamic acid-based Histone deacetylase inhibitor (HDACI) Vorinostat (SAHA) as monotherapy in patients with HDAC-positive, progressive, metastatic uterine sarcomas and mixed epithelial and mesenchymal tumors after prior anti-proliferative therapy.", "adenosarcoma_in_eligibility": true, "adenosarcoma_in_conditions": false, "adenosarcoma_anywhere": true }, { "nct": "NCT05481645", "url": "https://clinicaltrials.gov/api/v2/studies/NCT05481645?format=json", "http_status": 200, "briefTitle": "Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy \u00b1 Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.", "officialTitle": "Evaluating the Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy \u00b1 Anlotinib Hydrochloride Capsules for First-line Treatment of Patient With Advanced Endometrial Cancer or Sarcoma of Uterus: a Multi-center, Open-label, Randomized Controlled, Phase II Clinical Trial.", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2026-01-09", "startDate": "2022-08-26", "completionDate": "2025-11-30", "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 71, "enrollmentType": "ACTUAL", "phases": [ "PHASE2" ], "studyType": "INTERVENTIONAL", "conditions": [ "Advanced Endometrial Cancer", "Sarcoma of Uterus" ], "eligibilityText": "Inclusion Criteria:\n\n* The subjects voluntarily participated in this study, signed the informed consent, and had good compliance;\n* Age: \u226518 years old (when signing the informed consent form); ECOG PS score: 0-1; expected survival period of more than 3 months; body mass index (BMI) \\> 18.5 and weight \\> 40kg;\n* Who have not received first-line systemic anticancer therapy and are not suitable for receiving treatment other than systemic treatment:\n\n 1. Group 1 and 2: Stage III/IV epithelial endometrial cancer (including endometrioid carcinoma, non-endometrioid carcinoma, carcinosarcoma) confirmed by histopathology, and the subject also needs to meet one of the following categories:\n\n 1. Newly diagnosed subjects: there are still residual lesions visible on imaging after non-radical surgery;\n 2. Subjects with initial recurrence: if the subject received systemic platinum-based adjuvant and/or neoadjuvant chemotherapy\uff0cand the recurrence time is more than 6 months from the end of the last chemotherapy\uff0cthen the previous chemotherapy is allowed.\n 2. Group 3: Stage I-IV sarcoma of uterus, and the subject also needs to meet one of the following categories:\n\n 1. Newly diagnosed/initial recurrence subject of high grade endometrial stromal sarcoma (ESS)\u3001undifferentiated Uterine sarcoma (UUS) , uterine Leiomyosarcoma and adenosarcoma(uLMS) with sarcoma overgrowth (OS). The definition of new diagnosis and initial recurrence is the same as above.\n 2. Low grade ESS, adenosarcoma without SO and other Uterine sarcoma with ER+/PR+\uff0cthe subjects who failed in antiestrogen treatment.\n* According to the RECIST 1.1 criteria, there is at least one measurable lesion. If the measurable lesion is located in the area of previous radiotherapy, it should be clearly defined as progressing state;\n* Tumor tissue samples can be provided to detect MSI/MMR status or traceable test reports;\n* The main organs function well and meet the following standards:\n\n 1. Blood routine examination standards (no blood transfusion within 7 days before screening, no correction with hematopoietic stimulating factor drugs):\n\n 1. Hemoglobin (HGB) \u226590 g/L;\n 2. The absolute value of neutrophils (NEUT)\u22651.5\u00d7109/L;\n 3. Platelet count (PLT) \u2265 90 \u00d7 109/L;\n 2. The biochemical examination shall meet the following standards:\n\n 1. Total bilirubin (TBIL) \u2264 1.5 times the upper limit of normal (ULN);\n 2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5\u00d7ULN. If accompanied by liver metastasis, ALT and AST\u22645\u00d7ULN;\n 3. Serum creatinine (Cr) \u2264 1.5\u00d7ULN or creatinine clearance (Ccr) \u2265 60ml/min;\n 4. Serum albumin (ALB)\\>30g/L;\n 3. Urine routine examination standard: urine routine indicates urine protein \\<++; if urine protein \u2265++, it is necessary to confirm the 24-hour urine protein quantitative \u22641.0g;\n 4. Coagulation function or thyroid function tests should meet the following criteria:\n\n 1. Prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR) \u2264 1.5\u00d7ULN (no anticoagulation therapy);\n 2. Thyroid-stimulating hormone (TSH) \u2264 ULN; T3 and T4 levels should be investigated if abnormal, and normal T3 and T4 levels can be selected.\n 5. Echocardiography assessment: Left ventricular ejection fraction (LVEF) \u226550%.\n 6. 12-lead electrocardiogram evaluation: QTc\\<470ms.\n* Female subjects should agree that contraceptive measures (such as intrauterine devices or condoms) must be used during the study period and within 6 months after the end of the study; the serum pregnancy test must be negative within 7 days before study enrollment, and must be Non-lactating subjects.\n\nExclusion Criteria:\n\n* Tumor disease and medical history:\n\n 1. Other malignant tumors that have occurred or are currently concurrently present within 3 years. The following conditions were eligible for enrollment: other malignancies treated with a single surgery, achieving 5 consecutive years of disease-free survival (", "briefSummary": "This clinical study plans to enroll 69 endometrial cancer patients and 5-10 uterine sarcoma patients. The trial is divided into a lead-in phase and a main phase. The lead-in phase will include 9 subjects, while the main phase will enroll 60 endometrial cancer patients randomized 1:1. Additionally, 5-10 uterine sarcoma patients will be enrolled. The study aims to evaluate the efficacy and safety of TQB2450 injection combined with chemotherapy \u00b1 anlotinib hydrochloride capsules as first-line treatment, followed by TQB2450 injection monotherapy \u00b1 anlotinib hydrochloride capsules as maintenance therapy for advanced endometrial cancer or uterine sarcoma. The study will also explore efficacy-related biomarkers, mechanisms of action, safety and/or pathological mechanisms, and surgical conversion rates. The primary endpoint is ORR (Objective Response Rate).", "adenosarcoma_in_eligibility": true, "adenosarcoma_in_conditions": false, "adenosarcoma_anywhere": true }, { "nct": "NCT04123158", "url": "https://clinicaltrials.gov/api/v2/studies/NCT04123158?format=json", "http_status": 200, "briefTitle": "MYometrial Lesion UltrasouNd And mRi", "officialTitle": "MYometrial Lesion UltrasouNd And mRi", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-05-16", "startDate": "2019-01-17", "completionDate": "2023-12-04", "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 2353, "enrollmentType": "ACTUAL", "phases": null, "studyType": "OBSERVATIONAL", "conditions": [ "Sarcoma Uterus" ], "eligibilityText": "Inclusion Criteria:\n\n* Consecutive patients admitted to our Department for transvaginal ultrasound examination, in whom a myometrial lesion \\> 3cm in size is detected.\n* Informed consent form signed by the patient.\n\nExclusion Criteria:\n\n* Patients undergoing medical treatment for myometrial lesion;\n* Patients previously treated with hormonal therapy including estroprogestin in the last six months;\n* Patients previously treated by embolization", "briefSummary": "A monocentric prospective observational study aimed at assessing the accuracy of a diagnostic algorithm to pre-operatively identify uterine sarcomas..\n\nPrimary Aim:The primary outcome is to evaluate the accuracy (sensitivity/specificity) of \"Positive Orange Criteria\" category in predicting uterine sarcoma and STUMP in the population of patients with \\> 3 cm myometrial lesions.", "adenosarcoma_in_eligibility": false, "adenosarcoma_in_conditions": false, "adenosarcoma_anywhere": true }, { "nct": "NCT05881967", "url": "https://clinicaltrials.gov/api/v2/studies/NCT05881967?format=json", "http_status": 200, "briefTitle": "Molecular Mechanism Study of Uterine Sarcoma", "officialTitle": "Molecular Mechanism Study of Uterine Sarcoma", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2023-05-31", "startDate": "2023-03-01", "completionDate": "2025-11-30", "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 300, "enrollmentType": "ESTIMATED", "phases": null, "studyType": "OBSERVATIONAL", "conditions": [ "Uterine Sarcoma" ], "eligibilityText": "Inclusion Criteria:\n\n1. Age 18 or older;\n2. Newly treated or recurenced uterine sarcoma.\n\nExclusion Criteria:\n\n1. Diagnosis of other malignancies within the past 5 years;\n2. history of pelvic or vaginal radiation therapy;\n3. Known high-grade lesions of the cervix and endometrium.", "briefSummary": "The purpose of this project was to use multi-omics technology to screen the key factors for the occurrence and development of uterine sarcoma.", "adenosarcoma_in_eligibility": false, "adenosarcoma_in_conditions": false, "adenosarcoma_anywhere": true }, { "nct": "NCT04071704", "url": "https://clinicaltrials.gov/api/v2/studies/NCT04071704?format=json", "http_status": 200, "briefTitle": "Assessing Health-related Quality of Life in Sarcoma Patients", "officialTitle": "Incorporating the Patient Voice in Sarcoma Research: How Can we Assess Health-related Quality of Life in This Heterogeneous Group of Patients?", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2026-04-22", "startDate": "2019-05-01", "completionDate": "2024-09-01", "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 654, "enrollmentType": "ACTUAL", "phases": null, "studyType": "OBSERVATIONAL", "conditions": [ "Sarcoma" ], "eligibilityText": "Inclusion Criteria:\n\n* Age at diagnosis 18 years or older\n* Having a confirmed diagnosis of sarcoma\n\nExclusion Criteria:\n\n* Having any psychiatric condition or cognitive impairment that would hamper participation in interview/completion of self-reported questionnaires.\n* Patients with a Gastrointestinal Stroma Tumour (GIST) diagnosis, as they are quite unique in terms of type of disease and treatment.\n* Patients with Kaposi sarcoma, as this disease occurs quite often in people with AIDS\n* Patients with Carcinosarcoma as this disease is generally seen as a carcinoma", "briefSummary": "Although the clinical effectiveness of sarcoma treatment has improved, long-lasting and cumulative treatment side-effects may often detract from the overall marginal advantage. Information only on survival is insufficient to determine the net clinical benefit of a treatment. It is important to assess treatment effectiveness both in terms of objective outcomes (e.g., response, recurrence and survival) and in terms of subjective patient reported outcomes (PROs), objective functional outcomes including health-related quality of life (HRQoL).\n\nPrevious studies have predominantly used generic HRQoL instruments, which cover some relevant issues but do not capture all the unique experiences of patients with sarcoma, and thus lack content validity. A sarcoma-specific questionnaire should be able to detect, with more sensitivity, side-effects, symptoms and problems with function that are particularly relevant to patients with sarcoma. To date , there is no specific sarcoma HRQoL instrument available; and, given the heterogeneity of the disease in terms of subtype, location, age and treatment, the development of such an instrument may be challenging.\n\nThe aim of this collaborative project between the EORTC Quality of Life Group (QLG) and the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) is to raise the standard of HRQoL measurement in patients with sarcoma. An important question remains to be answered: Is it possible to develop one PROs questionnaire covering HRQoL issues that are relevant to all adult patients with sarcoma, or are the HRQoL issues related to the different localization / treatment sufficiently different to warrant the creation of separate item lists selected from the EORTC QLG Item Library?", "adenosarcoma_in_eligibility": false, "adenosarcoma_in_conditions": false, "adenosarcoma_anywhere": false }, { "nct": "NCT00413322", "url": "https://clinicaltrials.gov/api/v2/studies/NCT00413322?format=json", "http_status": 200, "briefTitle": "Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors", "officialTitle": "A Phase I Safety, Pharmacodynamic, Anti-Tumor Activity, and Pharmacokinetic Study of PXD101 Alone and in Combination With 5-Fluorouracil in Patients With Advanced Solid Tumors", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2015-07-08", "startDate": "2005-09", "completionDate": "2008-06", "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 35, "enrollmentType": "ACTUAL", "phases": [ "PHASE1" ], "studyType": "INTERVENTIONAL", "conditions": [ "Tumor" ], "eligibilityText": "Inclusion Criteria:\n\n* Histologically confirmed solid tumors\n* Advanced colorectal cancer or other adenocarcinomas\n* Tumor progression after standard chemotherapy, or where none yet approved\n* At least one unidimensionally measurable lesion\n* Karnofsky performance \\>= 70%\n* Life expectancy of at least 3 months\n* Age \\>= 18 years\n* Signed, written Institutional Review Board (IRB)-approved informed consent\n* Acceptable liver function:\n\n * Bilirubin \\<= 1.5 x upper limit of normal (ULN)\n * AST (SGOT) and ALT (SGPT) \\<= 2.5 x ULN, OR\n * AST (SGOT) and ALT (SGPT) \\<= 5 x ULN if liver metastasis\n* Acceptable renal function:\n\n * Serum creatinine within normal limits, OR\n * Calculated creatinine clearance of \\>= 60 mL/min/1.73 m2 for certain patients\n* Acceptable hematologic status:\n\n * Absolute neutrophil count (ANC) \\>= 1500 cells/mm3\n * Platelet count \\>= 100,000 (plt/mm3)\n * Hemoglobin \\>= 9 g/dL\n* Urinalysis: No clinically significant abnormalities\n* Acceptable coagulation status:\n\n * Prothrombin time (PT)/partial thromboplastin time (PTT) within normal limits, OR\n * For patients on anticoagulation therapy, status within therapeutic range\n* For men and women of child-producing potential, use of effective contraception\n* Tumors accessible for needle biopsy\n\nExclusion Criteria:\n\n* Significant cardiovascular disease.\n* A marked baseline prolongation of QT/QTc interval\n* Long QT syndrome\n* Required use of medication on dosing days that may cause torsade de pointes.\n* Infections requiring intravenous (IV) systemic therapy\n* Pregnant or nursing women\n* Treatment with chemotherapy or investigational therapy \\< 4 weeks (28 days) prior to study entry (6 weeks for nitrosoureas, mitomycin C, or Avastin).\n* Treatment with radiation therapy or surgery either within 2 weeks prior to study entry, or not yet recovered if 2-4 weeks prior to study entry.\n* Unwillingness or inability to comply with protocol procedures.\n* Known active uncontrolled infection with HIV, hepatitis B, or hepatitis C\n* Serious nonmalignant disease (e.g. hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor\n* Concurrent use of other investigational agent(s)\n* Serious concurrent medical illness", "briefSummary": "This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves within the body when given with 5-Fluorouracil (5-FU).", "adenosarcoma_in_eligibility": false, "adenosarcoma_in_conditions": false, "adenosarcoma_anywhere": true }, { "nct": "NCT00413075", "url": "https://clinicaltrials.gov/api/v2/studies/NCT00413075?format=json", "http_status": 200, "briefTitle": "Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma", "officialTitle": "Open Label, Dose Escalation Trial of Oral PXD101 in Patients With Advanced Solid Tumors", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2015-07-08", "startDate": "2006-06", "completionDate": "2011-08", "resultsFirstPostDate": null, "hasResults": false, "enrollmentCount": 121, "enrollmentType": "ACTUAL", "phases": [ "PHASE1" ], "studyType": "INTERVENTIONAL", "conditions": [ "Solid Tumor", "Lymphoma" ], "eligibilityText": "Inclusion Criteria Inclusion criteria must be met at the time of screening unless otherwise specified.\n\n* Age \u2265 18 years\n* Solid Tumor: Histologically documented diagnosis of primary or metastatic solid tumors refractory to standard therapy or for which no standard therapy exists. Entry will include, but is not limited to patients with androgen-independent prostate cancer, and cancers of the breast, ovary, head and neck, non-small cell lung, bladder, colorectal or kidney. Lymphoma: Relapsed or refractory B-Cell, T-Cell or NK-Cell lymphoma or Hodgkin's Disease. At Yale Cancer Center, lymphoma patients will be limited to those who are not eligible for potentially curative re-induction regimens and transplant and without a reasonable chance of having durable remissions with standard therapies.\n* At least one evaluable lesion. Lesions must be evaluated by CT-scan, MRI, or bone scan. Patients with prostate cancer, bone disease and rising PSA but no other evaluable disease are eligible and will be evaluated based on PSA. For lymphoma patients, lesions can also be measured by PET and/or evaluated in peripheral blood or bone marrow.\n* Progressive disease: Progressive disease will be defined as new or progressive lesions on CT-scan, MRI, bone scan or by rising PSA (see Section 11.3).\n* \u2265 4 weeks since prior RT or chemotherapy.\n* Karnofsky Performance Status \u2265 60%\n* Solid Tumor: Acceptable liver, renal and bone marrow function including the following:\n\n * Absolute neutrophil count \u2265 1.5 x 109/L\n * Hemoglobin \u2265 9.0 g/dl\n * Platelets \u2265 100 x 109/L\n * Bilirubin \u2264 1.5 times the upper limit of normal (x ULN)\n * Aspartate transaminase (AST) and alanine transaminase (ALT) \u2264 3.0 x ULN (\u2264 5.0 x ULN is acceptable if liver has tumor involvement)\n * Serum Creatinine \u2264 1.5 x ULN\n * PT-INR/PTT \u2264 1.5 x ULN or in the therapeutic range if on anticoagulation therapy\n* Lymphoma: Acceptable liver, renal and bone marrow function including the following:\n\n * Absolute Neutrophil Count \u2265 1.0 x 109/L\n * Platelets \u2265 50 x 109/L\n * Bilirubin \u2264 1.5 times the upper limit of normal (x ULN), or \u2264 3 times ULN if documented hepatic involvement with lymphoma, or \u2264 5 times ULN if history of Gilbert's disease\n * Aspartate transaminase (AST) and alanine transaminase (ALT) \u2264 3.0 x ULN (\u2264 5.0 x ULN is acceptable if liver has tumor involvement)\n * Serum Creatinine \u2264 1.5 x ULN\n * PT-INR/PTT \u2264 1.5 x ULN or in the therapeutic range if on anticoagulation therapy\n* Serum potassium within normal range\n* Estimated life expectancy greater than 3 months\n* Signed informed consent must be obtained prior to any study specific procedures\n\nExclusion Criteria\n\nPatients who meet any of the following criteria are not eligible to enroll in this trial:\n\n* Prior treatment with PXD101\n* Solid Tumor: Anticancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the last 4 weeks or a longer period depending on the defined characteristics of the agents used (e.g. 6 weeks for mitomycin or nitrosourea) Lymphoma: No anticancer therapy within 2 weeks except for Rituximab which patients should be off for greater than three months unless there is evidence of disease progression.\n* Lymphoma patients who have relapsed within 100 days of autologous or allogeneic transplantation.\n* Serious concomitant systemic disorders (eg, active infection) that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study.\n* Presence of metastatic disease that, in the opinion of the investigator, would require palliative treatment within 4 weeks of enrollment\n* Symptomatic brain metastases\n* Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension, congestive heart failure (NYHA Class III or IV) related to primary cardiac disease, a condition requiring anti-arrhythmic therapy, ischemic or severe valvular heart disease, or a ", "briefSummary": "This is a Phase I dose escalation study of PXD101 administered orally. Oral belinostat will be given once or twice daily at various dosing schedules to patients with solid tumors. Doses will be escalated until the maximum tolerated dose (MTD) is identified. In parallel, a cohort of lymphoma patients will be given oral belinostat on a discontinuous once daily dosing schedule.", "adenosarcoma_in_eligibility": false, "adenosarcoma_in_conditions": false, "adenosarcoma_anywhere": true } ], "keyword": [ { "url": "https://clinicaltrials.gov/api/v2/studies?query.term=uterine+adenosarcoma&pageSize=50&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CHasResults%2CLastUpdatePostDate", "http_status": 200, "params": { "query.term": "uterine adenosarcoma", "pageSize": "50", "countTotal": "true", "fields": "NCTId,BriefTitle,OverallStatus,HasResults,LastUpdatePostDate" }, "totalCount": 5, "studies": [ { "nctId": "NCT03926936", "briefTitle": "FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-05-28", "hasResults": false }, { "nctId": "NCT02020707", "briefTitle": "Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-07-26", "hasResults": false }, { "nctId": "NCT07467772", "briefTitle": "Ph 2 Elacestrant in ER Positive Uterine Sarcomas", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-05-22", "hasResults": false }, { "nctId": "NCT07394413", "briefTitle": "Surgical Handling of Fertility-preserving Treatments for Cervical Adenocarcinomas", "overallStatus": "NOT_YET_RECRUITING", "lastUpdatePostDate": "2026-02-06", "hasResults": false }, { "nctId": "NCT02834013", "briefTitle": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "overallStatus": "ACTIVE_NOT_RECRUITING", "lastUpdatePostDate": "2026-06-17", "hasResults": false } ] }, { "url": "https://clinicaltrials.gov/api/v2/studies?query.term=adenosarcoma&pageSize=50&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CHasResults%2CLastUpdatePostDate", "http_status": 200, "params": { "query.term": "adenosarcoma", "pageSize": "50", "countTotal": "true", "fields": "NCTId,BriefTitle,OverallStatus,HasResults,LastUpdatePostDate" }, "totalCount": 7, "studies": [ { "nctId": "NCT03926936", "briefTitle": "FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-05-28", "hasResults": false }, { "nctId": "NCT00413322", "briefTitle": "Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2015-07-08", "hasResults": false }, { "nctId": "NCT02020707", "briefTitle": "Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-07-26", "hasResults": false }, { "nctId": "NCT07467772", "briefTitle": "Ph 2 Elacestrant in ER Positive Uterine Sarcomas", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-05-22", "hasResults": false }, { "nctId": "NCT07394413", "briefTitle": "Surgical Handling of Fertility-preserving Treatments for Cervical Adenocarcinomas", "overallStatus": "NOT_YET_RECRUITING", "lastUpdatePostDate": "2026-02-06", "hasResults": false }, { "nctId": "NCT02834013", "briefTitle": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "overallStatus": "ACTIVE_NOT_RECRUITING", "lastUpdatePostDate": "2026-06-17", "hasResults": false }, { "nctId": "NCT00413075", "briefTitle": "Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2015-07-08", "hasResults": false } ] }, { "url": "https://clinicaltrials.gov/api/v2/studies?query.cond=uterine+sarcoma&pageSize=100&countTotal=true&fields=NCTId%2CBriefTitle%2COverallStatus%2CHasResults%2CLastUpdatePostDate", "http_status": 200, "params": { "query.cond": "uterine sarcoma", "pageSize": "100", "countTotal": "true", "fields": "NCTId,BriefTitle,OverallStatus,HasResults,LastUpdatePostDate" }, "totalCount": 292, "studies": [ { "nctId": "NCT03926936", "briefTitle": "FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-05-28", "hasResults": false }, { "nctId": "NCT04935333", "briefTitle": "Accuracy of the Preoperative Molecular Diagnosis of Uterine Tumors by Liquid Biopsy", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2021-09-10", "hasResults": false }, { "nctId": "NCT02428192", "briefTitle": "Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2025-02-25", "hasResults": true }, { "nctId": "NCT06943521", "briefTitle": "A Study of MT-4561 in Patients With Various Advanced Solid Tumors", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2025-12-11", "hasResults": false }, { "nctId": "NCT01793168", "briefTitle": "Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-10-28", "hasResults": false }, { "nctId": "NCT00659360", "briefTitle": "AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2018-06-29", "hasResults": true }, { "nctId": "NCT01637961", "briefTitle": "Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2019-07-23", "hasResults": true }, { "nctId": "NCT04837677", "briefTitle": "A Study of PRT1419 in Patients With Advanced Solid Tumors", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2023-03-15", "hasResults": false }, { "nctId": "NCT00231842", "briefTitle": "Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2019-01-23", "hasResults": true }, { "nctId": "NCT01958580", "briefTitle": "Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2023-08-16", "hasResults": true }, { "nctId": "NCT00662233", "briefTitle": "Combination Chemotherapy in Treating Patients With Sarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2018-10-09", "hasResults": false }, { "nctId": "NCT04123158", "briefTitle": "MYometrial Lesion UltrasouNd And mRi", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-05-16", "hasResults": false }, { "nctId": "NCT05881967", "briefTitle": "Molecular Mechanism Study of Uterine Sarcoma", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2023-05-31", "hasResults": false }, { "nctId": "NCT01220609", "briefTitle": "Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2019-08-08", "hasResults": true }, { "nctId": "NCT04028479", "briefTitle": "The Registry of Oncology Outcomes Associated With Testing and Treatment", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-12-18", "hasResults": false }, { "nctId": "NCT03752398", "briefTitle": "A Study of XmAb\u00ae23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-07-05", "hasResults": false }, { "nctId": "NCT00118300", "briefTitle": "Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer", "overallStatus": "WITHDRAWN", "lastUpdatePostDate": "2011-07-08", "hasResults": false }, { "nctId": "NCT03076372", "briefTitle": "A Study Evaluating MM-310 in Patients With Solid Tumors", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2018-02-27", "hasResults": false }, { "nctId": "NCT00620295", "briefTitle": "Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2017-11-29", "hasResults": false }, { "nctId": "NCT00014456", "briefTitle": "Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2013-08-28", "hasResults": false }, { "nctId": "NCT01582906", "briefTitle": "A Survivorship Care Plan for Gynaecological Cancer Patients", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2017-11-24", "hasResults": false }, { "nctId": "NCT01851928", "briefTitle": "Validation of a Nutrition Screening Tool", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2013-05-13", "hasResults": false }, { "nctId": "NCT06299163", "briefTitle": "NM32-2668 in Adult Patients With Selected Advanced Solid Tumors", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2025-07-23", "hasResults": false }, { "nctId": "NCT05955105", "briefTitle": "A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2024-05-21", "hasResults": false }, { "nctId": "NCT02150213", "briefTitle": "Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2016-12-05", "hasResults": true }, { "nctId": "NCT03395080", "briefTitle": "A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2025-08-01", "hasResults": true }, { "nctId": "NCT05510908", "briefTitle": "Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2026-08-14", "hasResults": true }, { "nctId": "NCT03896958", "briefTitle": "The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2020-12-04", "hasResults": false }, { "nctId": "NCT07723235", "briefTitle": "Web-based Lifestyle Program, mHealth and EMA Intervention, to Improve Weight Loss in Rural Stage I-III Postmenopausal Breast and Endometrial Cancer Survivors, HERO-C Trial", "overallStatus": "NOT_YET_RECRUITING", "lastUpdatePostDate": "2026-07-23", "hasResults": false }, { "nctId": "NCT01295463", "briefTitle": "Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2013-08-12", "hasResults": false }, { "nctId": "NCT00161187", "briefTitle": "Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2015-11-06", "hasResults": false }, { "nctId": "NCT00408655", "briefTitle": "Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2014-06-19", "hasResults": false }, { "nctId": "NCT00414076", "briefTitle": "Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2018-11-20", "hasResults": true }, { "nctId": "NCT02988817", "briefTitle": "Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2023-08-01", "hasResults": true }, { "nctId": "NCT01154452", "briefTitle": "Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2018-08-15", "hasResults": true }, { "nctId": "NCT00041236", "briefTitle": "Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2012-07-18", "hasResults": false }, { "nctId": "NCT05199584", "briefTitle": "A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2026-03-05", "hasResults": false }, { "nctId": "NCT01376349", "briefTitle": "Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2019-02-07", "hasResults": true }, { "nctId": "NCT05310318", "briefTitle": "Prognosis of Low-grade Endometrial Stromal Sarcoma", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2022-04-04", "hasResults": false }, { "nctId": "NCT07267780", "briefTitle": "Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.", "overallStatus": "NOT_YET_RECRUITING", "lastUpdatePostDate": "2025-12-05", "hasResults": false }, { "nctId": "NCT07269535", "briefTitle": "A Prospective Validation Study of Radiomics in the Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma", "overallStatus": "NOT_YET_RECRUITING", "lastUpdatePostDate": "2026-10-08", "hasResults": false }, { "nctId": "NCT04458597", "briefTitle": "Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2025-08-01", "hasResults": false }, { "nctId": "NCT07811297", "briefTitle": "A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers", "overallStatus": "NOT_YET_RECRUITING", "lastUpdatePostDate": "2026-09-10", "hasResults": false }, { "nctId": "NCT07118176", "briefTitle": "Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers", "overallStatus": "ACTIVE_NOT_RECRUITING", "lastUpdatePostDate": "2026-10-20", "hasResults": false }, { "nctId": "NCT00390234", "briefTitle": "Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2015-12-07", "hasResults": true }, { "nctId": "NCT00601406", "briefTitle": "Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2013-08-26", "hasResults": false }, { "nctId": "NCT00004066", "briefTitle": "Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2013-03-07", "hasResults": false }, { "nctId": "NCT00538850", "briefTitle": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2014-03-05", "hasResults": true }, { "nctId": "NCT01533207", "briefTitle": "Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2020-04-28", "hasResults": true }, { "nctId": "NCT06613230", "briefTitle": "Improved Early Diagnosis in Female Pelvic Cancer With OC Detect", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2025-04-18", "hasResults": false }, { "nctId": "NCT00033644", "briefTitle": "Combination Chemotherapy Plus Sargramostim in Treating Patients With Cancer of the Uterus", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2013-04-11", "hasResults": false }, { "nctId": "NCT07576725", "briefTitle": "Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial", "overallStatus": "NOT_YET_RECRUITING", "lastUpdatePostDate": "2026-09-17", "hasResults": false }, { "nctId": "NCT00031629", "briefTitle": "Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2016-12-08", "hasResults": false }, { "nctId": "NCT00002546", "briefTitle": "Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2016-02-11", "hasResults": false }, { "nctId": "NCT02940041", "briefTitle": "Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2023-12-26", "hasResults": false }, { "nctId": "NCT00815945", "briefTitle": "Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2017-02-14", "hasResults": false }, { "nctId": "NCT03860272", "briefTitle": "Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer", "overallStatus": "ACTIVE_NOT_RECRUITING", "lastUpdatePostDate": "2026-03-30", "hasResults": false }, { "nctId": "NCT03017573", "briefTitle": "Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-02-03", "hasResults": false }, { "nctId": "NCT00003718", "briefTitle": "Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2014-01-06", "hasResults": false }, { "nctId": "NCT00033709", "briefTitle": "Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2014-01-06", "hasResults": false }, { "nctId": "NCT05366881", "briefTitle": "cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-01-20", "hasResults": false }, { "nctId": "NCT06349642", "briefTitle": "Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-03-12", "hasResults": false }, { "nctId": "NCT04634617", "briefTitle": "Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors", "overallStatus": "ACTIVE_NOT_RECRUITING", "lastUpdatePostDate": "2026-05-20", "hasResults": false }, { "nctId": "NCT07064018", "briefTitle": "Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-07-17", "hasResults": false }, { "nctId": "NCT06805019", "briefTitle": "Construction of a Model for the Differential Diagnosis of SArcoma/myoma Based on the RAdiomics Features: Single-center Observational Study", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2025-02-03", "hasResults": false }, { "nctId": "NCT07059884", "briefTitle": "Distance-Based Exercise to Preserve Function and Prevent Disability", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-10-02", "hasResults": false }, { "nctId": "NCT06508307", "briefTitle": "A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2025-08-21", "hasResults": false }, { "nctId": "NCT06582108", "briefTitle": "UNDERSTANDING the RAREST GYNECOLOGICAL CANCERS: a MULTI -OMICS PLATFORM for IMPROVED PATIENTS MANAGEMENT", "overallStatus": "NOT_YET_RECRUITING", "lastUpdatePostDate": "2024-09-03", "hasResults": false }, { "nctId": "NCT00101127", "briefTitle": "Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2014-02-14", "hasResults": false }, { "nctId": "NCT01271959", "briefTitle": "A Study of ChemoFx\u00ae Chemoresponse Assay in Solid Tumors - ChemoFx\u00ae Registry Study", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2012-10-05", "hasResults": false }, { "nctId": "NCT04260802", "briefTitle": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2026-01-12", "hasResults": false }, { "nctId": "NCT02993705", "briefTitle": "Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2021-08-25", "hasResults": false }, { "nctId": "NCT00162721", "briefTitle": "The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2007-08-10", "hasResults": false }, { "nctId": "NCT00003212", "briefTitle": "Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2012-01-20", "hasResults": false }, { "nctId": "NCT01247571", "briefTitle": "Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2019-08-08", "hasResults": true }, { "nctId": "NCT00505739", "briefTitle": "Mifepristone for Patients With Endometrial Cancer and LGESS", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2012-07-30", "hasResults": false }, { "nctId": "NCT01367301", "briefTitle": "Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2023-08-21", "hasResults": true }, { "nctId": "NCT00032162", "briefTitle": "Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2012-05-31", "hasResults": false }, { "nctId": "NCT00087191", "briefTitle": "EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2013-01-16", "hasResults": false }, { "nctId": "NCT01442662", "briefTitle": "Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2020-01-31", "hasResults": false }, { "nctId": "NCT07458347", "briefTitle": "A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-10-15", "hasResults": false }, { "nctId": "NCT00856050", "briefTitle": "Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2017-04-18", "hasResults": true }, { "nctId": "NCT04604158", "briefTitle": "Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-05-21", "hasResults": false }, { "nctId": "NCT04224467", "briefTitle": "The Application of Real-Time Near-infrared Imaging in Gynecological Surgery", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2020-01-14", "hasResults": false }, { "nctId": "NCT00526149", "briefTitle": "BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2013-10-07", "hasResults": false }, { "nctId": "NCT04811196", "briefTitle": "A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2025-05-29", "hasResults": false }, { "nctId": "NCT05958199", "briefTitle": "A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7", "overallStatus": "SUSPENDED", "lastUpdatePostDate": "2025-06-27", "hasResults": false }, { "nctId": "NCT05515575", "briefTitle": "A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA", "overallStatus": "ACTIVE_NOT_RECRUITING", "lastUpdatePostDate": "2026-09-03", "hasResults": false }, { "nctId": "NCT03454451", "briefTitle": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2023-12-21", "hasResults": false }, { "nctId": "NCT00006005", "briefTitle": "Thalidomide in Treating Patients With Gynecologic Sarcomas", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2013-06-21", "hasResults": false }, { "nctId": "NCT04250766", "briefTitle": "Diagnostic Performances of Preoperative Echo-guided Uterine Biopsy in the Management of Suspect Uterine Sarcoma Tumors (BIOPSAR)", "overallStatus": "ACTIVE_NOT_RECRUITING", "lastUpdatePostDate": "2025-10-02", "hasResults": false }, { "nctId": "NCT01553539", "briefTitle": "Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2018-07-05", "hasResults": true }, { "nctId": "NCT00003054", "briefTitle": "Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2018-04-12", "hasResults": false }, { "nctId": "NCT07189871", "briefTitle": "177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-10-01", "hasResults": false }, { "nctId": "NCT00002764", "briefTitle": "Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2012-07-11", "hasResults": false }, { "nctId": "NCT02012699", "briefTitle": "Integrated Cancer Repository for Cancer Research", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-06-29", "hasResults": false }, { "nctId": "NCT00410462", "briefTitle": "Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2014-08-08", "hasResults": false }, { "nctId": "NCT00020579", "briefTitle": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2012-03-15", "hasResults": false }, { "nctId": "NCT02632448", "briefTitle": "A Study of LY2880070 in Participants With Advanced or Metastatic Cancer", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2025-05-02", "hasResults": false }, { "nctId": "NCT04200443", "briefTitle": "Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma", "overallStatus": "ACTIVE_NOT_RECRUITING", "lastUpdatePostDate": "2026-05-01", "hasResults": true } ] } ], "uterine_sarcoma_scan": { "pages": 3, "n_records_fetched": 292, "adenosarcoma_string_hits": [ { "nctId": "NCT03926936", "briefTitle": "FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-05-28", "adenosarcoma_in_eligibility": true }, { "nctId": "NCT04123158", "briefTitle": "MYometrial Lesion UltrasouNd And mRi", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2024-05-16", "adenosarcoma_in_eligibility": false }, { "nctId": "NCT05881967", "briefTitle": "Molecular Mechanism Study of Uterine Sarcoma", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2023-05-31", "adenosarcoma_in_eligibility": false }, { "nctId": "NCT00162721", "briefTitle": "The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas", "overallStatus": "UNKNOWN", "lastUpdatePostDate": "2007-08-10", "adenosarcoma_in_eligibility": true }, { "nctId": "NCT07467772", "briefTitle": "Ph 2 Elacestrant in ER Positive Uterine Sarcomas", "overallStatus": "RECRUITING", "lastUpdatePostDate": "2026-05-22", "adenosarcoma_in_eligibility": true }, { "nctId": "NCT03509207", "briefTitle": "Vorinostat (SAHA) in Uterine Sarcoma", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2020-08-04", "adenosarcoma_in_eligibility": true }, { "nctId": "NCT05481645", "briefTitle": "Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy \u00b1 Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.", "overallStatus": "TERMINATED", "lastUpdatePostDate": "2026-01-09", "adenosarcoma_in_eligibility": true }, { "nctId": "NCT02834013", "briefTitle": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors", "overallStatus": "ACTIVE_NOT_RECRUITING", "lastUpdatePostDate": "2026-06-17", "adenosarcoma_in_eligibility": false }, { "nctId": "NCT01979393", "briefTitle": "IRCI Gynae Sarcomas, High Grade Uterine Sarcoma", "overallStatus": "COMPLETED", "lastUpdatePostDate": "2025-08-01", "adenosarcoma_in_eligibility": true } ], "n_hits": 9, "nct_ids": [ "NCT03926936", "NCT04935333", "NCT02428192", "NCT06943521", "NCT01793168", "NCT00659360", "NCT01637961", "NCT04837677", "NCT00231842", "NCT01958580", "NCT00662233", "NCT04123158", "NCT05881967", "NCT01220609", "NCT04028479", "NCT03752398", "NCT00118300", "NCT03076372", "NCT00620295", "NCT00014456", "NCT01582906", "NCT01851928", "NCT06299163", "NCT05955105", "NCT02150213", "NCT03395080", "NCT05510908", "NCT03896958", "NCT07723235", "NCT01295463", "NCT00161187", "NCT00408655", "NCT00414076", "NCT02988817", "NCT01154452", "NCT00041236", "NCT05199584", "NCT01376349", "NCT05310318", "NCT07267780", "NCT07269535", "NCT04458597", "NCT07811297", "NCT07118176", "NCT00390234", "NCT00601406", "NCT00004066", "NCT00538850", "NCT01533207", "NCT06613230", "NCT00033644", "NCT07576725", "NCT00031629", "NCT00002546", "NCT02940041", "NCT00815945", "NCT03860272", "NCT03017573", "NCT00003718", "NCT00033709", "NCT05366881", "NCT06349642", "NCT04634617", "NCT07064018", "NCT06805019", "NCT07059884", "NCT06508307", "NCT06582108", "NCT00101127", "NCT01271959", "NCT04260802", "NCT02993705", "NCT00162721", "NCT00003212", "NCT01247571", "NCT00505739", "NCT01367301", "NCT00032162", "NCT00087191", "NCT01442662", "NCT07458347", "NCT00856050", "NCT04604158", "NCT04224467", "NCT00526149", "NCT04811196", "NCT05958199", "NCT05515575", "NCT03454451", "NCT00006005", "NCT04250766", "NCT01553539", "NCT00003054", "NCT07189871", "NCT00002764", "NCT02012699", "NCT00410462", "NCT00020579", "NCT02632448", "NCT04200443", "NCT05691504", "NCT06242470", "NCT01012297", "NCT05229601", "NCT00002459", "NCT01846520", "NCT02611024", "NCT00003704", "NCT01132547", "NCT04239443", "NCT00025220", "NCT04704661", "NCT03842865", "NCT04214067", "NCT01303094", "NCT00003597", "NCT05578820", "NCT04681248", "NCT03367741", "NCT07467772", "NCT05039801", "NCT00003939", "NCT01079832", "NCT02900248", "NCT01764802", "NCT00474994", "NCT00433407", "NCT06277154", "NCT07197554", "NCT06244251", "NCT00258401", "NCT02829437", "NCT00132704", "NCT02086435", "NCT03660826", "NCT00788125", "NCT00055705", "NCT00053794", "NCT04065269", "NCT00383279", "NCT00006357", "NCT04464967", "NCT04517019", "NCT05655598", "NCT03601897", "NCT02249702", "NCT06760819", "NCT00499291", "NCT00020267", "NCT04556669", "NCT00245102", "NCT07215832", "NCT03007771", "NCT00075400", "NCT05646316", "NCT05697198", "NCT00842452", "NCT03624244", "NCT00005095", "NCT05864144", "NCT05252416", "NCT00033605", "NCT06336148", "NCT06004011", "NCT06904365", "NCT00002526", "NCT00006981", "NCT06531486", "NCT00154388", "NCT04430842", "NCT00897442", "NCT07229313", "NCT00637637", "NCT05563272", "NCT00687778", "NCT00004241", "NCT01652794", "NCT04889742", "NCT00587964", "NCT03509207", "NCT04171700", "NCT04513665", "NCT01392352", "NCT00002993", "NCT01155258", "NCT01216813", "NCT01548482", "NCT00082823", "NCT01170299", "NCT01210222", "NCT00003316", "NCT07811232", "NCT04140526", "NCT00003308", "NCT00954174", "NCT04149691", "NCT04990076", "NCT03902379", "NCT04383210", "NCT03382158", "NCT00477919", "NCT05269381", "NCT00003778", "NCT00899496", "NCT00003657", "NCT00550654", "NCT00379145", "NCT03914612", "NCT03345485", "NCT07129005", "NCT03493165", "NCT04106492", "NCT00378911", "NCT01168232", "NCT06840886", "NCT00287885", "NCT00005643", "NCT00445965", "NCT00003128", "NCT00003624", "NCT05012397", "NCT03570437", "NCT01234012", "NCT00378781", "NCT01087268", "NCT04851119", "NCT02052128", "NCT07696169", "NCT00003156", "NCT05062707", "NCT00114218", "NCT05481645", "NCT00049296", "NCT04802876", "NCT00002706", "NCT02203760", "NCT00614835", "NCT03241745", "NCT00905658", "NCT01061606", "NCT05610501", "NCT03206177", "NCT00505492", "NCT00381888", "NCT06887673", "NCT00028405", "NCT00003334", "NCT05238883", "NCT00227669", "NCT00002641", "NCT00093678", "NCT00083213", "NCT01764789", "NCT01806350", "NCT06967961", "NCT00031681", "NCT02834013", "NCT02374411", "NCT06910657", "NCT01979393", "NCT01098630", "NCT04099277", "NCT04214457", "NCT05949632", "NCT07406087", "NCT00025441", "NCT00253383", "NCT06171945", "NCT00295945", "NCT02096783", "NCT04158414", "NCT05187338", "NCT00003548", "NCT05538572", "NCT07124000", "NCT05944237", "NCT05812027", "NCT00004261", "NCT00112489", "NCT05708950", "NCT01522820", "NCT00423254", "NCT00238121", "NCT00499733", "NCT02601209", "NCT03422198", "NCT00025506", "NCT07675967", "NCT05542407", "NCT00282087", "NCT07883798", "NCT02069769" ] } }, "notes": [ "All-time PubMed uterine adenosarcoma count 263 (was 262 on 2026-10-24).", "CDSR adenosarcoma all-time 0; all windowed CDSR topic queries 0.", "ClinicalTrials.gov keyword counts unchanged: uterine adenosarcoma 5, adenosarcoma 7, uterine sarcoma 292. Nine adenosarcoma string matches, same IDs as 2026-10-24.", "No NCT status/enrolment/results change among 14 tracked IDs." ], "window_pmids": [ "42939826", "42942324", "42948072", "42949538", "42951232", "42951388", "42951389", "42951390", "42952303", "42955969", "42957266" ], "esummary": { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&id=42939826%2C42942324%2C42948072%2C42949538%2C42951232%2C42951388%2C42951389%2C42951390%2C42952303%2C42955969%2C42957266&retmode=json", "http_status": 200, "response": { "header": { "type": "esummary", "version": "0.3" }, "result": { "uids": [ "42939826", "42942324", "42948072", "42949538", "42951232", "42951388", "42951389", "42951390", "42952303", "42955969", "42957266" ], "42939826": { "uid": "42939826", "pubdate": "2026 Sep 30", "epubdate": "2026 Sep 30", "source": "Antioxidants (Basel)", "authors": [ { "name": "Kourti A", "authtype": "Author", "clusterid": "" }, { "name": "Karioti P", "authtype": "Author", "clusterid": "" }, { "name": "Chouliara F", "authtype": "Author", "clusterid": "" }, { "name": "Georgiou E", "authtype": "Author", "clusterid": "" }, { "name": "Makedou K", "authtype": "Author", "clusterid": "" }, { "name": "Kalogiannidis I", "authtype": "Author", "clusterid": "" } ], "lastauthor": "Kalogiannidis I", "title": "Oxidative Stress and Its Molecular Effectors in Uterine Smooth Muscle Tumors: Bridging Epigenetic Regulation and Glycoprotein Biomarkers.", "sorttitle": "oxidative stress and its molecular effectors in uterine smooth muscle tumors bridging epigenetic regulation and glycoprotein biomarkers", "volume": "15", "issue": "10", "pages": "", "lang": [ "eng" ], "nlmuniqueid": "101668981", "issn": "2076-3921", "essn": "2076-3921", "pubtype": [ "Journal Article", "Review" ], "recordstatus": "PubMed", "pubstatus": "3", "articleids": [ { "idtype": "pubmed", "idtypen": 1, "value": "42939826" }, { "idtype": "pmc", "idtypen": 8, "value": "PMC13700633" }, { "idtype": "pmcid", "idtypen": 5, "value": "pmc-id: PMC13700633;" }, { "idtype": "doi", "idtypen": 3, "value": "10.3390/antiox15101252" }, { "idtype": "pii", "idtypen": 4, "value": "antiox15101252" } ], "history": [ { "pubstatus": "received", "date": "2026/08/24 00:00" }, { "pubstatus": "revised", "date": "2026/09/25 00:00" }, { "pubstatus": "accepted", "date": "2026/09/29 00:00" }, { "pubstatus": "medline", "date": "2026/10/27 11:33" }, { "pubstatus": "pubmed", "date": "2026/10/27 11:32" }, { "pubstatus": "entrez", "date": "2026/10/27 10:34" }, { "pubstatus": "pmc-release", "date": "2026/09/30 00:00" } ], "references": [], "attributes": [ "Has Abstract" ], "pmcrefcount": 37, "fulljournalname": "Antioxidants (Basel, Switzerland)", "elocationid": "doi: 10.3390/antiox15101252", "doctype": "citation", "srccontriblist": [], "booktitle": "", "medium": "", "edition": "", "publisherlocation": "", "publishername": "", "srcdate": "", "reportnumber": "", "availablefromurl": "", "locationlabel": "", "doccontriblist": [], "docdate": "", "bookname": "", "chapter": "", "sortpubdate": "2026/09/30 00:00", "sortfirstauthor": "Kourti A", "vernaculartitle": "" }, "42942324": { "uid": "42942324", "pubdate": "2026 Oct 16", "epubdate": "2026 Oct 16", "source": "Life (Basel)", "authors": [ { "name": "Solomon Condriuc IP", "authtype": "Author", "clusterid": "" }, { "name": "Mogos RA", "authtype": "Author", "clusterid": "" }, { "name": "Popovici R", "authtype": "Author", "clusterid": "" }, { "name": "Matasariu DR", "authtype": "Author", "clusterid": "" }, { "name": "Cosovanu EO", "authtype": "Author", "clusterid": "" }, { "name": "Buzduga CM", "authtype": "Author", "clusterid": "" }, { "name": "Scripcariu IS", "authtype": "Author", "clusterid": "" }, { "name": "Socolov D", "authtype": "Author", "clusterid": "" }, { "name": "Carauleanu A", "authtype": "Author", "clusterid": "" } ], "lastauthor": "Carauleanu A", "title": "Pretreatment Assessment of Occult Uterine Sarcoma Risk Before Uterus-Preserving Treatment of Presumed Fibroids: A Narrative Review.", "sorttitle": "pretreatment assessment of occult uterine sarcoma risk before uterus preserving treatment of presumed fibroids a narrative review", "volume": "16", "issue": "10", "pages": "", "lang": [ "eng" ], "nlmuniqueid": "101580444", "issn": "2075-1729", "essn": "2075-1729", "pubtype": [ "Journal Article", "Review" ], "recordstatus": "PubMed", "pubstatus": "3", "articleids": [ { "idtype": "pubmed", "idtypen": 1, "value": "42942324" }, { "idtype": "pmc", "idtypen": 8, "value": "PMC13706578" }, { "idtype": "pmcid", "idtypen": 5, "value": "pmc-id: PMC13706578;" }, { "idtype": "doi", "idtypen": 3, "value": "10.3390/life16101738" }, { "idtype": "pii", "idtypen": 4, "value": "life16101738" } ], "history": [ { "pubstatus": "received", "date": "2026/09/22 00:00" }, { "pubstatus": "revised", "date": "2026/10/10 00:00" }, { "pubstatus": "accepted", "date": "2026/10/13 00:00" }, { "pubstatus": "medline", "date": "2026/10/27 11:33" }, { "pubstatus": "pubmed", "date": "2026/10/27 11:32" }, { "pubstatus": "entrez", "date": "2026/10/27 10:42" }, { "pubstatus": "pmc-release", "date": "2026/10/16 00:00" } ], "references": [], "attributes": [ "Has Abstract" ], "pmcrefcount": 102, "fulljournalname": "Life (Basel, Switzerland)", "elocationid": "doi: 10.3390/life16101738", "doctype": "citation", "srccontriblist": [], "booktitle": "", "medium": "", "edition": "", "publisherlocation": "", "publishername": "", "srcdate": "", "reportnumber": "", "availablefromurl": "", "locationlabel": "", "doccontriblist": [], "docdate": "", "bookname": "", "chapter": "", "sortpubdate": "2026/10/16 00:00", "sortfirstauthor": "Solomon Condriuc IP", "vernaculartitle": "" }, "42948072": { "uid": "42948072", "pubdate": "2026", "epubdate": "2026 Oct 13", "source": "Front Med (Lausanne)", "authors": [ { "name": "Li Q", "authtype": "Author", "clusterid": "" }, { "name": "Wu M", "authtype": "Author", "clusterid": "" } ], "lastauthor": "Wu M", "title": "KAT6B::KANSL1 fusion-positive uterine mesenchymal neoplasm with hybrid endometrial stromal and smooth muscle features: a case report.", "sorttitle": "kat6b kansl1 fusion positive uterine mesenchymal neoplasm with hybrid endometrial stromal and smooth muscle features a case report", "volume": "13", "issue": "", "pages": "1859849", "lang": [ "eng" ], "nlmuniqueid": "101648047", "issn": "2296-858X", "essn": "2296-858X", "pubtype": [ "Case Reports", "Journal Article" ], "recordstatus": "PubMed", "pubstatus": "258", "articleids": [ { "idtype": "pubmed", "idtypen": 1, "value": "42948072" }, { "idtype": "pmc", "idtypen": 8, "value": "PMC13710359" }, { "idtype": "pmcid", "idtypen": 5, "value": "pmc-id: PMC13710359;" }, { "idtype": "doi", "idtypen": 3, "value": "10.3389/fmed.2026.1859849" } ], "history": [ { "pubstatus": "received", "date": "2026/04/19 00:00" }, { "pubstatus": "revised", "date": "2026/08/30 00:00" }, { "pubstatus": "accepted", "date": "2026/09/14 00:00" }, { "pubstatus": "medline", "date": "2026/10/28 11:37" }, { "pubstatus": "pubmed", "date": "2026/10/28 11:36" }, { "pubstatus": "entrez", "date": "2026/10/28 05:10" }, { "pubstatus": "pmc-release", "date": "2026/10/13 00:00" } ], "references": [], "attributes": [ "Has Abstract" ], "pmcrefcount": 24, "fulljournalname": "Frontiers in medicine", "elocationid": "doi: 10.3389/fmed.2026.1859849", "doctype": "citation", "srccontriblist": [], "booktitle": "", "medium": "", "edition": "", "publisherlocation": "", "publishername": "", "srcdate": "", "reportnumber": "", "availablefromurl": "", "locationlabel": "", "doccontriblist": [], "docdate": "", "bookname": "", "chapter": "", "sortpubdate": "2026/10/13 00:00", "sortfirstauthor": "Li Q", "vernaculartitle": "" }, "42949538": { "uid": "42949538", "pubdate": "2026 Sep 1", "epubdate": "", "source": "Brief Bioinform", "authors": [ { "name": "Wang Z", "authtype": "Author", "clusterid": "" }, { "name": "Wang Q", "authtype": "Author", "clusterid": "" }, { "name": "Wang G", "authtype": "Author", "clusterid": "" }, { "name": "Wang G", "authtype": "Author", "clusterid": "" }, { "name": "Zhao Y", "authtype": "Author", "clusterid": "" } ], "lastauthor": "Zhao Y", "title": "TRACER: response-protected cross-domain alignment of cancer pharmacogenomic models with patient tumors.", "sorttitle": "tracer response protected cross domain alignment of cancer pharmacogenomic models with patient tumors", "volume": "27", "issue": "5", "pages": "", "lang": [ "eng" ], "nlmuniqueid": "100912837", "issn": "1467-5463", "essn": "1477-4054", "pubtype": [ "Journal Article" ], "recordstatus": "PubMed - indexed for MEDLINE", "pubstatus": "4", "articleids": [ { "idtype": "pubmed", "idtypen": 1, "value": "42949538" }, { "idtype": "pmc", "idtypen": 8, "value": "PMC13714793" }, { "idtype": "pmcid", "idtypen": 5, "value": "pmc-id: PMC13714793;" }, { "idtype": "doi", "idtypen": 3, "value": "10.1093/bib/bbag593" }, { "idtype": "pii", "idtypen": 4, "value": "9003614" } ], "history": [ { "pubstatus": "received", "date": "2026/08/21 00:00" }, { "pubstatus": "revised", "date": "2026/09/24 00:00" }, { "pubstatus": "accepted", "date": "2026/10/05 00:00" }, { "pubstatus": "medline", "date": "2026/10/28 11:37" }, { "pubstatus": "pubmed", "date": "2026/10/28 11:36" }, { "pubstatus": "entrez", "date": "2026/10/28 10:03" }, { "pubstatus": "pmc-release", "date": "2026/10/28 00:00" } ], "references": [], "attributes": [ "Has Abstract" ], "pmcrefcount": 48, "fulljournalname": "Briefings in bioinformatics", "elocationid": "doi: 10.1093/bib/bbag593", "doctype": "citation", "srccontriblist": [], "booktitle": "", "medium": "", "edition": "", "publisherlocation": "", "publishername": "", "srcdate": "", "reportnumber": "", "availablefromurl": "", "locationlabel": "", "doccontriblist": [], "docdate": "", "bookname": "", "chapter": "", "sortpubdate": "2026/09/01 00:00", "sortfirstauthor": "Wang Z", "vernaculartitle": "" }, "42951232": { "uid": "42951232", "pubdate": "2026 Oct 28", "epubdate": "2026 Oct 28", "source": "Am J Obstet Gynecol", "authors": [ { "name": "Dave D", "authtype": "Author", "clusterid": "" }, { "name": "Arend RC", "authtype": "Author", "clusterid": "" }, { "name": "Leath CA 3rd", "authtype": "Author", "clusterid": "" }, { "name": "Toboni MD", "authtype": "Author", "clusterid": "" }, { "name": "Wentzensen N", "authtype": "Author", "clusterid": "" }, { "name": "K\u00f6bel M", "authtype": "Author", "clusterid": "" }, { "name": "Erickson BK", "authtype": "Author", "clusterid": "" }, { "name": "Wijayabahu AT", "authtype": "Author", "clusterid": "" }, { "name": "Clarke MA", "authtype": "Author", "clusterid": "" } ], "lastauthor": "Clarke MA", "title": "Hysterectomy-corrected, age-specific incidence and survival of uterine sarcomas by histotype, race and ethnicity in the United States, 2000-2019.", "sorttitle": "hysterectomy corrected age specific incidence and survival of uterine sarcomas by histotype race and ethnicity in the united states 2000 2019", "volume": "", "issue": "", "pages": "", "lang": [ "eng" ], "nlmuniqueid": "0370476", "issn": "0002-9378", "essn": "1097-6868", "pubtype": [ "Journal Article" ], "recordstatus": "PubMed - as supplied by publisher", "pubstatus": "10", "articleids": [ { "idtype": "pubmed", "idtypen": 1, "value": "42951232" }, { "idtype": "doi", "idtypen": 3, "value": "10.1016/j.ajog.2026.10.034" }, { "idtype": "pii", "idtypen": 4, "value": "S0002-9378(26)00591-0" } ], "history": [ { "pubstatus": "received", "date": "2026/06/24 00:00" }, { "pubstatus": "revised", "date": "2026/10/07 00:00" }, { "pubstatus": "accepted", "date": "2026/10/18 00:00" }, { "pubstatus": "medline", "date": "2026/10/28 23:27" }, { "pubstatus": "pubmed", "date": "2026/10/28 23:27" }, { "pubstatus": "entrez", "date": "2026/10/28 20:37" } ], "references": [], "attributes": [ "Has Abstract" ], "pmcrefcount": "", "fulljournalname": "American journal of obstetrics and gynecology", "elocationid": "pii: S0002-9378(26)00591-0. doi: 10.1016/j.ajog.2026.10.034", "doctype": "citation", "srccontriblist": [], "booktitle": "", "medium": "", "edition": "", "publisherlocation": "", "publishername": "", "srcdate": "", "reportnumber": "", "availablefromurl": "", "locationlabel": "", "doccontriblist": [], "docdate": "", "bookname": "", "chapter": "", "sortpubdate": "2026/10/28 00:00", "sortfirstauthor": "Dave D", "vernaculartitle": "" }, "42951388": { "uid": "42951388", "pubdate": "2026 Dec", "epubdate": "2026 Aug 5", "source": "Surg Pathol Clin", "authors": [ { "name": "Gu W", "authtype": "Author", "clusterid": "" }, { "name": "Howitt BE", "authtype": "Author", "clusterid": "" } ], "lastauthor": "Howitt BE", "title": "DNA Methylation Profiling: Current and Emerging Uses in Gynecologic Pathology.", "sorttitle": "dna methylation profiling current and emerging uses in gynecologic pathology", "volume": "19", "issue": "4", "pages": "605-616", "lang": [ "eng" ], "nlmuniqueid": "101491209", "issn": "", "essn": "1875-9157", "pubtype": [ "Journal Article", "Review" ], "recordstatus": "PubMed - indexed for MEDLINE", "pubstatus": "256", "articleids": [ { "idtype": "pubmed", "idtypen": 1, "value": "42951388" }, { "idtype": "doi", "idtypen": 3, "value": "10.1016/j.path.2026.06.003" }, { "idtype": "pii", "idtypen": 4, "value": "S1875-9181(26)00061-9" } ], "history": [ { "pubstatus": "medline", "date": "2026/10/28 23:28" }, { "pubstatus": "pubmed", "date": "2026/10/28 23:27" }, { "pubstatus": "entrez", "date": "2026/10/28 21:53" } ], "references": [], "attributes": [ "Has Abstract" ], "pmcrefcount": "", "fulljournalname": "Surgical pathology clinics", "elocationid": "doi: 10.1016/j.path.2026.06.003", "doctype": "citation", "srccontriblist": [], "booktitle": "", "medium": "", "edition": "", "publisherlocation": "", "publishername": "", "srcdate": "", "reportnumber": "", "availablefromurl": "", "locationlabel": "", "doccontriblist": [], "docdate": "", "bookname": "", "chapter": "", "sortpubdate": "2026/12/01 00:00", "sortfirstauthor": "Gu W", "vernaculartitle": "" }, "42951389": { "uid": "42951389", "pubdate": "2026 Dec", "epubdate": "2026 Aug 5", "source": "Surg Pathol Clin", "authors": [ { "name": "Dinh TA", "authtype": "Author", "clusterid": "" }, { "name": "Chapel DB", "authtype": "Author", "clusterid": "" } ], "lastauthor": "Chapel DB", "title": "Uterine Adenosarcoma: Unusual Presentations and Mimics.", "sorttitle": "uterine adenosarcoma unusual presentations and mimics", "volume": "19", "issue": "4", "pages": "617-636", "lang": [ "eng" ], "nlmuniqueid": "101491209", "issn": "", "essn": "1875-9157", "pubtype": [ "Journal Article", "Review" ], "recordstatus": "PubMed - indexed for MEDLINE", "pubstatus": "256", "articleids": [ { "idtype": "pubmed", "idtypen": 1, "value": "42951389" }, { "idtype": "doi", "idtypen": 3, "value": "10.1016/j.path.2026.06.009" }, { "idtype": "pii", "idtypen": 4, "value": "S1875-9181(26)00067-X" } ], "history": [ { "pubstatus": "medline", "date": "2026/10/28 23:28" }, { "pubstatus": "pubmed", "date": "2026/10/28 23:27" }, { "pubstatus": "entrez", "date": "2026/10/28 21:53" } ], "references": [], "attributes": [ "Has Abstract" ], "pmcrefcount": "", "fulljournalname": "Surgical pathology clinics", "elocationid": "doi: 10.1016/j.path.2026.06.009", "doctype": "citation", "srccontriblist": [], "booktitle": "", "medium": "", "edition": "", "publisherlocation": "", "publishername": "", "srcdate": "", "reportnumber": "", "availablefromurl": "", "locationlabel": "", "doccontriblist": [], "docdate": "", "bookname": "", "chapter": "", "sortpubdate": "2026/12/01 00:00", "sortfirstauthor": "Dinh TA", "vernaculartitle": "" }, "42951390": { "uid": "42951390", "pubdate": "2026 Dec", "epubdate": "2026 Aug 5", "source": "Surg Pathol Clin", "authors": [ { "name": "Devins KM", "authtype": "Author", "clusterid": "" } ], "lastauthor": "Devins KM", "title": "Rhabdomyosarcoma of the Cervix/Vagina and Its Mimics.", "sorttitle": "rhabdomyosarcoma of the cervix vagina and its mimics", "volume": "19", "issue": "4", "pages": "637-646", "lang": [ "eng" ], "nlmuniqueid": "101491209", "issn": "", "essn": "1875-9157", "pubtype": [ "Journal Article", "Review" ], "recordstatus": "PubMed - indexed for MEDLINE", "pubstatus": "256", "articleids": [ { "idtype": "pubmed", "idtypen": 1, "value": "42951390" }, { "idtype": "doi", "idtypen": 3, "value": "10.1016/j.path.2026.06.012" }, { "idtype": "pii", "idtypen": 4, "value": "S1875-9181(26)00070-X" } ], "history": [ { "pubstatus": "medline", "date": "2026/10/28 23:28" }, { "pubstatus": "pubmed", "date": "2026/10/28 23:27" }, { "pubstatus": "entrez", "date": "2026/10/28 21:53" } ], "references": [], "attributes": [ "Has Abstract" ], "pmcrefcount": "", "fulljournalname": "Surgical pathology clinics", "elocationid": "doi: 10.1016/j.path.2026.06.012", "doctype": "citation", "srccontriblist": [], "booktitle": "", "medium": "", "edition": "", "publisherlocation": "", "publishername": "", "srcdate": "", "reportnumber": "", "availablefromurl": "", "locationlabel": "", "doccontriblist": [], "docdate": "", "bookname": "", "chapter": "", "sortpubdate": "2026/12/01 00:00", "sortfirstauthor": "Devins KM", "vernaculartitle": "" }, "42952303": { "uid": "42952303", "pubdate": "2026 Oct 29", "epubdate": "2026 Oct 29", "source": "Mol Cancer Ther", "authors": [ { "name": "Doherty ME", "authtype": "Author", "clusterid": "" }, { "name": "Malik M", "authtype": "Author", "clusterid": "" }, { "name": "Otsuka Y", "authtype": "Author", "clusterid": "" }, { "name": "Bateman NW", "authtype": "Author", "clusterid": "" }, { "name": "Risinger JI", "authtype": "Author", "clusterid": "" }, { "name": "Pyskir N", "authtype": "Author", "clusterid": "" }, { "name": "Conrads TP", "authtype": "Author", "clusterid": "" }, { "name": "Darcy KM", "authtype": "Author", "clusterid": "" }, { "name": "Maxwell GL", "authtype": "Author", "clusterid": "" }, { "name": "Ganakammal SR", "authtype": "Author", "clusterid": "" }, { "name": "Dalgard CL", "authtype": "Author", "clusterid": "" }, { "name": "Wilkerson MD", "authtype": "Author", "clusterid": "" }, { "name": "Sukumar G", "authtype": "Author", "clusterid": "" }, { "name": "LaMorte JP", "authtype": "Author", "clusterid": "" }, { "name": "Finniff BA", "authtype": "Author", "clusterid": "" }, { "name": "Kortum RL", "authtype": "Author", "clusterid": "" }, { "name": "Catherino WH", "authtype": "Author", "clusterid": "" } ], "lastauthor": "Catherino WH", "title": "ATR inhibitors and gemcitabine synergize to induce cell death in TP53-mutant, ATRX-wildtype uterine leiomyosarcoma.", "sorttitle": "atr inhibitors and gemcitabine synergize to induce cell death in tp53 mutant atrx wildtype uterine leiomyosarcoma", "volume": "", "issue": "", "pages": "", "lang": [ "eng" ], "nlmuniqueid": "101132535", "issn": "1535-7163", "essn": "1538-8514", "pubtype": [ "Journal Article" ], "recordstatus": "PubMed - as supplied by publisher", "pubstatus": "10", "articleids": [ { "idtype": "pubmed", "idtypen": 1, "value": "42952303" }, { "idtype": "doi", "idtypen": 3, "value": "10.1158/1535-7163.MCT-26-0434" }, { "idtype": "pii", "idtypen": 4, "value": "789710" } ], "history": [ { "pubstatus": "accepted", "date": "2026/10/27 00:00" }, { "pubstatus": "received", "date": "2026/05/01 00:00" }, { "pubstatus": "revised", "date": "2026/08/24 00:00" }, { "pubstatus": "medline", "date": "2026/10/29 05:30" }, { "pubstatus": "pubmed", "date": "2026/10/29 05:30" }, { "pubstatus": "entrez", "date": "2026/10/29 03:13" } ], "references": [], "attributes": [ "Has Abstract" ], "pmcrefcount": "", "fulljournalname": "Molecular cancer therapeutics", "elocationid": "doi: 10.1158/1535-7163.MCT-26-0434", "doctype": "citation", "srccontriblist": [], "booktitle": "", "medium": "", "edition": "", "publisherlocation": "", "publishername": "", "srcdate": "", "reportnumber": "", "availablefromurl": "", "locationlabel": "", "doccontriblist": [], "docdate": "", "bookname": "", "chapter": "", "sortpubdate": "2026/10/29 00:00", "sortfirstauthor": "Doherty ME", "vernaculartitle": "" }, "42955969": { "uid": "42955969", "pubdate": "2026 Jul 1", "epubdate": "2026 Oct 29", "source": "J Cancer Res Ther", "authors": [ { "name": "Sekar A", "authtype": "Author", "clusterid": "" }, { "name": "Rekhi B", "authtype": "Author", "clusterid": "" }, { "name": "Ghosh J", "authtype": "Author", "clusterid": "" }, { "name": "Menon S", "authtype": "Author", "clusterid": "" }, { "name": "Shetty O", "authtype": "Author", "clusterid": "" }, { "name": "Deodhar K", "authtype": "Author", "clusterid": "" }, { "name": "Rath S", "authtype": "Author", "clusterid": "" }, { "name": "Mittal N", "authtype": "Author", "clusterid": "" }, { "name": "Mehta A", "authtype": "Author", "clusterid": "" }, { "name": "Gulia S", "authtype": "Author", "clusterid": "" }, { "name": "Maheshwari A", "authtype": "Author", "clusterid": "" }, { "name": "Chopra S", "authtype": "Author", "clusterid": "" }, { "name": "Gupta S", "authtype": "Author", "clusterid": "" } ], "lastauthor": "Gupta S", "title": "A retrospective analysis of BCOR-immunohistochemistry positive uterine sarcomas: Clinical features and survival.", "sorttitle": "retrospective analysis of bcor immunohistochemistry positive uterine sarcomas clinical features and survival", "volume": "22", "issue": "5", "pages": "884-891", "lang": [ "eng" ], "nlmuniqueid": "101249598", "issn": "", "essn": "1998-4138", "pubtype": [ "Journal Article" ], "recordstatus": "PubMed - indexed for MEDLINE", "pubstatus": "256", "articleids": [ { "idtype": "pubmed", "idtypen": 1, "value": "42955969" }, { "idtype": "doi", "idtypen": 3, "value": "10.4103/jcrt.jcrt_582_26" }, { "idtype": "pii", "idtypen": 4, "value": "01363817-202610000-00015" } ], "history": [ { "pubstatus": "received", "date": "2026/04/15 00:00" }, { "pubstatus": "accepted", "date": "2026/08/29 00:00" }, { "pubstatus": "medline", "date": "2026/10/29 17:37" }, { "pubstatus": "pubmed", "date": "2026/10/29 17:36" }, { "pubstatus": "entrez", "date": "2026/10/29 13:35" } ], "references": [], "attributes": [ "Has Abstract" ], "pmcrefcount": "", "fulljournalname": "Journal of cancer research and therapeutics", "elocationid": "doi: 10.4103/jcrt.jcrt_582_26", "doctype": "citation", "srccontriblist": [], "booktitle": "", "medium": "", "edition": "", "publisherlocation": "", "publishername": "", "srcdate": "", "reportnumber": "", "availablefromurl": "", "locationlabel": "", "doccontriblist": [], "docdate": "", "bookname": "", "chapter": "", "sortpubdate": "2026/07/01 00:00", "sortfirstauthor": "Sekar A", "vernaculartitle": "" }, "42957266": { "uid": "42957266", "pubdate": "2026 Nov-Dec", "epubdate": "", "source": "In Vivo", "authors": [ { "name": "Lim SC", "authtype": "Author", "clusterid": "" } ], "lastauthor": "Lim SC", "title": "Uterine Carcinosarcoma With an Adenosquamous Carcinoma and Low-Grade Endometrial Stromal Sarcoma-like Component: A Case Report.", "sorttitle": "uterine carcinosarcoma with an adenosquamous carcinoma and low grade endometrial stromal sarcoma like component a case report", "volume": "40", "issue": "6", "pages": "3956-3969", "lang": [ "eng" ], "nlmuniqueid": "8806809", "issn": "0258-851X", "essn": "1791-7549", "pubtype": [ "Journal Article", "Case Reports" ], "recordstatus": "PubMed - indexed for MEDLINE", "pubstatus": "4", "articleids": [ { "idtype": "pubmed", "idtypen": 1, "value": "42957266" }, { "idtype": "doi", "idtypen": 3, "value": "10.21873/invivo.14533" }, { "idtype": "pii", "idtypen": 4, "value": "40/6/3956" } ], "history": [ { "pubstatus": "received", "date": "2026/08/12 00:00" }, { "pubstatus": "revised", "date": "2026/09/08 00:00" }, { "pubstatus": "accepted", "date": "2026/09/11 00:00" }, { "pubstatus": "medline", "date": "2026/10/29 23:29" }, { "pubstatus": "pubmed", "date": "2026/10/29 23:28" }, { "pubstatus": "entrez", "date": "2026/10/29 20:53" } ], "references": [], "attributes": [ "Has Abstract" ], "pmcrefcount": "", "fulljournalname": "In vivo (Athens, Greece)", "elocationid": "doi: 10.21873/invivo.14533", "doctype": "citation", "srccontriblist": [], "booktitle": "", "medium": "", "edition": "", "publisherlocation": "", "publishername": "", "srcdate": "", "reportnumber": "", "availablefromurl": "", "locationlabel": "", "doccontriblist": [], "docdate": "", "bookname": "", "chapter": "", "sortpubdate": "2026/11/01 00:00", "sortfirstauthor": "Lim SC", "vernaculartitle": "" } } } }, "efetch": { "url": "https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42939826%2C42942324%2C42948072%2C42949538%2C42951232%2C42951388%2C42951389%2C42951390%2C42952303%2C42955969%2C42957266&retmode=xml&rettype=abstract", "http_status": 200, "note": "Full XML fetched this session and used for triage; omitted from the published manifest to keep the file size down. Abstracts for the two retained/triaged records are restated under triage." }, "triage": { "window_pmids": [ "42939826", "42942324", "42948072", "42949538", "42951232", "42951388", "42951389", "42951390", "42952303", "42955969", "42957266" ], "retained": [ { "pmid": "42951232", "decision": "add", "reason": "First retrieved hysterectomy-corrected adenosarcoma incidence (0.1/100000) and 5-year relative survival 78.3% (75.7-80.6%) in SEER 22; n=1884 adenosarcomas of 14801 mesenchymal uterine sarcomas (12.7%). Abstract only; full text not served.", "pubtypes": [ "Journal Article" ], "doi": "10.1016/j.ajog.2026.10.034", "crossref_updated_by": [], "retraction": "none in PubMed publication types or Crossref updated-by" } ], "logged_not_added": [ { "pmid": "42951389", "decision": "bibliography-skip", "reason": "Dedicated review of unusual presentations and mimics (Dinh/Chapel). Abstract restates known biphasic morphology, SO, invasion, LVSI, heterologous elements, atypia, and polyp/sarcoma differentials without new numbers. Full text not served. Not added to the cited set.", "pubtypes": [ "Journal Article", "Review" ], "doi": "10.1016/j.path.2026.06.009", "crossref_updated_by": [] } ], "dropped": [ { "pmid": "42939826", "reason": "uterine smooth-muscle tumours / LMS oxidative-stress review; not adenosarcoma" }, { "pmid": "42942324", "reason": "class-level occult-sarcoma narrative review (0.1-0.4%); not adenosarcoma-specific" }, { "pmid": "42948072", "reason": "KAT6B::KANSL1 ESS/smooth-muscle hybrid case report" }, { "pmid": "42949538", "reason": "TRACER pharmacogenomic methods paper; sarcoma as one cancer type" }, { "pmid": "42951388", "reason": "DNA methylation in gyn pathology; mentions SMARCA4-deficient uterine sarcoma, not adenosarcoma data" }, { "pmid": "42951390", "reason": "cervical/vaginal rhabdomyosarcoma review" }, { "pmid": "42952303", "reason": "ATR inhibitors in TP53-mutant uLMS" }, { "pmid": "42955969", "reason": "BCOR-IHC uterine sarcomas; HG-ESS" }, { "pmid": "42957266", "reason": "uterine carcinosarcoma case (adenosquamous carcinoma + LG-ESS-like); not adenosarcoma" } ] }, "crossref": { "dois_checked": [ { "doi": "10.1016/j.ajog.2026.10.034", "http": 200, "updated_by": [], "title": "Hysterectomy-corrected, age-specific incidence and survival of uterine sarcomas by histotype, race and ethnicity in the United States, 2000\u2013" }, { "doi": "10.1016/j.path.2026.06.009", "http": 200, "updated_by": [], "title": "Uterine Adenosarcoma" }, { "doi": "10.3390/life16101738", "http": 200, "updated_by": [] }, { "doi": "10.21873/invivo.14533", "http": 200, "updated_by": [] }, { "doi": "10.1136/ijgc-2023-005229", "http": 200, "updated_by": [] } ] }, "registries_non_us": { "eudract_search_adenosarcoma": { "url": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=adenosarcoma", "http": 200, "count": 5, "ids": [ "2017-005018-76", "2021-002540-67", "2013-000762-11", "2009-011454-17", "2014-004697-41" ], "note": "Same five as 2026-10-24: FUCHSia, EORTC 62113, plus three paediatric protocols." }, "eudract_2013-000762-11_results": { "url": "https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000762-11/results", "http": 200, "histology_in_baseline": false, "primary_analysed": "30 cabozantinib / 29 placebo", "note": "Adenosarcoma appears only in an eligibility-amendment sentence (HGAS). No histology counts. No new primary publication in PubMed this window." }, "isrctn": { "url": "https://www.isrctn.com/search?q=adenosarcoma", "http": 200, "usable": false, "note": "cookie/JavaScript holding page" }, "chictr": { "usable": false, "note": "searchproj.aspx 404 whitelabel; English search form not a result set" }, "ctri": { "usable": false, "note": "request failed/timeout" }, "who_ictrp": { "url": "https://trialsearch.who.int/", "http": 200, "usable": false, "note": "JS portal; programmatic search not counted" } }, "guidelines_orgs_stats": { "esgo_guidelines_page": { "url": "https://www.esgo.org/guidelines/", "http": 200, "adenosarcoma_in_static_html": false, "note": "JS-rendered" }, "esgo_pocket_pdf": { "url": "https://www.esgo.org/media/2025/03/Pocket-Guidelines_UTERINE-sarcomas_tisk.pdf", "http": 200, "bytes": 2454675 }, "nccn_detail": { "url": "https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473", "http": 200, "version_listed": "Version 3.2026" }, "nci_pdq_hp": { "url": "https://www.cancer.gov/types/uterine/hp/uterine-sarcoma-treatment-pdq", "http": 200, "content_updated": "2024-12-17", "dcterms.issued": "2026-10-28", "adenosarcoma_present": true }, "nci_patient_hub": { "url": "https://www.cancer.gov/types/uterine/sarcoma/treatment", "http": 200, "adenosarcoma_present": false }, "acs": { "url": "https://www.cancer.org/cancer/types/uterine-sarcoma/detection-diagnosis-staging.html", "http": 200, "cites_nccn": "Version 2.2026 \u2013 November 14, 2025" }, "fwc": { "url": "https://foundationforwomenscancer.org/", "http": 403 }, "sarcoma_uk": { "url": "https://sarcoma.org.uk/", "http": 200 }, "sfa_home": { "url": "https://curesarcoma.org/", "http": 200 }, "sfa_stats": { "url": "https://curesarcoma.org/sarcoma-statistics/", "http": 403 }, "sfa_subtype": { "url": "https://curesarcoma.org/sarcoma-subtypes/", "http": 403 }, "sarcoma_alliance": { "url": "https://sarcomaalliance.org/", "http": 200 }, "seer_data": { "url": "https://seer.cancer.gov/data/", "http": 200, "adenosarcoma_on_page": false }, "openalex_uterine_adenosarcoma_window": { "count": 0 }, "openalex_adenosarcoma_window": { "count": 0 }, "doaj_adenosarcoma": { "total": 129, "newest_created": "2026-09-27", "note": "newest already triaged 2026-10-10; nothing in this window" } }, "unpaywall": "skipped; LIFEBANK_CONTACT_EMAIL unset", "cochrane_library": "not queried; HTTP 403 documented in SOURCES.md", "scielo_lilacs": "not queried; HTTP 403; no regional-absence claim" }